{"elements": [{"data": {"id": "TNBC", "label": "TNBC"}}, {"data": {"id": "Human cancers, malignant melanoma", "label": "Human cancers, malignant melanoma"}}, {"data": {"id": "Breast cancer, melanoma, leukemia, lymphoma", "label": "Breast cancer, melanoma, leukemia, lymphoma"}}, {"data": {"id": "FGFR-altered IGs", "label": "FGFR-altered IGs"}}, {"data": {"id": "IBC cells", "label": "IBC cells"}}, {"data": {"id": "Well-differentiated spindle cell liposarcoma", "label": "Well-differentiated spindle cell liposarcoma"}}, {"data": {"id": "HR+/HER2- breast cancer", "label": "HR+/HER2- breast cancer"}}, {"data": {"id": "gliomas, cancers", "label": "gliomas, cancers"}}, {"data": {"id": "MAPK, AKT", "label": "MAPK, AKT"}}, {"data": {"id": "G1-S transition", "label": "G1-S transition"}}, {"data": {"id": "Metabolic pathway, ROS signaling pathway, HIF1a, mTOR signaling", "label": "Metabolic pathway, ROS signaling pathway, HIF1a, mTOR signaling"}}, {"data": {"id": "SB431542", "label": "SB431542"}}, {"data": {"id": "Esophageal squamous cell carcinoma", "label": "Esophageal squamous cell carcinoma"}}, {"data": {"id": "CA-Pheo", "label": "CA-Pheo"}}, {"data": {"id": "HER2-positive breast cancer", "label": "HER2-positive breast cancer"}}, {"data": {"id": "Fulvestrant", "label": "Fulvestrant"}}, {"data": {"id": "CDKN2A", "label": "CDKN2A"}}, {"data": {"id": "intestinal epithelial cells", "label": "intestinal epithelial cells"}}, {"data": {"id": "Primary cutaneous melanoma (PCM)", "label": "Primary cutaneous melanoma (PCM)"}}, {"data": {"id": "tumors", "label": "tumors"}}, {"data": {"id": "Palbociclib, Fulvestrant", "label": "Palbociclib, Fulvestrant"}}, {"data": {"id": "Estrogen receptor-positive, HER2-positive breast cancer", "label": "Estrogen receptor-positive, HER2-positive breast cancer"}}, {"data": {"id": "Rb-deficient tumors", "label": "Rb-deficient tumors"}}, {"data": {"id": "Melanoma cell lines", "label": "Melanoma cell lines"}}, {"data": {"id": "Malignant peripheral nerve sheath tumors (MPNSTs)", "label": "Malignant peripheral nerve sheath tumors (MPNSTs)"}}, {"data": {"id": "Neuroblastoma", "label": "Neuroblastoma"}}, {"data": {"id": "Glioblastoma (GBM)", "label": "Glioblastoma (GBM)"}}, {"data": {"id": "Braf(V600E) melanoma cells", "label": "Braf(V600E) melanoma cells"}}, {"data": {"id": "MAPK, PI3K, S6K1", "label": "MAPK, PI3K, S6K1"}}, {"data": {"id": "CA", "label": "CA"}}, {"data": {"id": "Melanocytic tumors", "label": "Melanocytic tumors"}}, {"data": {"id": "Liver tumors", "label": "Liver tumors"}}, {"data": {"id": "Metastatic breast cancer (mBC)", "label": "Metastatic breast cancer (mBC)"}}, {"data": {"id": "Binimetinib", "label": "Binimetinib"}}, {"data": {"id": "CDK4/6 inhibitors, mTOR inhibitors", "label": "CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"id": "CRPC", "label": "CRPC"}}, {"data": {"id": "T2DM-CAD", "label": "T2DM-CAD"}}, {"data": {"id": "Capivasertib, fulvestrant", "label": "Capivasertib, fulvestrant"}}, {"data": {"id": "Multiple cancer types", "label": "Multiple cancer types"}}, {"data": {"id": "Ganglioneuroma", "label": "Ganglioneuroma"}}, {"data": {"id": "T-cell acute lymphoblastic leukemia", "label": "T-cell acute lymphoblastic leukemia"}}, {"data": {"id": "Serous ovarian tumor", "label": "Serous ovarian tumor"}}, {"data": {"id": "SRJ23", "label": "SRJ23"}}, {"data": {"id": "Glioblastoma cells", "label": "Glioblastoma cells"}}, {"data": {"id": "FMD", "label": "FMD"}}, {"data": {"id": "Olaparib", "label": "Olaparib"}}, {"data": {"id": "AKT/mTOR", "label": "AKT/mTOR"}}, {"data": {"id": "Cutaneous malignant melanoma", "label": "Cutaneous malignant melanoma"}}, {"data": {"id": "B-cells", "label": "B-cells"}}, {"data": {"id": "Endocrine resistance", "label": "Endocrine resistance"}}, {"data": {"id": "breast cancer", "label": "breast cancer"}}, {"data": {"id": "PIK3CA/mTOR inhibitors", "label": "PIK3CA/mTOR inhibitors"}}, {"data": {"id": "Trastuzumab", "label": "Trastuzumab"}}, {"data": {"id": "Diffuse high-grade glioma (DHG)", "label": "Diffuse high-grade glioma (DHG)"}}, {"data": {"id": "HER2-negative/HR-positive breast cancer", "label": "HER2-negative/HR-positive breast cancer"}}, {"data": {"id": "PS1", "label": "PS1"}}, {"data": {"id": "CDK4/6-cyclin D1", "label": "CDK4/6-cyclin D1"}}, {"data": {"id": "UHGPS", "label": "UHGPS"}}, {"data": {"id": "CKI-CDK-Rb pathway", "label": "CKI-CDK-Rb pathway"}}, {"data": {"id": "PD0332991", "label": "PD0332991"}}, {"data": {"id": "Head and neck cancer", "label": "Head and neck cancer"}}, {"data": {"id": "Rhabdomyosarcomatous cells", "label": "Rhabdomyosarcomatous cells"}}, {"data": {"id": "CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors", "label": "CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors"}}, {"data": {"id": "Gedatolisib", "label": "Gedatolisib"}}, {"data": {"id": "Resveratrol", "label": "Resveratrol"}}, {"data": {"id": "BRAF inhibitors, MEK inhibitors, CDK4/6 inhibitors", "label": "BRAF inhibitors, MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "Everolimus", "label": "Everolimus"}}, {"data": {"id": "rapamycin", "label": "rapamycin"}}, {"data": {"id": "Cyclin pathway", "label": "Cyclin pathway"}}, {"data": {"id": "BZD", "label": "BZD"}}, {"data": {"id": "CDKN1A", "label": "CDKN1A"}}, {"data": {"id": "Metastasis", "label": "Metastasis"}}, {"data": {"id": "Early breast cancer", "label": "Early breast cancer"}}, {"data": {"id": "Triple-negative breast cancer", "label": "Triple-negative breast cancer"}}, {"data": {"id": "keratinocytes", "label": "keratinocytes"}}, {"data": {"id": "MEFs", "label": "MEFs"}}, {"data": {"id": "Anaplastic astrocytomas, GBMs", "label": "Anaplastic astrocytomas, GBMs"}}, {"data": {"id": "CDK-Rb-E2F", "label": "CDK-Rb-E2F"}}, {"data": {"id": "G1/S transition", "label": "G1/S transition"}}, {"data": {"id": "HR+ breast cancer", "label": "HR+ breast cancer"}}, {"data": {"id": "DDLPS,PLPS", "label": "DDLPS,PLPS"}}, {"data": {"id": "Salivary gland tumor", "label": "Salivary gland tumor"}}, {"data": {"id": "Uterine myosarcoma", "label": "Uterine myosarcoma"}}, {"data": {"id": "BRAF inhibitors", "label": "BRAF inhibitors"}}, {"data": {"id": "Triple negative breast cancer", "label": "Triple negative breast cancer"}}, {"data": {"id": "WDL,DDL", "label": "WDL,DDL"}}, {"data": {"id": "Synovial sarcoma", "label": "Synovial sarcoma"}}, {"data": {"id": "Lipomatous tumor", "label": "Lipomatous tumor"}}, {"data": {"id": "CTL, ERA", "label": "CTL, ERA"}}, {"data": {"id": "B-cell precursors", "label": "B-cell precursors"}}, {"data": {"id": "Gliosarcoma", "label": "Gliosarcoma"}}, {"data": {"id": "APLT", "label": "APLT"}}, {"data": {"id": "HUC senescence", "label": "HUC senescence"}}, {"data": {"id": "BRAF", "label": "BRAF"}}, {"data": {"id": "Geldanamycin", "label": "Geldanamycin"}}, {"data": {"id": "Salivary gland tumors", "label": "Salivary gland tumors"}}, {"data": {"id": "Combined drugs", "label": "Combined drugs"}}, {"data": {"id": "TQB3616", "label": "TQB3616"}}, {"data": {"id": "PI3K, AKT, mTOR", "label": "PI3K, AKT, mTOR"}}, {"data": {"id": "Anti-EGFR therapy,CDK4/6 inhibitors", "label": "Anti-EGFR therapy,CDK4/6 inhibitors"}}, {"data": {"id": "AM", "label": "AM"}}, {"data": {"id": "Triple-negative breast cancer (TNBC)", "label": "Triple-negative breast cancer (TNBC)"}}, {"data": {"id": "Breast cancer", "label": "Breast cancer"}}, {"data": {"id": "Raf-Mek-Erk pathway", "label": "Raf-Mek-Erk pathway"}}, {"data": {"id": "granulocyte-monocyte precursors", "label": "granulocyte-monocyte precursors"}}, {"data": {"id": "Atypical lipomatous tumor", "label": "Atypical lipomatous tumor"}}, {"data": {"id": "EGCG", "label": "EGCG"}}, {"data": {"id": "Carcinoma cells", "label": "Carcinoma cells"}}, {"data": {"id": "MEK1/2 inhibitors, CDK4/6 inhibitors", "label": "MEK1/2 inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "ER-positive, HER2-negative breast cancer", "label": "ER-positive, HER2-negative breast cancer"}}, {"data": {"id": "Urothelial cells", "label": "Urothelial cells"}}, {"data": {"id": "ribociclib,palbociclib,abemaciclib", "label": "ribociclib,palbociclib,abemaciclib"}}, {"data": {"id": "palbociclib, erlotinib", "label": "palbociclib, erlotinib"}}, {"data": {"id": "PM", "label": "PM"}}, {"data": {"id": "Circulating tumor cells (CTCs)", "label": "Circulating tumor cells (CTCs)"}}, {"data": {"id": "ESCC", "label": "ESCC"}}, {"data": {"id": "EGFR-TKI", "label": "EGFR-TKI"}}, {"data": {"id": "HR-positive breast cancer", "label": "HR-positive breast cancer"}}, {"data": {"id": "PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators", "label": "PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators"}}, {"data": {"id": "Tamoxifen", "label": "Tamoxifen"}}, {"data": {"id": "ER伪 inhibitors", "label": "ER伪 inhibitors"}}, {"data": {"id": "p16-cdk4-cyclin D1-pRb", "label": "p16-cdk4-cyclin D1-pRb"}}, {"data": {"id": "IDH-wildtype glioblastoma", "label": "IDH-wildtype glioblastoma"}}, {"data": {"id": "5-aza-2'-deoxycytidine", "label": "5-aza-2'-deoxycytidine"}}, {"data": {"id": "histiocytic sarcoma", "label": "histiocytic sarcoma"}}, {"data": {"id": "T2DM", "label": "T2DM"}}, {"data": {"id": "PI3K-AKT, CCND1-CDK4/6", "label": "PI3K-AKT, CCND1-CDK4/6"}}, {"data": {"id": "PI3K/AKT pathway", "label": "PI3K/AKT pathway"}}, {"data": {"id": "Advanced ER+ breast cancer", "label": "Advanced ER+ breast cancer"}}, {"data": {"id": "Hibernoma-like areas", "label": "Hibernoma-like areas"}}, {"data": {"id": "Palbociclib,Abemaciclib", "label": "Palbociclib,Abemaciclib"}}, {"data": {"id": "CDK4/6-RB", "label": "CDK4/6-RB"}}, {"data": {"id": "Vemurafenib", "label": "Vemurafenib"}}, {"data": {"id": "Smurf2 siRNA", "label": "Smurf2 siRNA"}}, {"data": {"id": "DNA repair pathway", "label": "DNA repair pathway"}}, {"data": {"id": "MCF7, T47D", "label": "MCF7, T47D"}}, {"data": {"id": "T-ALL cell line", "label": "T-ALL cell line"}}, {"data": {"id": "CA-Para", "label": "CA-Para"}}, {"data": {"id": "ALT", "label": "ALT"}}, {"data": {"id": "HNSCC", "label": "HNSCC"}}, {"data": {"id": "Brain tumors", "label": "Brain tumors"}}, {"data": {"id": "RB1", "label": "RB1"}}, {"data": {"id": "RP-6306, Gemcitabine", "label": "RP-6306, Gemcitabine"}}, {"data": {"id": "Bladder tumors", "label": "Bladder tumors"}}, {"data": {"id": "PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors", "label": "PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"id": "PI3K, Cell-cycle, Apoptosis", "label": "PI3K, Cell-cycle, Apoptosis"}}, {"data": {"id": "PARP inhibitors", "label": "PARP inhibitors"}}, {"data": {"id": "Neratinib,Trastuzumab deruxtecan,Palbociclib", "label": "Neratinib,Trastuzumab deruxtecan,Palbociclib"}}, {"data": {"id": "Retinoblastoma, Osteosarcoma", "label": "Retinoblastoma, Osteosarcoma"}}, {"data": {"id": "G1 control pathway", "label": "G1 control pathway"}}, {"data": {"id": "Cobimetinib", "label": "Cobimetinib"}}, {"data": {"id": "Melanomas,Digestive cancers", "label": "Melanomas,Digestive cancers"}}, {"data": {"id": "Fulvestrant, anastrozole", "label": "Fulvestrant, anastrozole"}}, {"data": {"id": "ATP-competitive inhibitors", "label": "ATP-competitive inhibitors"}}, {"data": {"id": "Endocrine therapy resistance", "label": "Endocrine therapy resistance"}}, {"data": {"id": "HR+/HER2+ metastatic breast cancer", "label": "HR+/HER2+ metastatic breast cancer"}}, {"data": {"id": "Aromatase inhibitors", "label": "Aromatase inhibitors"}}, {"data": {"id": "Spindle cell lipoma, pleomorphic lipoma", "label": "Spindle cell lipoma, pleomorphic lipoma"}}, {"data": {"id": "MEK inhibitors, EGFR inhibitors", "label": "MEK inhibitors, EGFR inhibitors"}}, {"data": {"id": "Epidermal stem cells", "label": "Epidermal stem cells"}}, {"data": {"id": "Medulloblastoma", "label": "Medulloblastoma"}}, {"data": {"id": "Alpelisib, Ribociclib", "label": "Alpelisib, Ribociclib"}}, {"data": {"id": "Trametinib, BKM120, LEE011", "label": "Trametinib, BKM120, LEE011"}}, {"data": {"id": "Endothelial cells", "label": "Endothelial cells"}}, {"data": {"id": "WHO grade II oligodendroglioma", "label": "WHO grade II oligodendroglioma"}}, {"data": {"id": "ER伪+ breast cancer", "label": "ER伪+ breast cancer"}}, {"data": {"id": "Cutaneous melanoma", "label": "Cutaneous melanoma"}}, {"data": {"id": "PI3K/AKT", "label": "PI3K/AKT"}}, {"data": {"id": "Dalpiciclib", "label": "Dalpiciclib"}}, {"data": {"id": "Palbociclib, Cetuximab", "label": "Palbociclib, Cetuximab"}}, {"data": {"id": "Advanced breast cancer", "label": "Advanced breast cancer"}}, {"data": {"id": "Letrozole", "label": "Letrozole"}}, {"data": {"id": "Alpelisib, MLN0128, palbociclib", "label": "Alpelisib, MLN0128, palbociclib"}}, {"data": {"id": "Moyamoya disease (MMD)", "label": "Moyamoya disease (MMD)"}}, {"data": {"id": "MCL", "label": "MCL"}}, {"data": {"id": "PI3K/AKT/mTOR", "label": "PI3K/AKT/mTOR"}}, {"data": {"id": "Binimetinib, Ribociclib", "label": "Binimetinib, Ribociclib"}}, {"data": {"id": "Luteoloside", "label": "Luteoloside"}}, {"data": {"id": "mTORC1/2,CDK4/6,ER", "label": "mTORC1/2,CDK4/6,ER"}}, {"data": {"id": "NAC-resistant tumors", "label": "NAC-resistant tumors"}}, {"data": {"id": "Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)", "label": "Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)"}}, {"data": {"id": "Ribociclib", "label": "Ribociclib"}}, {"data": {"id": "Melanoma, Cancer", "label": "Melanoma, Cancer"}}, {"data": {"id": "MPT0L145, abemaciclib", "label": "MPT0L145, abemaciclib"}}, {"data": {"id": "Palbociclib,Erlotinib", "label": "Palbociclib,Erlotinib"}}, {"data": {"id": "Cetuximab, Afatinib, Palbociclib", "label": "Cetuximab, Afatinib, Palbociclib"}}, {"data": {"id": "PI3K/mTOR inhibitors", "label": "PI3K/mTOR inhibitors"}}, {"data": {"id": "HER2-low breast cancer", "label": "HER2-low breast cancer"}}, {"data": {"id": "HHT", "label": "HHT"}}, {"data": {"id": "Well-differentiated and dedifferentiated liposarcomas", "label": "Well-differentiated and dedifferentiated liposarcomas"}}, {"data": {"id": "breast cancer cells", "label": "breast cancer cells"}}, {"data": {"id": "PI3K/AKT/mTOR, CDK4/6", "label": "PI3K/AKT/mTOR, CDK4/6"}}, {"data": {"id": "Bilateral retinoblastoma", "label": "Bilateral retinoblastoma"}}, {"data": {"id": "Non-small cell lung cancer (NSCLC)", "label": "Non-small cell lung cancer (NSCLC)"}}, {"data": {"id": "Metastatic melanoma", "label": "Metastatic melanoma"}}, {"data": {"id": "Cyclin D1/CDK4", "label": "Cyclin D1/CDK4"}}, {"data": {"id": "Luminal A BC cells", "label": "Luminal A BC cells"}}, {"data": {"id": "METex 14 alteration", "label": "METex 14 alteration"}}, {"data": {"id": "AML", "label": "AML"}}, {"data": {"id": "G1-S regulatory pathway", "label": "G1-S regulatory pathway"}}, {"data": {"id": "Luminal ABC", "label": "Luminal ABC"}}, {"data": {"id": "Pituitary adenomas", "label": "Pituitary adenomas"}}, {"data": {"id": "MPNST", "label": "MPNST"}}, {"data": {"id": "Adenocarcinomas", "label": "Adenocarcinomas"}}, {"data": {"id": "ATRA", "label": "ATRA"}}, {"data": {"id": "Adipocytic tumors, atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL)", "label": "Adipocytic tumors, atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL)"}}, {"data": {"id": "ER+ xenografts", "label": "ER+ xenografts"}}, {"data": {"id": "PIK3CA/mTOR", "label": "PIK3CA/mTOR"}}, {"data": {"id": "Palbociclib, Abemaciclib, Ribociclib", "label": "Palbociclib, Abemaciclib, Ribociclib"}}, {"data": {"id": "TGF-beta", "label": "TGF-beta"}}, {"data": {"id": "Hedgehog, Akt, p53", "label": "Hedgehog, Akt, p53"}}, {"data": {"id": "High-grade astrocytic tumors", "label": "High-grade astrocytic tumors"}}, {"data": {"id": "B cell non-Hodgkin's lymphoma (B-NHL)", "label": "B cell non-Hodgkin's lymphoma (B-NHL)"}}, {"data": {"id": "Abemaciclib, lenvatinib", "label": "Abemaciclib, lenvatinib"}}, {"data": {"id": "High-grade glioma", "label": "High-grade glioma"}}, {"data": {"id": "Skin cancer, SCCs, BCCs", "label": "Skin cancer, SCCs, BCCs"}}, {"data": {"id": "Erufosine", "label": "Erufosine"}}, {"data": {"id": "Canine mammary carcinoma", "label": "Canine mammary carcinoma"}}, {"data": {"id": "Hormone receptor-positive (HR+) breast cancer", "label": "Hormone receptor-positive (HR+) breast cancer"}}, {"data": {"id": "NPC (nasopharyngeal carcinoma)", "label": "NPC (nasopharyngeal carcinoma)"}}, {"data": {"id": "Breast cancer,RAS-mutant cancers", "label": "Breast cancer,RAS-mutant cancers"}}, {"data": {"id": "WDLPS, DDLPS", "label": "WDLPS, DDLPS"}}, {"data": {"id": "MAP kinase pathway", "label": "MAP kinase pathway"}}, {"data": {"id": "PI3K", "label": "PI3K"}}, {"data": {"id": "CDK4/6 inhibitors, MEK inhibitors", "label": "CDK4/6 inhibitors, MEK inhibitors"}}, {"data": {"id": "Elacestrant", "label": "Elacestrant"}}, {"data": {"id": "LH-RH agonist, aromatase inhibitor", "label": "LH-RH agonist, aromatase inhibitor"}}, {"data": {"id": "CDK4/6 inhibitors, EGFR inhibitors", "label": "CDK4/6 inhibitors, EGFR inhibitors"}}, {"data": {"id": "CDK4/6 inhibitors, PI3K/mTOR inhibitors", "label": "CDK4/6 inhibitors, PI3K/mTOR inhibitors"}}, {"data": {"id": "Diffuse astrocytic glioma", "label": "Diffuse astrocytic glioma"}}, {"data": {"id": "Wnt, Hippo", "label": "Wnt, Hippo"}}, {"data": {"id": "Doxazosin", "label": "Doxazosin"}}, {"data": {"id": "mTOR", "label": "mTOR"}}, {"data": {"id": "Pancreatic cancer, melanoma", "label": "Pancreatic cancer, melanoma"}}, {"data": {"id": "Estrogen-accelerating PDX", "label": "Estrogen-accelerating PDX"}}, {"data": {"id": "p16-CDK4/6-RB,AREG/EGFR", "label": "p16-CDK4/6-RB,AREG/EGFR"}}, {"data": {"id": "CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors", "label": "CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors"}}, {"data": {"id": "CDK4/6 inhibitors, Aromatase inhibitors", "label": "CDK4/6 inhibitors, Aromatase inhibitors"}}, {"data": {"id": "SBX", "label": "SBX"}}, {"data": {"id": "Gallbladder cells", "label": "Gallbladder cells"}}, {"data": {"id": "Gynecologic cancers", "label": "Gynecologic cancers"}}, {"data": {"id": "Lipoma, ALT/WDL", "label": "Lipoma, ALT/WDL"}}, {"data": {"id": "ER-positive, HER2-negative metastatic breast cancer", "label": "ER-positive, HER2-negative metastatic breast cancer"}}, {"data": {"id": "Lung metastases (LM)", "label": "Lung metastases (LM)"}}, {"data": {"id": "Desmoplastic small round cell tumor (DSRCT)", "label": "Desmoplastic small round cell tumor (DSRCT)"}}, {"data": {"id": "Intestinal neoplasia", "label": "Intestinal neoplasia"}}, {"data": {"id": "T2DM, T2DM-CAD", "label": "T2DM, T2DM-CAD"}}, {"data": {"id": "Mammary carcinoma", "label": "Mammary carcinoma"}}, {"data": {"id": "cancer", "label": "cancer"}}, {"data": {"id": "Squamous Cell Carcinomas", "label": "Squamous Cell Carcinomas"}}, {"data": {"id": "luminal androgen receptor (LAR) breast cancer", "label": "luminal androgen receptor (LAR) breast cancer"}}, {"data": {"id": "Cobimetinib, ALK inhibitors", "label": "Cobimetinib, ALK inhibitors"}}, {"data": {"id": "RAS-RAF-MEK-ERK", "label": "RAS-RAF-MEK-ERK"}}, {"data": {"id": "Rapamycin", "label": "Rapamycin"}}, {"data": {"id": "anti-PD-1", "label": "anti-PD-1"}}, {"data": {"id": "PI3K inhibitors, mTOR inhibitors", "label": "PI3K inhibitors, mTOR inhibitors"}}, {"data": {"id": "papillary thyroid carcinoma", "label": "papillary thyroid carcinoma"}}, {"data": {"id": "E6201", "label": "E6201"}}, {"data": {"id": "Melanoma, tumors", "label": "Melanoma, tumors"}}, {"data": {"id": "Amelanotic melanoma", "label": "Amelanotic melanoma"}}, {"data": {"id": "B cells", "label": "B cells"}}, {"data": {"id": "CDK4/6 inhibitor", "label": "CDK4/6 inhibitor"}}, {"data": {"id": "Breast tumors", "label": "Breast tumors"}}, {"data": {"id": "NRAS-mutant melanoma", "label": "NRAS-mutant melanoma"}}, {"data": {"id": "Neuroendocrine tumors (NETs)", "label": "Neuroendocrine tumors (NETs)"}}, {"data": {"id": "ALM", "label": "ALM"}}, {"data": {"id": "ESOS", "label": "ESOS"}}, {"data": {"id": "Prostate cancer", "label": "Prostate cancer"}}, {"data": {"id": "Mouse MEL erythroleukemia cells", "label": "Mouse MEL erythroleukemia cells"}}, {"data": {"id": "Dalpiciclib, pyrotinib", "label": "Dalpiciclib, pyrotinib"}}, {"data": {"id": "sPNET, GBM", "label": "sPNET, GBM"}}, {"data": {"id": "Carcinogenesis", "label": "Carcinogenesis"}}, {"data": {"id": "Familial cutaneous malignant melanoma", "label": "Familial cutaneous malignant melanoma"}}, {"data": {"id": "GPX4 inhibitors", "label": "GPX4 inhibitors"}}, {"data": {"id": "Stage III and IV tumors", "label": "Stage III and IV tumors"}}, {"data": {"id": "Temozolomide, CDK4/6 inhibitors, EGFR inhibitors", "label": "Temozolomide, CDK4/6 inhibitors, EGFR inhibitors"}}, {"data": {"id": "Parathyroid tumors", "label": "Parathyroid tumors"}}, {"data": {"id": "MHPCs", "label": "MHPCs"}}, {"data": {"id": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway", "label": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway"}}, {"data": {"id": "Selective ER degraders", "label": "Selective ER degraders"}}, {"data": {"id": "A549 cells", "label": "A549 cells"}}, {"data": {"id": "Cell cycle progression", "label": "Cell cycle progression"}}, {"data": {"id": "Mitogen-activated protein kinase pathway", "label": "Mitogen-activated protein kinase pathway"}}, {"data": {"id": "Atherosclerosis, T2DM", "label": "Atherosclerosis, T2DM"}}, {"data": {"id": "Afatinib,Palbociclib", "label": "Afatinib,Palbociclib"}}, {"data": {"id": "MYC", "label": "MYC"}}, {"data": {"id": "G1 arrest", "label": "G1 arrest"}}, {"data": {"id": "Metastatic breast cancer (MBC)", "label": "Metastatic breast cancer (MBC)"}}, {"data": {"id": "PFS", "label": "PFS"}}, {"data": {"id": "CCND1", "label": "CCND1"}}, {"data": {"id": "Liposarcomas", "label": "Liposarcomas"}}, {"data": {"id": "AKT/mTOR pathway", "label": "AKT/mTOR pathway"}}, {"data": {"id": "Ibrutinib", "label": "Ibrutinib"}}, {"data": {"id": "SPA", "label": "SPA"}}, {"data": {"id": "Low-grade central osteosarcoma", "label": "Low-grade central osteosarcoma"}}, {"data": {"id": "Palbociclib, fulvestrant", "label": "Palbociclib, fulvestrant"}}, {"data": {"id": "Nasopharyngeal carcinoma", "label": "Nasopharyngeal carcinoma"}}, {"data": {"id": "Non-small cell lung cancer", "label": "Non-small cell lung cancer"}}, {"data": {"id": "non-IBC cells", "label": "non-IBC cells"}}, {"data": {"id": "Cell lines", "label": "Cell lines"}}, {"data": {"id": "EGFR, HER2", "label": "EGFR, HER2"}}, {"data": {"id": "HER2-positive advanced breast cancer", "label": "HER2-positive advanced breast cancer"}}, {"data": {"id": "Lipomatous neoplasms", "label": "Lipomatous neoplasms"}}, {"data": {"id": "Multiple cancers", "label": "Multiple cancers"}}, {"data": {"id": "Uterine leiomyosarcoma", "label": "Uterine leiomyosarcoma"}}, {"data": {"id": "Dedifferentiated liposarcoma", "label": "Dedifferentiated liposarcoma"}}, {"data": {"id": "ER+ metastatic breast cancer", "label": "ER+ metastatic breast cancer"}}, {"data": {"id": "Acquired resistance", "label": "Acquired resistance"}}, {"data": {"id": "Olaparib, Palbociclib", "label": "Olaparib, Palbociclib"}}, {"data": {"id": "Fatty tumors", "label": "Fatty tumors"}}, {"data": {"id": "ER-positive, HER2-positive breast cancer", "label": "ER-positive, HER2-positive breast cancer"}}, {"data": {"id": "Polycystic kidney disease", "label": "Polycystic kidney disease"}}, {"data": {"id": "c-Myc", "label": "c-Myc"}}, {"data": {"id": "Chicken PGCs", "label": "Chicken PGCs"}}, {"data": {"id": "GRN163L", "label": "GRN163L"}}, {"data": {"id": "Advanced gastric cancer", "label": "Advanced gastric cancer"}}, {"data": {"id": "Cell cycle control", "label": "Cell cycle control"}}, {"data": {"id": "Abemaciclib", "label": "Abemaciclib"}}, {"data": {"id": "Abemaciclib, Ribociclib, Lenvatinib", "label": "Abemaciclib, Ribociclib, Lenvatinib"}}, {"data": {"id": "Recurrent glioblastoma", "label": "Recurrent glioblastoma"}}, {"data": {"id": "Varicocele", "label": "Varicocele"}}, {"data": {"id": "Glioblastoma (GB)", "label": "Glioblastoma (GB)"}}, {"data": {"id": "Therapy-refractory solid malignancies", "label": "Therapy-refractory solid malignancies"}}, {"data": {"id": "UPSC sarcomas", "label": "UPSC sarcomas"}}, {"data": {"id": "Hepatocellular carcinoma (HCC)", "label": "Hepatocellular carcinoma (HCC)"}}, {"data": {"id": "Acute Myeloid Leukemia (AML)", "label": "Acute Myeloid Leukemia (AML)"}}, {"data": {"id": "Peritoneal metastasis", "label": "Peritoneal metastasis"}}, {"data": {"id": "ARF-p53", "label": "ARF-p53"}}, {"data": {"id": "Propionate", "label": "Propionate"}}, {"data": {"id": "Malignancies", "label": "Malignancies"}}, {"data": {"id": "berberine, evodiamine", "label": "berberine, evodiamine"}}, {"data": {"id": "Metastatic disease", "label": "Metastatic disease"}}, {"data": {"id": "OSCC cells", "label": "OSCC cells"}}, {"data": {"id": "Mucosal melanoma", "label": "Mucosal melanoma"}}, {"data": {"id": "Butein", "label": "Butein"}}, {"data": {"id": "Lung adenocarcinoma", "label": "Lung adenocarcinoma"}}, {"data": {"id": "Hereditary cutaneous melanoma", "label": "Hereditary cutaneous melanoma"}}, {"data": {"id": "retinoblastoma", "label": "retinoblastoma"}}, {"data": {"id": "Cyclin D1", "label": "Cyclin D1"}}, {"data": {"id": "ER-cyclin D1-CDK4/6-RB pathway", "label": "ER-cyclin D1-CDK4/6-RB pathway"}}, {"data": {"id": "palbociclib", "label": "palbociclib"}}, {"data": {"id": "COS cells, RCJ3.1C5.18 cells", "label": "COS cells, RCJ3.1C5.18 cells"}}, {"data": {"id": "Capivasertib, anti-HER2 agents, endocrine treatment", "label": "Capivasertib, anti-HER2 agents, endocrine treatment"}}, {"data": {"id": "PCNSL", "label": "PCNSL"}}, {"data": {"id": "Glioma", "label": "Glioma"}}, {"data": {"id": "Cyclin D-CDK4/6-Rb", "label": "Cyclin D-CDK4/6-Rb"}}, {"data": {"id": "mTOR pathway", "label": "mTOR pathway"}}, {"data": {"id": "Ribociclib, everolimus", "label": "Ribociclib, everolimus"}}, {"data": {"id": "Lymph node metastasis, depth of invasion", "label": "Lymph node metastasis, depth of invasion"}}, {"data": {"id": "Lung cancer, Colon cancer", "label": "Lung cancer, Colon cancer"}}, {"data": {"id": "Lipoma", "label": "Lipoma"}}, {"data": {"id": "Melanocytic neoplasms", "label": "Melanocytic neoplasms"}}, {"data": {"id": "Sarcoma", "label": "Sarcoma"}}, {"data": {"id": "Familial human melanoma", "label": "Familial human melanoma"}}, {"data": {"id": "Alcohol", "label": "Alcohol"}}, {"data": {"id": "MLN0128", "label": "MLN0128"}}, {"data": {"id": "Hepatoid adenocarcinoma of the stomach (HAS)", "label": "Hepatoid adenocarcinoma of the stomach (HAS)"}}, {"data": {"id": "Endometrioid-type endometrial carcinomas", "label": "Endometrioid-type endometrial carcinomas"}}, {"data": {"id": "Esophageal cancer", "label": "Esophageal cancer"}}, {"data": {"id": "Adenoma", "label": "Adenoma"}}, {"data": {"id": "ERBB2", "label": "ERBB2"}}, {"data": {"id": "NB cell lines", "label": "NB cell lines"}}, {"data": {"id": "Beta-catenin-Tcf", "label": "Beta-catenin-Tcf"}}, {"data": {"id": "STAT3,Erk,p38", "label": "STAT3,Erk,p38"}}, {"data": {"id": "E2F1", "label": "E2F1"}}, {"data": {"id": "Melanoma cells", "label": "Melanoma cells"}}, {"data": {"id": "Childhood retinoblastoma", "label": "Childhood retinoblastoma"}}, {"data": {"id": "AP-1", "label": "AP-1"}}, {"data": {"id": "Melanoma, GBM", "label": "Melanoma, GBM"}}, {"data": {"id": "Barrett's adenocarcinomas", "label": "Barrett's adenocarcinomas"}}, {"data": {"id": "Dedifferentiated osteosarcoma", "label": "Dedifferentiated osteosarcoma"}}, {"data": {"id": "ALT, parosteal osteosarcoma", "label": "ALT, parosteal osteosarcoma"}}, {"data": {"id": "Testicular cells", "label": "Testicular cells"}}, {"data": {"id": "Mesenchymal stem cells", "label": "Mesenchymal stem cells"}}, {"data": {"id": "Atypical lipomatous tumor, Well-differentiated liposarcoma", "label": "Atypical lipomatous tumor, Well-differentiated liposarcoma"}}, {"data": {"id": "Osteosarcoma", "label": "Osteosarcoma"}}, {"data": {"id": "Autophagy regulators", "label": "Autophagy regulators"}}, {"data": {"id": "Glioblastoma multiforme (GBM)", "label": "Glioblastoma multiforme (GBM)"}}, {"data": {"id": "Fulvestrant, BKM120", "label": "Fulvestrant, BKM120"}}, {"data": {"id": "DBF", "label": "DBF"}}, {"data": {"id": "elacestrant", "label": "elacestrant"}}, {"data": {"id": "B7-H3", "label": "B7-H3"}}, {"data": {"id": "NSCLC", "label": "NSCLC"}}, {"data": {"id": "Amplifications", "label": "Amplifications"}}, {"data": {"id": "PI3K inhibitors, CDK4/6 inhibitors", "label": "PI3K inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "Metastatic HR+/HER2- breast cancer", "label": "Metastatic HR+/HER2- breast cancer"}}, {"data": {"id": "Ceritinib, Ribociclib", "label": "Ceritinib, Ribociclib"}}, {"data": {"id": "WDLS, DDLS", "label": "WDLS, DDLS"}}, {"data": {"id": "Mesenchymal tumors", "label": "Mesenchymal tumors"}}, {"data": {"id": "Alpelisib", "label": "Alpelisib"}}, {"data": {"id": "Nonbreast solid tumors", "label": "Nonbreast solid tumors"}}, {"data": {"id": "cancers", "label": "cancers"}}, {"data": {"id": "mTOR inhibitor", "label": "mTOR inhibitor"}}, {"data": {"id": "Familial melanoma, multiple melanoma", "label": "Familial melanoma, multiple melanoma"}}, {"data": {"id": "FAP (Familial Adenomatous Polyposis)", "label": "FAP (Familial Adenomatous Polyposis)"}}, {"data": {"id": "MPM", "label": "MPM"}}, {"data": {"id": "PIK3CA inhibitors, AR inhibitors, BCL2 inhibitors", "label": "PIK3CA inhibitors, AR inhibitors, BCL2 inhibitors"}}, {"data": {"id": "Everolimus,Palbociclib,Ribociclib,Abemaciclib,Alpelisib", "label": "Everolimus,Palbociclib,Ribociclib,Abemaciclib,Alpelisib"}}, {"data": {"id": "ESCC, esophageal dysplasia", "label": "ESCC, esophageal dysplasia"}}, {"data": {"id": "MSCs", "label": "MSCs"}}, {"data": {"id": "Beta cells", "label": "Beta cells"}}, {"data": {"id": "Cyclin D-CDK4/6", "label": "Cyclin D-CDK4/6"}}, {"data": {"id": "NRAS", "label": "NRAS"}}, {"data": {"id": "Pembrolizumab, Durvalumab, Atezolizumab, BRAF inhibitors, MEK inhibitors", "label": "Pembrolizumab, Durvalumab, Atezolizumab, BRAF inhibitors, MEK inhibitors"}}, {"data": {"id": "Sarcomatoid CRCC", "label": "Sarcomatoid CRCC"}}, {"data": {"id": "HER2+ advanced breast cancer", "label": "HER2+ advanced breast cancer"}}, {"data": {"id": "fulvestrant", "label": "fulvestrant"}}, {"data": {"id": "MCF7 cells", "label": "MCF7 cells"}}, {"data": {"id": "Melanoma,Neural system tumors", "label": "Melanoma,Neural system tumors"}}, {"data": {"id": "Primary tumor, Secondary lesions", "label": "Primary tumor, Secondary lesions"}}, {"data": {"id": "nab-sirolimus", "label": "nab-sirolimus"}}, {"data": {"id": "Parathyroid adenomas", "label": "Parathyroid adenomas"}}, {"data": {"id": "Ossifying fibroma (OF)", "label": "Ossifying fibroma (OF)"}}, {"data": {"id": "eGBM", "label": "eGBM"}}, {"data": {"id": "Tumor, normal skin tissue", "label": "Tumor, normal skin tissue"}}, {"data": {"id": "MAPK", "label": "MAPK"}}, {"data": {"id": "HPV(neg) HNSCC", "label": "HPV(neg) HNSCC"}}, {"data": {"id": "MAPK, Cell cycle", "label": "MAPK, Cell cycle"}}, {"data": {"id": "Various tumor types", "label": "Various tumor types"}}, {"data": {"id": "Familial melanoma, Tumours", "label": "Familial melanoma, Tumours"}}, {"data": {"id": "PV", "label": "PV"}}, {"data": {"id": "Benign lipomatous lesions", "label": "Benign lipomatous lesions"}}, {"data": {"id": "Cyclin signaling", "label": "Cyclin signaling"}}, {"data": {"id": "Burkitt lymphoma", "label": "Burkitt lymphoma"}}, {"data": {"id": "PI3K-mTOR", "label": "PI3K-mTOR"}}, {"data": {"id": "mTOR/p70-S6k", "label": "mTOR/p70-S6k"}}, {"data": {"id": "Pigmentation pathway", "label": "Pigmentation pathway"}}, {"data": {"id": "Cancers", "label": "Cancers"}}, {"data": {"id": "Fulvestrant, Camizestrant", "label": "Fulvestrant, Camizestrant"}}, {"data": {"id": "Non-invasive follicular thyroid neoplasm", "label": "Non-invasive follicular thyroid neoplasm"}}, {"data": {"id": "Disease progression", "label": "Disease progression"}}, {"data": {"id": "UHGPS, DDLS", "label": "UHGPS, DDLS"}}, {"data": {"id": "HR+ metastatic breast cancer", "label": "HR+ metastatic breast cancer"}}, {"data": {"id": "breast cancer,head and neck cancer,non-small-cell lung cancer,mantle cell lymphomas", "label": "breast cancer,head and neck cancer,non-small-cell lung cancer,mantle cell lymphomas"}}, {"data": {"id": "Hormone receptor-positive, HER2-negative breast cancer", "label": "Hormone receptor-positive, HER2-negative breast cancer"}}, {"data": {"id": "ATR:CHK1", "label": "ATR:CHK1"}}, {"data": {"id": "GLS1i", "label": "GLS1i"}}, {"data": {"id": "Esophageal conditions", "label": "Esophageal conditions"}}, {"data": {"id": "T cells", "label": "T cells"}}, {"data": {"id": "trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine", "label": "trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine"}}, {"data": {"id": "Endocrine therapy-resistant ESR1(+) breast cancer", "label": "Endocrine therapy-resistant ESR1(+) breast cancer"}}, {"data": {"id": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma", "label": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma"}}, {"data": {"id": "Malignant gliomas", "label": "Malignant gliomas"}}, {"data": {"id": "Leptomeningeal metastases of lung adenocarcinoma", "label": "Leptomeningeal metastases of lung adenocarcinoma"}}, {"data": {"id": "GBM", "label": "GBM"}}, {"data": {"id": "Seminal vesicle tumors", "label": "Seminal vesicle tumors"}}, {"data": {"id": "Erk1/2 inhibitors,CDK4/6 inhibitors", "label": "Erk1/2 inhibitors,CDK4/6 inhibitors"}}, {"data": {"id": "Brain cancer", "label": "Brain cancer"}}, {"data": {"id": "Osimertinib, Palbociclib", "label": "Osimertinib, Palbociclib"}}, {"data": {"id": "High-grade astrocytomas", "label": "High-grade astrocytomas"}}, {"data": {"id": "pRb pathway", "label": "pRb pathway"}}, {"data": {"id": "Pertuzumab,T-DM1,Tyrosine kinase inhibitors", "label": "Pertuzumab,T-DM1,Tyrosine kinase inhibitors"}}, {"data": {"id": "CDK4/6/RB pathway", "label": "CDK4/6/RB pathway"}}, {"data": {"id": "tamoxifen,aromatase inhibitors", "label": "tamoxifen,aromatase inhibitors"}}, {"data": {"id": "PI3K/mTOR inhibitors, fulvestrant", "label": "PI3K/mTOR inhibitors, fulvestrant"}}, {"data": {"id": "CDKN2B", "label": "CDKN2B"}}, {"data": {"id": "Abemaciclib, fulvestrant, palbociclib, ribociclib", "label": "Abemaciclib, fulvestrant, palbociclib, ribociclib"}}, {"data": {"id": "Osimertinib", "label": "Osimertinib"}}, {"data": {"id": "NRAS melanoma", "label": "NRAS melanoma"}}, {"data": {"id": "Estrogen receptor-positive breast tumors", "label": "Estrogen receptor-positive breast tumors"}}, {"data": {"id": "Pancreatic ductal adenocarcinoma", "label": "Pancreatic ductal adenocarcinoma"}}, {"data": {"id": "BRAF inhibitor-resistant tumor", "label": "BRAF inhibitor-resistant tumor"}}, {"data": {"id": "MDM2 inhibitors", "label": "MDM2 inhibitors"}}, {"data": {"id": "MEK inhibitors", "label": "MEK inhibitors"}}, {"data": {"id": "Tucatinib, letrozole, palbociclib", "label": "Tucatinib, letrozole, palbociclib"}}, {"data": {"id": "ARMS", "label": "ARMS"}}, {"data": {"id": "HER2-directed therapy, Chemotherapy", "label": "HER2-directed therapy, Chemotherapy"}}, {"data": {"id": "Pituitary tumours", "label": "Pituitary tumours"}}, {"data": {"id": "PDCs", "label": "PDCs"}}, {"data": {"id": "Luminal A cancer", "label": "Luminal A cancer"}}, {"data": {"id": "NIH3T3 fibroblasts", "label": "NIH3T3 fibroblasts"}}, {"data": {"id": "GBM (glioblastoma)", "label": "GBM (glioblastoma)"}}, {"data": {"id": "PDAC", "label": "PDAC"}}, {"data": {"id": "BCC", "label": "BCC"}}, {"data": {"id": "cis-nerolidol,trans-nerolidol", "label": "cis-nerolidol,trans-nerolidol"}}, {"data": {"id": "Squamous cell lung cancer", "label": "Squamous cell lung cancer"}}, {"data": {"id": "p53 pathway", "label": "p53 pathway"}}, {"data": {"id": "Camizestrant", "label": "Camizestrant"}}, {"data": {"id": "Camizestrant, Fulvestrant", "label": "Camizestrant, Fulvestrant"}}, {"data": {"id": "Talazoparib", "label": "Talazoparib"}}, {"data": {"id": "Gallbladder cancer", "label": "Gallbladder cancer"}}, {"data": {"id": "Primary lesion, Metastatic lesion", "label": "Primary lesion, Metastatic lesion"}}, {"data": {"id": "Ewing's sarcoma", "label": "Ewing's sarcoma"}}, {"data": {"id": "CDK4/6,IGF1R/FGFR/EGFR", "label": "CDK4/6,IGF1R/FGFR/EGFR"}}, {"data": {"id": "12q13-15 region", "label": "12q13-15 region"}}, {"data": {"id": "Oligodendroglioma", "label": "Oligodendroglioma"}}, {"data": {"id": "SERD, SSH-CDK4/6 inhibitors", "label": "SERD, SSH-CDK4/6 inhibitors"}}, {"data": {"id": "HMBA", "label": "HMBA"}}, {"data": {"id": "pRB", "label": "pRB"}}, {"data": {"id": "elacestrant, fulvestrant", "label": "elacestrant, fulvestrant"}}, {"data": {"id": "HAOSMCs", "label": "HAOSMCs"}}, {"data": {"id": "Sclerosing liposarcoma", "label": "Sclerosing liposarcoma"}}, {"data": {"id": "CDK4/6 inhibitors, Endocrine therapy", "label": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"id": "Head and neck tumors", "label": "Head and neck tumors"}}, {"data": {"id": "Anti-MDM2 therapies", "label": "Anti-MDM2 therapies"}}, {"data": {"id": "EGFR inhibitors, HER2 inhibitors", "label": "EGFR inhibitors, HER2 inhibitors"}}, {"data": {"id": "Fibroblasts", "label": "Fibroblasts"}}, {"data": {"id": "PIK3CA-mutated advanced breast cancer", "label": "PIK3CA-mutated advanced breast cancer"}}, {"data": {"id": "Human tumor cell lines", "label": "Human tumor cell lines"}}, {"data": {"id": "S6K1", "label": "S6K1"}}, {"data": {"id": "Resistant tumors", "label": "Resistant tumors"}}, {"data": {"id": "MEK inhibitors, CDK4/6 inhibitors", "label": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "Pleomorphic xanthoastrocytoma", "label": "Pleomorphic xanthoastrocytoma"}}, {"data": {"id": "Diabetes", "label": "Diabetes"}}, {"data": {"id": "Cell cycle", "label": "Cell cycle"}}, {"data": {"id": "RAS-MAPK", "label": "RAS-MAPK"}}, {"data": {"id": "SAHA", "label": "SAHA"}}, {"data": {"id": "Advanced-stage breast cancer", "label": "Advanced-stage breast cancer"}}, {"data": {"id": "Growth factor receptor signaling", "label": "Growth factor receptor signaling"}}, {"data": {"id": "Senescence escape", "label": "Senescence escape"}}, {"data": {"id": "Lymphoid tumors", "label": "Lymphoid tumors"}}, {"data": {"id": "PI3K inhibitors", "label": "PI3K inhibitors"}}, {"data": {"id": "Endocrine-resistant breast cancer", "label": "Endocrine-resistant breast cancer"}}, {"data": {"id": "DDLPS", "label": "DDLPS"}}, {"data": {"id": "Hepatocellular carcinoma", "label": "Hepatocellular carcinoma"}}, {"data": {"id": "Squamous cell carcinoma", "label": "Squamous cell carcinoma"}}, {"data": {"id": "BRAF inhibitors, MEK inhibitors", "label": "BRAF inhibitors, MEK inhibitors"}}, {"data": {"id": "Leukemia", "label": "Leukemia"}}, {"data": {"id": "hMSCs", "label": "hMSCs"}}, {"data": {"id": "Placental explants", "label": "Placental explants"}}, {"data": {"id": "p53(wild-type)", "label": "p53(wild-type)"}}, {"data": {"id": "Multiple myeloma", "label": "Multiple myeloma"}}, {"data": {"id": "HGC-27 cells", "label": "HGC-27 cells"}}, {"data": {"id": "Piceatannol", "label": "Piceatannol"}}, {"data": {"id": "Endosulfan", "label": "Endosulfan"}}, {"data": {"id": "CDK4/6 inhibitors, immunotherapy", "label": "CDK4/6 inhibitors, immunotherapy"}}, {"data": {"id": "Non-clear cell RCC", "label": "Non-clear cell RCC"}}, {"data": {"id": "RAR signaling", "label": "RAR signaling"}}, {"data": {"id": "MAPK, Akt", "label": "MAPK, Akt"}}, {"data": {"id": "Carcinomas", "label": "Carcinomas"}}, {"data": {"id": "H3B-6545", "label": "H3B-6545"}}, {"data": {"id": "PI3K/AKT/mTOR pathway", "label": "PI3K/AKT/mTOR pathway"}}, {"data": {"id": "ECFCs", "label": "ECFCs"}}, {"data": {"id": "TNBC cell lines", "label": "TNBC cell lines"}}, {"data": {"id": "CMT cells", "label": "CMT cells"}}, {"data": {"id": "Endocrine therapy-resistant breast cancer", "label": "Endocrine therapy-resistant breast cancer"}}, {"data": {"id": "abemaciclib", "label": "abemaciclib"}}, {"data": {"id": "PEComa", "label": "PEComa"}}, {"data": {"id": "Alveolar subtype", "label": "Alveolar subtype"}}, {"data": {"id": "Cancer predisposition syndrome", "label": "Cancer predisposition syndrome"}}, {"data": {"id": "Cyclin D1-CDK4/6-retinoblastoma pathway", "label": "Cyclin D1-CDK4/6-retinoblastoma pathway"}}, {"data": {"id": "MDA-MB-231 cells", "label": "MDA-MB-231 cells"}}, {"data": {"id": "9za", "label": "9za"}}, {"data": {"id": "RMC-6272", "label": "RMC-6272"}}, {"data": {"id": "BBR", "label": "BBR"}}, {"data": {"id": "diabetes", "label": "diabetes"}}, {"data": {"id": "UHGPS,DDL", "label": "UHGPS,DDL"}}, {"data": {"id": "Palbociclib", "label": "Palbociclib"}}, {"data": {"id": "Cell-cycle pathway", "label": "Cell-cycle pathway"}}, {"data": {"id": "Senescence", "label": "Senescence"}}, {"data": {"id": "Soft tissue metastasis", "label": "Soft tissue metastasis"}}, {"data": {"id": "Multiple myeloma (MM)", "label": "Multiple myeloma (MM)"}}, {"data": {"id": "Liposarcoma (LPS)", "label": "Liposarcoma (LPS)"}}, {"data": {"id": "Parosteal osteosarcoma", "label": "Parosteal osteosarcoma"}}, {"data": {"id": "Uveal melanoma", "label": "Uveal melanoma"}}, {"data": {"id": "RB1-deficient tumors", "label": "RB1-deficient tumors"}}, {"data": {"id": "Lung metastases", "label": "Lung metastases"}}, {"data": {"id": "Thymic lymphomas", "label": "Thymic lymphomas"}}, {"data": {"id": "Cholangiocarcinoma", "label": "Cholangiocarcinoma"}}, {"data": {"id": "LEE011", "label": "LEE011"}}, {"data": {"id": "Fibrosarcomatous DFSP", "label": "Fibrosarcomatous DFSP"}}, {"data": {"id": "Oral squamous cell carcinoma", "label": "Oral squamous cell carcinoma"}}, {"data": {"id": "CDK4/CDK6-cyclin D1 pathway", "label": "CDK4/CDK6-cyclin D1 pathway"}}, {"data": {"id": "CDK4/6 inhibitors,ET", "label": "CDK4/6 inhibitors,ET"}}, {"data": {"id": "NF-魏B", "label": "NF-魏B"}}, {"data": {"id": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT", "label": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"id": "B-cell neoplasms", "label": "B-cell neoplasms"}}, {"data": {"id": "ALL T, ATL, CML", "label": "ALL T, ATL, CML"}}, {"data": {"id": "Astrocytomas", "label": "Astrocytomas"}}, {"data": {"id": "Advanced estrogen receptor-positive, HER2-negative breast cancer", "label": "Advanced estrogen receptor-positive, HER2-negative breast cancer"}}, {"data": {"id": "ICC", "label": "ICC"}}, {"data": {"id": "Vitamin K2, Vitamin K3", "label": "Vitamin K2, Vitamin K3"}}, {"data": {"id": "HCC cells", "label": "HCC cells"}}, {"data": {"id": "ERα-positive breast cancer", "label": "ERα-positive breast cancer"}}, {"data": {"id": "Bone tumor", "label": "Bone tumor"}}, {"data": {"id": "JNK/CDK4-dependent pSmad3L", "label": "JNK/CDK4-dependent pSmad3L"}}, {"data": {"id": "Plasmacytoma", "label": "Plasmacytoma"}}, {"data": {"id": "mTOR inhibitors", "label": "mTOR inhibitors"}}, {"data": {"id": "OSCC", "label": "OSCC"}}, {"data": {"id": "Melanoma, Pancreatic cancer", "label": "Melanoma, Pancreatic cancer"}}, {"data": {"id": "Tumor", "label": "Tumor"}}, {"data": {"id": "metastatic breast cancer", "label": "metastatic breast cancer"}}, {"data": {"id": "Acral melanoma", "label": "Acral melanoma"}}, {"data": {"id": "stromal cells", "label": "stromal cells"}}, {"data": {"id": "Piqray, Fulvestrant", "label": "Piqray, Fulvestrant"}}, {"data": {"id": "Primary lesion", "label": "Primary lesion"}}, {"data": {"id": "PMM", "label": "PMM"}}, {"data": {"id": "Inflammatory MFH", "label": "Inflammatory MFH"}}, {"data": {"id": "MCF-7 breast cancer cells", "label": "MCF-7 breast cancer cells"}}, {"data": {"id": "EGFR", "label": "EGFR"}}, {"data": {"id": "CDK4/6-RB pathway", "label": "CDK4/6-RB pathway"}}, {"data": {"id": "Cell cycle pathway", "label": "Cell cycle pathway"}}, {"data": {"id": "Osimertinib, palbociclib", "label": "Osimertinib, palbociclib"}}, {"data": {"id": "IL-17 signaling", "label": "IL-17 signaling"}}, {"data": {"id": "FPA", "label": "FPA"}}, {"data": {"id": "CDK4/6 inhibitors, anti-HER2", "label": "CDK4/6 inhibitors, anti-HER2"}}, {"data": {"id": "Malignant mesothelioma", "label": "Malignant mesothelioma"}}, {"data": {"id": "Tumor cells", "label": "Tumor cells"}}, {"data": {"id": "Chordoma", "label": "Chordoma"}}, {"data": {"id": "Notch, PI3K/AKT", "label": "Notch, PI3K/AKT"}}, {"data": {"id": "pituitary cells", "label": "pituitary cells"}}, {"data": {"id": "Familial malignant melanoma", "label": "Familial malignant melanoma"}}, {"data": {"id": "CDK4/6,Erk1/2", "label": "CDK4/6,Erk1/2"}}, {"data": {"id": "p53, p16", "label": "p53, p16"}}, {"data": {"id": "Hormone-resistant tumors", "label": "Hormone-resistant tumors"}}, {"data": {"id": "FAMMM", "label": "FAMMM"}}, {"data": {"id": "MCF7", "label": "MCF7"}}, {"data": {"id": "Quercetin", "label": "Quercetin"}}, {"data": {"id": "H3B-6545, fulvestrant", "label": "H3B-6545, fulvestrant"}}, {"data": {"id": "DPedHGG", "label": "DPedHGG"}}, {"data": {"id": "Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors", "label": "Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "PI3K, AKT", "label": "PI3K, AKT"}}, {"data": {"id": "Undifferentiated sarcoma", "label": "Undifferentiated sarcoma"}}, {"data": {"id": "TGFB", "label": "TGFB"}}, {"data": {"id": "Circulating tumor cells", "label": "Circulating tumor cells"}}, {"data": {"id": "Trametinib, Dabrafenib", "label": "Trametinib, Dabrafenib"}}, {"data": {"id": "KRAS inhibitors, PI3K inhibitors, HSP90 inhibitors, CDK4/6 inhibitors, SHP2 inhibitors", "label": "KRAS inhibitors, PI3K inhibitors, HSP90 inhibitors, CDK4/6 inhibitors, SHP2 inhibitors"}}, {"data": {"id": "MTORC1, E2F, MYC", "label": "MTORC1, E2F, MYC"}}, {"data": {"id": "Thick melanoma", "label": "Thick melanoma"}}, {"data": {"id": "Doxorubicin", "label": "Doxorubicin"}}, {"data": {"id": "mTORC1", "label": "mTORC1"}}, {"data": {"id": "KT", "label": "KT"}}, {"data": {"id": "MCF-7, MDA-MB-231", "label": "MCF-7, MDA-MB-231"}}, {"data": {"id": "Leukemia, many cancers", "label": "Leukemia, many cancers"}}, {"data": {"id": "mTOR inhibitors, BRAF inhibitors, MEK inhibitors", "label": "mTOR inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"id": "Glioma cell lines", "label": "Glioma cell lines"}}, {"data": {"id": "doxorubicin", "label": "doxorubicin"}}, {"data": {"id": "PD-0332991", "label": "PD-0332991"}}, {"data": {"id": "Recurrent tumors", "label": "Recurrent tumors"}}, {"data": {"id": "Triple negative cancer", "label": "Triple negative cancer"}}, {"data": {"id": "Cyclin D-CDK4/6-Rb-INK4", "label": "Cyclin D-CDK4/6-Rb-INK4"}}, {"data": {"id": "Liposarcoma, lipoma, liponecrosis", "label": "Liposarcoma, lipoma, liponecrosis"}}, {"data": {"id": "IB-MECA", "label": "IB-MECA"}}, {"data": {"id": "MAPK, mTORC1/p70S6K, src/FAK", "label": "MAPK, mTORC1/p70S6K, src/FAK"}}, {"data": {"id": "Everolimus, sunitinib", "label": "Everolimus, sunitinib"}}, {"data": {"id": "IBC", "label": "IBC"}}, {"data": {"id": "HPV(U) tumors", "label": "HPV(U) tumors"}}, {"data": {"id": "GAA", "label": "GAA"}}, {"data": {"id": "MEK, p38, ERK1/2", "label": "MEK, p38, ERK1/2"}}, {"data": {"id": "Oligodendrogliomas", "label": "Oligodendrogliomas"}}, {"data": {"id": "Endometrial carcinomas", "label": "Endometrial carcinomas"}}, {"data": {"id": "Soft tissue sarcoma", "label": "Soft tissue sarcoma"}}, {"data": {"id": "PI3K pathway", "label": "PI3K pathway"}}, {"data": {"id": "HLCA", "label": "HLCA"}}, {"data": {"id": "Myeloma", "label": "Myeloma"}}, {"data": {"id": "Pituitary gland", "label": "Pituitary gland"}}, {"data": {"id": "PDX mouse models", "label": "PDX mouse models"}}, {"data": {"id": "POS", "label": "POS"}}, {"data": {"id": "Breast cancer cells", "label": "Breast cancer cells"}}, {"data": {"id": "CDK4/6 inhibitors, BRAF inhibitors, MEK inhibitors", "label": "CDK4/6 inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"id": "Metastatic NPC", "label": "Metastatic NPC"}}, {"data": {"id": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma", "label": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma"}}, {"data": {"id": "AKT1", "label": "AKT1"}}, {"data": {"id": "palbociclib,celecoxib", "label": "palbociclib,celecoxib"}}, {"data": {"id": "G1 phase", "label": "G1 phase"}}, {"data": {"id": "Gastric cancer", "label": "Gastric cancer"}}, {"data": {"id": "Neoplasms", "label": "Neoplasms"}}, {"data": {"id": "EGFR inhibitors", "label": "EGFR inhibitors"}}, {"data": {"id": "Tumor recurrence", "label": "Tumor recurrence"}}, {"data": {"id": "Breast cancer cell lines", "label": "Breast cancer cell lines"}}, {"data": {"id": "G1-phase pathway", "label": "G1-phase pathway"}}, {"data": {"id": "Retinoblastoma", "label": "Retinoblastoma"}}, {"data": {"id": "PI3K/AKT, PTEN, mTOR", "label": "PI3K/AKT, PTEN, mTOR"}}, {"data": {"id": "Cyclin D-CDK4/6-INK4-Rb", "label": "Cyclin D-CDK4/6-INK4-Rb"}}, {"data": {"id": "Neuroblastic tumors", "label": "Neuroblastic tumors"}}, {"data": {"id": "Head and neck squamous cell carcinoma", "label": "Head and neck squamous cell carcinoma"}}, {"data": {"id": "Rosiglitazone", "label": "Rosiglitazone"}}, {"data": {"id": "Notopterol", "label": "Notopterol"}}, {"data": {"id": "Dermatofibrosarcoma protuberans", "label": "Dermatofibrosarcoma protuberans"}}, {"data": {"id": "Mantle cell NHL", "label": "Mantle cell NHL"}}, {"data": {"id": "Medulloblastoma (Group3/4)", "label": "Medulloblastoma (Group3/4)"}}, {"data": {"id": "Myeloma cells", "label": "Myeloma cells"}}, {"data": {"id": "Lung adenocarcinoma, liposarcoma", "label": "Lung adenocarcinoma, liposarcoma"}}, {"data": {"id": "PIK3CA", "label": "PIK3CA"}}, {"data": {"id": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN", "label": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"id": "Cervical cancer cell lines", "label": "Cervical cancer cell lines"}}, {"data": {"id": "NF1", "label": "NF1"}}, {"data": {"id": "Intimal sarcoma", "label": "Intimal sarcoma"}}, {"data": {"id": "Neuronal cells", "label": "Neuronal cells"}}, {"data": {"id": "Metastases to pelvis and spine", "label": "Metastases to pelvis and spine"}}, {"data": {"id": "Lung adenocarcinoma (LUAD)", "label": "Lung adenocarcinoma (LUAD)"}}, {"data": {"id": "DLOS", "label": "DLOS"}}, {"data": {"id": "Atypical lipomatous tumor, well-differentiated liposarcoma, dedifferentiated liposarcoma", "label": "Atypical lipomatous tumor, well-differentiated liposarcoma, dedifferentiated liposarcoma"}}, {"data": {"id": "Bortezomib", "label": "Bortezomib"}}, {"data": {"id": "MEK", "label": "MEK"}}, {"data": {"id": "Palbociclib, Letrozole", "label": "Palbociclib, Letrozole"}}, {"data": {"id": "Cervical carcinoma", "label": "Cervical carcinoma"}}, {"data": {"id": "Human cancers", "label": "Human cancers"}}, {"data": {"id": "ALT/WDL", "label": "ALT/WDL"}}, {"data": {"id": "ERBB2 inhibitors, EGFR inhibitors", "label": "ERBB2 inhibitors, EGFR inhibitors"}}, {"data": {"id": "Hereditary melanoma", "label": "Hereditary melanoma"}}, {"data": {"id": "thyroid tumor", "label": "thyroid tumor"}}, {"data": {"id": "Ovarian tumors", "label": "Ovarian tumors"}}, {"data": {"id": "Primary human melanocytes", "label": "Primary human melanocytes"}}, {"data": {"id": "Melanoma, multiple cancers", "label": "Melanoma, multiple cancers"}}, {"data": {"id": "CDK4/6 inhibitors,mTOR inhibitors", "label": "CDK4/6 inhibitors,mTOR inhibitors"}}, {"data": {"id": "MBC", "label": "MBC"}}, {"data": {"id": "NOTCH", "label": "NOTCH"}}, {"data": {"id": "TP53", "label": "TP53"}}, {"data": {"id": "NMBA", "label": "NMBA"}}, {"data": {"id": "MTOR", "label": "MTOR"}}, {"data": {"id": "Cyclin D-CDK4/6-Rb pathway", "label": "Cyclin D-CDK4/6-Rb pathway"}}, {"data": {"id": "mTORC1/2,CDK4/6", "label": "mTORC1/2,CDK4/6"}}, {"data": {"id": "ER(+)/FGFR1(+) metastatic breast cancer", "label": "ER(+)/FGFR1(+) metastatic breast cancer"}}, {"data": {"id": "Imatinib", "label": "Imatinib"}}, {"data": {"id": "Salidroside", "label": "Salidroside"}}, {"data": {"id": "Advanced sarcomas", "label": "Advanced sarcomas"}}, {"data": {"id": "Intestinal adenomas", "label": "Intestinal adenomas"}}, {"data": {"id": "multiciliated cells", "label": "multiciliated cells"}}, {"data": {"id": "HR+, HER2- breast cancer", "label": "HR+, HER2- breast cancer"}}, {"data": {"id": "CDK4/6 inhibitors, BRAF/MEK-targeting agents", "label": "CDK4/6 inhibitors, BRAF/MEK-targeting agents"}}, {"data": {"id": "OVCAR-3, Caov-4", "label": "OVCAR-3, Caov-4"}}, {"data": {"id": "Malignant melanoma", "label": "Malignant melanoma"}}, {"data": {"id": "Pleural tumor", "label": "Pleural tumor"}}, {"data": {"id": "Atypical spindle cell/pleomorphic lipomatous tumor", "label": "Atypical spindle cell/pleomorphic lipomatous tumor"}}, {"data": {"id": "P114,CF41 cells", "label": "P114,CF41 cells"}}, {"data": {"id": "Inhibitors of CDK4 and MDM2", "label": "Inhibitors of CDK4 and MDM2"}}, {"data": {"id": "Retinoblastoma pathway", "label": "Retinoblastoma pathway"}}, {"data": {"id": "Thin melanoma", "label": "Thin melanoma"}}, {"data": {"id": "Ovarian cancer", "label": "Ovarian cancer"}}, {"data": {"id": "mTOR inhibitors, CDK4/6 inhibitors", "label": "mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "OVCAR-3, Caov-4 cell lines", "label": "OVCAR-3, Caov-4 cell lines"}}, {"data": {"id": "Encorafenib, Cetuximab, CDK4/6 inhibitors", "label": "Encorafenib, Cetuximab, CDK4/6 inhibitors"}}, {"data": {"id": "TP53-modulating drugs", "label": "TP53-modulating drugs"}}, {"data": {"id": "High-grade astrocytomas, glioma", "label": "High-grade astrocytomas, glioma"}}, {"data": {"id": "Metastatic ER+ breast cancer", "label": "Metastatic ER+ breast cancer"}}, {"data": {"id": "Cancer", "label": "Cancer"}}, {"data": {"id": "RB pathway", "label": "RB pathway"}}, {"data": {"id": "MGC-803 cells", "label": "MGC-803 cells"}}, {"data": {"id": "Rb pathway", "label": "Rb pathway"}}, {"data": {"id": "multi-kinase inhibitors", "label": "multi-kinase inhibitors"}}, {"data": {"id": "Gastric carcinoma", "label": "Gastric carcinoma"}}, {"data": {"id": "ER+ breast cancer", "label": "ER+ breast cancer"}}, {"data": {"id": "Primary cells", "label": "Primary cells"}}, {"data": {"id": "TMOC", "label": "TMOC"}}, {"data": {"id": "Pediatric ALL", "label": "Pediatric ALL"}}, {"data": {"id": "PTEN-related pathways", "label": "PTEN-related pathways"}}, {"data": {"id": "Acral melanoma (AM)", "label": "Acral melanoma (AM)"}}, {"data": {"id": "p-SCs", "label": "p-SCs"}}, {"data": {"id": "NF1-associated PNF", "label": "NF1-associated PNF"}}, {"data": {"id": "tumor", "label": "tumor"}}, {"data": {"id": "Mucosal melanomas", "label": "Mucosal melanomas"}}, {"data": {"id": "Myeloproliferative neoplasms (MPN)", "label": "Myeloproliferative neoplasms (MPN)"}}, {"data": {"id": "GBM cells", "label": "GBM cells"}}, {"data": {"id": "CDK inhibitors", "label": "CDK inhibitors"}}, {"data": {"id": "TP53 pathway", "label": "TP53 pathway"}}, {"data": {"id": "Well-differentiated liposarcomas, Dedifferentiated liposarcomas", "label": "Well-differentiated liposarcomas, Dedifferentiated liposarcomas"}}, {"data": {"id": "Endocrine signaling", "label": "Endocrine signaling"}}, {"data": {"id": "CD34+ cells", "label": "CD34+ cells"}}, {"data": {"id": "Epithelial cancers", "label": "Epithelial cancers"}}, {"data": {"id": "Palbociclib,BRAF inhibitors,MEK inhibitors", "label": "Palbociclib,BRAF inhibitors,MEK inhibitors"}}, {"data": {"id": "RAS/MAPK", "label": "RAS/MAPK"}}, {"data": {"id": "Liver tumor", "label": "Liver tumor"}}, {"data": {"id": "Skin tumors", "label": "Skin tumors"}}, {"data": {"id": "AB680", "label": "AB680"}}, {"data": {"id": "Metastases", "label": "Metastases"}}, {"data": {"id": "Lung cancer", "label": "Lung cancer"}}, {"data": {"id": "Penile squamous cell carcinoma", "label": "Penile squamous cell carcinoma"}}, {"data": {"id": "PeSCCA", "label": "PeSCCA"}}, {"data": {"id": "Low-grade gliomas", "label": "Low-grade gliomas"}}, {"data": {"id": "Oral cancer, OSCC", "label": "Oral cancer, OSCC"}}, {"data": {"id": "Extramammary Paget's disease (EMPD)", "label": "Extramammary Paget's disease (EMPD)"}}, {"data": {"id": "CDK4/6-Rb-E2F pathway", "label": "CDK4/6-Rb-E2F pathway"}}, {"data": {"id": "PI3K-mTOR pathway,RAS/RAF/MAPK pathway", "label": "PI3K-mTOR pathway,RAS/RAF/MAPK pathway"}}, {"data": {"id": "EESB", "label": "EESB"}}, {"data": {"id": "Cervical cancer", "label": "Cervical cancer"}}, {"data": {"id": "Metastatic breast cancer", "label": "Metastatic breast cancer"}}, {"data": {"id": "Atherosclerosis, Type 2 diabetes mellitus (T2DM)", "label": "Atherosclerosis, Type 2 diabetes mellitus (T2DM)"}}, {"data": {"id": "ERK1/2", "label": "ERK1/2"}}, {"data": {"id": "Cell-cycle markers", "label": "Cell-cycle markers"}}, {"data": {"id": "ARV-825, Fulvestrant, Palbociclib", "label": "ARV-825, Fulvestrant, Palbociclib"}}, {"data": {"id": "Aromatase inhibitors, mTOR inhibitors, CDK4/6 inhibitors", "label": "Aromatase inhibitors, mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "NF-魏B, AKT", "label": "NF-魏B, AKT"}}, {"data": {"id": "Retroperitoneal pleomorphic MFH, dedifferentiated liposarcoma", "label": "Retroperitoneal pleomorphic MFH, dedifferentiated liposarcoma"}}, {"data": {"id": "Breast cancer cell lines, PDX models", "label": "Breast cancer cell lines, PDX models"}}, {"data": {"id": "BRCA(mut)/TNBC", "label": "BRCA(mut)/TNBC"}}, {"data": {"id": "Atypical meningiomas", "label": "Atypical meningiomas"}}, {"data": {"id": "TGF beta", "label": "TGF beta"}}, {"data": {"id": "IS", "label": "IS"}}, {"data": {"id": "BRAF/MEK inhibitors", "label": "BRAF/MEK inhibitors"}}, {"data": {"id": "ESR1", "label": "ESR1"}}, {"data": {"id": "Anti-estrogens", "label": "Anti-estrogens"}}, {"data": {"id": "GBM, GS", "label": "GBM, GS"}}, {"data": {"id": "Advanced/metastatic breast cancer", "label": "Advanced/metastatic breast cancer"}}, {"data": {"id": "Astrocytic tumor, Oligodendroglial tumor", "label": "Astrocytic tumor, Oligodendroglial tumor"}}, {"data": {"id": "VEGF inhibitors, mTOR inhibitors", "label": "VEGF inhibitors, mTOR inhibitors"}}, {"data": {"id": "Chordoma cells", "label": "Chordoma cells"}}, {"data": {"id": "HaCaT cells", "label": "HaCaT cells"}}, {"data": {"id": "Cyclin D/CDK4", "label": "Cyclin D/CDK4"}}, {"data": {"id": "Familial melanoma, Sporadic melanoma", "label": "Familial melanoma, Sporadic melanoma"}}, {"data": {"id": "p16INK4/CDK4/RB", "label": "p16INK4/CDK4/RB"}}, {"data": {"id": "Neurofibromas, malignant peripheral nerve sheath tumors", "label": "Neurofibromas, malignant peripheral nerve sheath tumors"}}, {"data": {"id": "Juvenile ossifying fibroma (JOF)", "label": "Juvenile ossifying fibroma (JOF)"}}, {"data": {"id": "MAPK, PI3K, CDK4/6", "label": "MAPK, PI3K, CDK4/6"}}, {"data": {"id": "Necitumumab, afatinib, erlotinib", "label": "Necitumumab, afatinib, erlotinib"}}, {"data": {"id": "Disease", "label": "Disease"}}, {"data": {"id": "MCF-7 cells", "label": "MCF-7 cells"}}, {"data": {"id": "Acral melanocytic nevus", "label": "Acral melanocytic nevus"}}, {"data": {"id": "PDX models, PDCs", "label": "PDX models, PDCs"}}, {"data": {"id": "Prostate carcinoma", "label": "Prostate carcinoma"}}, {"data": {"id": "Rb-CDK4, p53 pathways", "label": "Rb-CDK4, p53 pathways"}}, {"data": {"id": "Malignant astrocytomas", "label": "Malignant astrocytomas"}}, {"data": {"id": "Tumors", "label": "Tumors"}}, {"data": {"id": "HPV(neg) HNSCC cell lines", "label": "HPV(neg) HNSCC cell lines"}}, {"data": {"id": "Primary GBM cell lines", "label": "Primary GBM cell lines"}}, {"data": {"id": "PTEN", "label": "PTEN"}}, {"data": {"id": "Rb1", "label": "Rb1"}}, {"data": {"id": "HCC", "label": "HCC"}}, {"data": {"id": "MDM2", "label": "MDM2"}}, {"data": {"id": "CDKN2A-CCND-CDK4/6-Rb", "label": "CDKN2A-CCND-CDK4/6-Rb"}}, {"data": {"id": "Anaplasia", "label": "Anaplasia"}}, {"data": {"id": "AST", "label": "AST"}}, {"data": {"id": "3-carene", "label": "3-carene"}}, {"data": {"id": "MAPK, AKT, STAT3, Src, Abl", "label": "MAPK, AKT, STAT3, Src, Abl"}}, {"data": {"id": "EGFR-TKIs", "label": "EGFR-TKIs"}}, {"data": {"id": "Amplified tumors", "label": "Amplified tumors"}}, {"data": {"id": "Astrocytomas, glioma", "label": "Astrocytomas, glioma"}}, {"data": {"id": "Leiomyosarcomatous cells", "label": "Leiomyosarcomatous cells"}}, {"data": {"id": "Oral cancer", "label": "Oral cancer"}}, {"data": {"id": "MCF-7", "label": "MCF-7"}}, {"data": {"id": "deucravacitinib, CDK4/6 inhibitors, mTOR inhibitors", "label": "deucravacitinib, CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"id": "Antiestrogens", "label": "Antiestrogens"}}, {"data": {"id": "Well-differentiated liposarcoma, Dedifferentiated liposarcoma", "label": "Well-differentiated liposarcoma, Dedifferentiated liposarcoma"}}, {"data": {"id": "Familial melanoma", "label": "Familial melanoma"}}, {"data": {"id": "Lower grade astrocytomas", "label": "Lower grade astrocytomas"}}, {"data": {"id": "Inflammatory myofibroblastic tumor", "label": "Inflammatory myofibroblastic tumor"}}, {"data": {"id": "Abiraterone", "label": "Abiraterone"}}, {"data": {"id": "Hematopoietic malignancies", "label": "Hematopoietic malignancies"}}, {"data": {"id": "Neoadjuvant therapy", "label": "Neoadjuvant therapy"}}, {"data": {"id": "Skin cancer", "label": "Skin cancer"}}, {"data": {"id": "ALL", "label": "ALL"}}, {"data": {"id": "ER-positive breast cancer", "label": "ER-positive breast cancer"}}, {"data": {"id": "ALT/WDL, DDLPS", "label": "ALT/WDL, DDLPS"}}, {"data": {"id": "Immune-refractory cancer", "label": "Immune-refractory cancer"}}, {"data": {"id": "CD34+ progenitors", "label": "CD34+ progenitors"}}, {"data": {"id": "EAs", "label": "EAs"}}, {"data": {"id": "EGFR-TKI pathway", "label": "EGFR-TKI pathway"}}, {"data": {"id": "Glioblastomas", "label": "Glioblastomas"}}, {"data": {"id": "PMA", "label": "PMA"}}, {"data": {"id": "pRb-competent cells", "label": "pRb-competent cells"}}, {"data": {"id": "Metastatic extramammary Paget's disease", "label": "Metastatic extramammary Paget's disease"}}, {"data": {"id": "CCNE1", "label": "CCNE1"}}, {"data": {"id": "RP sarcoma", "label": "RP sarcoma"}}, {"data": {"id": "Human tumors", "label": "Human tumors"}}, {"data": {"id": "Ovarian tumor", "label": "Ovarian tumor"}}, {"data": {"id": "AKT/mTOR axis", "label": "AKT/mTOR axis"}}, {"data": {"id": "Low-grade serous ovarian cancer (LGSC)", "label": "Low-grade serous ovarian cancer (LGSC)"}}, {"data": {"id": "Malignant peripheral nerve sheath tumors", "label": "Malignant peripheral nerve sheath tumors"}}, {"data": {"id": "Estrogen receptor-positive breast cancer", "label": "Estrogen receptor-positive breast cancer"}}, {"data": {"id": "HR+/HER2- metastatic breast cancer", "label": "HR+/HER2- metastatic breast cancer"}}, {"data": {"id": "EGFR-amplified tumours", "label": "EGFR-amplified tumours"}}, {"data": {"id": "Artemisinin", "label": "Artemisinin"}}, {"data": {"id": "Soft tissue sarcomas", "label": "Soft tissue sarcomas"}}, {"data": {"id": "Anaplastic oligodendroglioma", "label": "Anaplastic oligodendroglioma"}}, {"data": {"id": "CDK4 inhibitors, MDM2 inhibitors, cediranib, eribulin, crizotinib", "label": "CDK4 inhibitors, MDM2 inhibitors, cediranib, eribulin, crizotinib"}}, {"data": {"id": "osteosarcoma", "label": "osteosarcoma"}}, {"data": {"id": "Advanced non-small cell lung cancer (NSCLC)", "label": "Advanced non-small cell lung cancer (NSCLC)"}}, {"data": {"id": "Cyclin D-dependent kinases", "label": "Cyclin D-dependent kinases"}}, {"data": {"id": "Mesothelioma", "label": "Mesothelioma"}}, {"data": {"id": "Lymphoproliferative disorder (LPD)", "label": "Lymphoproliferative disorder (LPD)"}}, {"data": {"id": "Glioma cells", "label": "Glioma cells"}}, {"data": {"id": "Advanced cancers", "label": "Advanced cancers"}}, {"data": {"id": "Solid tumors", "label": "Solid tumors"}}, {"data": {"id": "Nasopharyngeal carcinoma (NPC)", "label": "Nasopharyngeal carcinoma (NPC)"}}, {"data": {"id": "Mammalian cells", "label": "Mammalian cells"}}, {"data": {"id": "BTC", "label": "BTC"}}, {"data": {"id": "Intestinal carcinogenesis", "label": "Intestinal carcinogenesis"}}, {"data": {"id": "RAS-BRAF", "label": "RAS-BRAF"}}, {"data": {"id": "Flavopiridol,Doxorubicin", "label": "Flavopiridol,Doxorubicin"}}, {"data": {"id": "Breast cancer, cancer", "label": "Breast cancer, cancer"}}, {"data": {"id": "Primary tumor", "label": "Primary tumor"}}, {"data": {"id": "Glial cell transformation", "label": "Glial cell transformation"}}, {"data": {"id": "PKC,MAPK", "label": "PKC,MAPK"}}, {"data": {"id": "Mantle cell lymphoma", "label": "Mantle cell lymphoma"}}, {"data": {"id": "Spindle cell lipoma", "label": "Spindle cell lipoma"}}, {"data": {"id": "GBM, sPNET", "label": "GBM, sPNET"}}, {"data": {"id": "Diet-induced obesity (DIO)", "label": "Diet-induced obesity (DIO)"}}, {"data": {"id": "Resistance in hormone-receptor-positive breast cancer", "label": "Resistance in hormone-receptor-positive breast cancer"}}, {"data": {"id": "Adenocarcinoma", "label": "Adenocarcinoma"}}, {"data": {"id": "Proliferating cells", "label": "Proliferating cells"}}, {"data": {"id": "Lymphoid cells", "label": "Lymphoid cells"}}, {"data": {"id": "Pleural mesothelioma", "label": "Pleural mesothelioma"}}, {"data": {"id": "PD-0332991, LEE011", "label": "PD-0332991, LEE011"}}, {"data": {"id": "PL", "label": "PL"}}, {"data": {"id": "PI3K/Akt/mTOR,CDK4/6/RB", "label": "PI3K/Akt/mTOR,CDK4/6/RB"}}, {"data": {"id": "Liposarcoma (WDLPS, DDLPS)", "label": "Liposarcoma (WDLPS, DDLPS)"}}, {"data": {"id": "Metformin", "label": "Metformin"}}, {"data": {"id": "COS cells, osteoprogenitor C3H10T1/2 cells, chondrogenic RCJ3.1C5.18 cells", "label": "COS cells, osteoprogenitor C3H10T1/2 cells, chondrogenic RCJ3.1C5.18 cells"}}, {"data": {"id": "Myoblasts", "label": "Myoblasts"}}, {"data": {"id": "PI3K/mTOR", "label": "PI3K/mTOR"}}, {"data": {"id": "MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy", "label": "MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy"}}, {"data": {"id": "PI3K-PTEN-AKT-FoxO3a", "label": "PI3K-PTEN-AKT-FoxO3a"}}, {"data": {"id": "Acral melanomas", "label": "Acral melanomas"}}, {"data": {"id": "Bortezomib (BTZ)", "label": "Bortezomib (BTZ)"}}, {"data": {"id": "Colorectal cancer (CRC)", "label": "Colorectal cancer (CRC)"}}, {"data": {"id": "Mannoprotein", "label": "Mannoprotein"}}, {"data": {"id": "Dedifferentiated liposarcoma (DDL), leiomyosarcoma (LMS)", "label": "Dedifferentiated liposarcoma (DDL), leiomyosarcoma (LMS)"}}, {"data": {"id": "Antiandrogen-resistant disease", "label": "Antiandrogen-resistant disease"}}, {"data": {"id": "Rhabdomyosarcoma", "label": "Rhabdomyosarcoma"}}, {"data": {"id": "Gliosarcoma, glioblastoma", "label": "Gliosarcoma, glioblastoma"}}, {"data": {"id": "RB1,TP53", "label": "RB1,TP53"}}, {"data": {"id": "Tumours", "label": "Tumours"}}, {"data": {"id": "Fulvestrant, Capivasertib", "label": "Fulvestrant, Capivasertib"}}, {"data": {"id": "Li-Fraumeni syndrome", "label": "Li-Fraumeni syndrome"}}, {"data": {"id": "Liposarcoma", "label": "Liposarcoma"}}, {"data": {"id": "PI3K/Akt/mTOR", "label": "PI3K/Akt/mTOR"}}, {"data": {"id": "Prostate tumor", "label": "Prostate tumor"}}, {"data": {"id": "palbociclib, trametinib", "label": "palbociclib, trametinib"}}, {"data": {"id": "TGF-β", "label": "TGF-β"}}, {"data": {"id": "palbociclib, doxorubicin, AZD1775", "label": "palbociclib, doxorubicin, AZD1775"}}, {"data": {"id": "TE-1 cells", "label": "TE-1 cells"}}, {"data": {"id": "Canine mammary gland cancer", "label": "Canine mammary gland cancer"}}, {"data": {"id": "Breast cancer, gastric cancer with bone metastasis", "label": "Breast cancer, gastric cancer with bone metastasis"}}, {"data": {"id": "G1 cyclin-dependent kinase", "label": "G1 cyclin-dependent kinase"}}, {"data": {"id": "PI3K inhibitors, FGFR inhibitors, CDK4/6 inhibitors", "label": "PI3K inhibitors, FGFR inhibitors, CDK4/6 inhibitors"}}, {"data": {"id": "Uterine Adenosarcomas", "label": "Uterine Adenosarcomas"}}, {"data": {"id": "EGFR signaling", "label": "EGFR signaling"}}, {"data": {"id": "SCLC", "label": "SCLC"}}, {"data": {"id": "Astrocytes", "label": "Astrocytes"}}, {"data": {"id": "Neuroblastoma cells", "label": "Neuroblastoma cells"}}, {"data": {"id": "ZEN-3694", "label": "ZEN-3694"}}, {"data": {"id": "CDK4-pRb, p53", "label": "CDK4-pRb, p53"}}, {"data": {"id": "Osteosarcoma, Liposarcoma", "label": "Osteosarcoma, Liposarcoma"}}, {"data": {"id": "Trastuzumab deruxtecan", "label": "Trastuzumab deruxtecan"}}, {"data": {"id": "Basal cell carcinoma", "label": "Basal cell carcinoma"}}, {"data": {"id": "Colorectal cancer", "label": "Colorectal cancer"}}, {"data": {"id": "HR+ ABC", "label": "HR+ ABC"}}, {"data": {"id": "P16(INK4A)-CDK4/6-RB", "label": "P16(INK4A)-CDK4/6-RB"}}, {"data": {"id": "alpelisib", "label": "alpelisib"}}, {"data": {"id": "Marginal zone lymphoma/Splenic B-cell lymphoma", "label": "Marginal zone lymphoma/Splenic B-cell lymphoma"}}, {"data": {"id": "Anaplastic oligodendrogliomas", "label": "Anaplastic oligodendrogliomas"}}, {"data": {"id": "Gliomas, Sarcomas, Melanoma, Breast cancer, Colorectal cancer", "label": "Gliomas, Sarcomas, Melanoma, Breast cancer, Colorectal cancer"}}, {"data": {"id": "Cyclin D-CDK4,CDK6", "label": "Cyclin D-CDK4,CDK6"}}, {"data": {"id": "Ovarian cancer cells", "label": "Ovarian cancer cells"}}, {"data": {"id": "HEK293T cells", "label": "HEK293T cells"}}, {"data": {"id": "PF-7006", "label": "PF-7006"}}, {"data": {"id": "Hepatocarcinogenesis", "label": "Hepatocarcinogenesis"}}, {"data": {"id": "Akt/GSK-3/Cdc2 pathway", "label": "Akt/GSK-3/Cdc2 pathway"}}, {"data": {"id": "Malignant fibrous histiocytoma", "label": "Malignant fibrous histiocytoma"}}, {"data": {"id": "Estrogen receptor-positive metastatic breast cancer", "label": "Estrogen receptor-positive metastatic breast cancer"}}, {"data": {"id": "Melanoma", "label": "Melanoma"}}, {"data": {"id": "Metaplastic breast carcinoma", "label": "Metaplastic breast carcinoma"}}, {"data": {"id": "Malignant mesothelioma, Other cancers", "label": "Malignant mesothelioma, Other cancers"}}, {"data": {"id": "ALT/WDL, DDL", "label": "ALT/WDL, DDL"}}, {"data": {"id": "WDLPS,DDLPS", "label": "WDLPS,DDLPS"}}, {"data": {"id": "Palbociclib, Everolimus", "label": "Palbociclib, Everolimus"}}, {"data": {"id": "Tucatinib, Palbociclib, Fulvestrant", "label": "Tucatinib, Palbociclib, Fulvestrant"}}, {"data": {"id": "non-IBC", "label": "non-IBC"}}, {"data": {"id": "Glioblastoma, Brain metastases", "label": "Glioblastoma, Brain metastases"}}, {"data": {"id": "PI3K/mTOR, CDK4/6", "label": "PI3K/mTOR, CDK4/6"}}, {"data": {"id": "G1T38", "label": "G1T38"}}, {"data": {"id": "Adult tumors", "label": "Adult tumors"}}, {"data": {"id": "Nasal mixed exocrine-neuroendocrine carcinoma", "label": "Nasal mixed exocrine-neuroendocrine carcinoma"}}, {"data": {"id": "PI3K-AKT, mTOR, CDK4/6", "label": "PI3K-AKT, mTOR, CDK4/6"}}, {"data": {"id": "pRb", "label": "pRb"}}, {"data": {"id": "RP-6306, gemcitabine", "label": "RP-6306, gemcitabine"}}, {"data": {"id": "p16INK4a/cyclin D/CDK4/6/RB pathway", "label": "p16INK4a/cyclin D/CDK4/6/RB pathway"}}, {"data": {"id": "Pediatric medulloblastoma (MB)", "label": "Pediatric medulloblastoma (MB)"}}, {"data": {"id": "Pituitary neuroendocrine tumors (PitNET)", "label": "Pituitary neuroendocrine tumors (PitNET)"}}, {"data": {"id": "Liposarcoma, Lipoma", "label": "Liposarcoma, Lipoma"}}, {"data": {"id": "Rb/p16INK4a/cyclin D-dependent kinase", "label": "Rb/p16INK4a/cyclin D-dependent kinase"}}, {"data": {"id": "Esophageal carcinoma", "label": "Esophageal carcinoma"}}, {"data": {"id": "AML cells", "label": "AML cells"}}, {"data": {"id": "Cancer cells", "label": "Cancer cells"}}, {"data": {"id": "Neuroblasts", "label": "Neuroblasts"}}, {"data": {"id": "HR", "label": "HR"}}, {"data": {"id": "Neoplastic tissue", "label": "Neoplastic tissue"}}, {"data": {"id": "PFE", "label": "PFE"}}, {"data": {"id": "LPS", "label": "LPS"}}, {"data": {"id": "CDK4-cyclin D1 pathway", "label": "CDK4-cyclin D1 pathway"}}, {"data": {"id": "EGFR blockers, CDK4/6 inhibitors", "label": "EGFR blockers, CDK4/6 inhibitors"}}, {"data": {"id": "EGFR, HER2, AKT", "label": "EGFR, HER2, AKT"}}, {"data": {"id": "BRAF pathway", "label": "BRAF pathway"}}, {"data": {"id": "Palbociclib, MLN0128", "label": "Palbociclib, MLN0128"}}, {"data": {"id": "Ubiquitin-proteasome system", "label": "Ubiquitin-proteasome system"}}, {"data": {"id": "HER2-low tumors", "label": "HER2-low tumors"}}, {"data": {"id": "DNA damage response", "label": "DNA damage response"}}, {"data": {"id": "Endocrine therapy", "label": "Endocrine therapy"}}, {"data": {"id": "Liposarcomatous differentiation", "label": "Liposarcomatous differentiation"}}, {"data": {"id": "p53 control, growth signaling, cell cycle control", "label": "p53 control, growth signaling, cell cycle control"}}, {"data": {"id": "Ribociclib, Alpelisib", "label": "Ribociclib, Alpelisib"}}, {"data": {"id": "CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors", "label": "CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors"}}, {"data": {"id": "HPV-positive carcinoma", "label": "HPV-positive carcinoma"}}, {"data": {"id": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma", "label": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"id": "Non-small cell lung carcinoma", "label": "Non-small cell lung carcinoma"}}, {"data": {"id": "Mouse embryo fibroblasts", "label": "Mouse embryo fibroblasts"}}, {"data": {"id": "Tyrosine kinase inhibitors", "label": "Tyrosine kinase inhibitors"}}, {"data": {"id": "vemurafenib", "label": "vemurafenib"}}, {"data": {"id": "Hormone therapy", "label": "Hormone therapy"}}, {"data": {"id": "HER2-positive/HR-positive advanced breast cancer", "label": "HER2-positive/HR-positive advanced breast cancer"}}, {"data": {"id": "PI3K-AKT", "label": "PI3K-AKT"}}, {"data": {"id": "mTORC1/2", "label": "mTORC1/2"}}, {"data": {"id": "Rb-CDK4,p53", "label": "Rb-CDK4,p53"}}, {"data": {"id": "Follicle center lymphomas, extranodal marginal zone lymphomas, mantle cell lymphomas", "label": "Follicle center lymphomas, extranodal marginal zone lymphomas, mantle cell lymphomas"}}, {"data": {"id": "letrozole, everolimus, palbociclib", "label": "letrozole, everolimus, palbociclib"}}, {"data": {"id": "Capivasertib", "label": "Capivasertib"}}, {"data": {"id": "BRAF/MEK, ALK, CDK4/6", "label": "BRAF/MEK, ALK, CDK4/6"}}, {"data": {"id": "ALL, CML, ATL", "label": "ALL, CML, ATL"}}, {"data": {"id": "Wnt signaling", "label": "Wnt signaling"}}, {"data": {"id": "Ependymoma", "label": "Ependymoma"}}, {"data": {"id": "Palbociclib, Abemaciclib", "label": "Palbociclib, Abemaciclib"}}, {"data": {"id": "PD 0332991", "label": "PD 0332991"}}, {"data": {"id": "PI3K inhibitors, HSP90 inhibitors", "label": "PI3K inhibitors, HSP90 inhibitors"}}, {"data": {"id": "CDK4/6 inhibitors", "label": "CDK4/6 inhibitors"}}, {"data": {"id": "RB-deficient cells", "label": "RB-deficient cells"}}, {"data": {"id": "PI3K/AKT/mTOR signaling pathway", "label": "PI3K/AKT/mTOR signaling pathway"}}, {"data": {"id": "Estrogen signaling, HER2 signaling", "label": "Estrogen signaling, HER2 signaling"}}, {"data": {"id": "ERMS", "label": "ERMS"}}, {"data": {"id": "MCA", "label": "MCA"}}, {"data": {"id": "MHPC", "label": "MHPC"}}, {"data": {"id": "Pemrametostat, Fulvestrant", "label": "Pemrametostat, Fulvestrant"}}, {"data": {"id": "Sarcomas", "label": "Sarcomas"}}, {"data": {"id": "Lung squamous cell carcinoma (LUSC)", "label": "Lung squamous cell carcinoma (LUSC)"}}, {"data": {"id": "p38 MAPK", "label": "p38 MAPK"}}, {"data": {"id": "EGFR and HER2 inhibitors", "label": "EGFR and HER2 inhibitors"}}, {"data": {"id": "Rb and p53/MDM2/p14ARF", "label": "Rb and p53/MDM2/p14ARF"}}, {"data": {"id": "COX-2/Wnt", "label": "COX-2/Wnt"}}, {"data": {"id": "Mammary gland tumors", "label": "Mammary gland tumors"}}, {"data": {"id": "MPLPS", "label": "MPLPS"}}, {"data": {"id": "NPC", "label": "NPC"}}, {"data": {"id": "CDK4/6", "label": "CDK4/6"}}, {"data": {"id": "Colon Cancer", "label": "Colon Cancer"}}, {"data": {"id": "Fulvestrant, aromatase inhibitors", "label": "Fulvestrant, aromatase inhibitors"}}, {"data": {"id": "ER(+) breast cancer", "label": "ER(+) breast cancer"}}, {"data": {"id": "Meningeal hemangiopericytomas", "label": "Meningeal hemangiopericytomas"}}, {"data": {"id": "Enzalutamide", "label": "Enzalutamide"}}, {"data": {"id": "Glioblastoma", "label": "Glioblastoma"}}, {"data": {"id": "PIK3CA-AKT", "label": "PIK3CA-AKT"}}, {"data": {"id": "Palbociclib, 7rh", "label": "Palbociclib, 7rh"}}, {"data": {"id": "Metastatic colorectal cancer", "label": "Metastatic colorectal cancer"}}, {"data": {"id": "Head and neck squamous cell carcinoma (HNSCC)", "label": "Head and neck squamous cell carcinoma (HNSCC)"}}, {"data": {"id": "ER+/RB-deficient xenografts", "label": "ER+/RB-deficient xenografts"}}, {"data": {"id": "Malignant lipomatous tumors", "label": "Malignant lipomatous tumors"}}, {"data": {"id": "PI3K/AKT/mTOR, Cell-cycle machinery", "label": "PI3K/AKT/mTOR, Cell-cycle machinery"}}, {"data": {"id": "G1-S checkpoint", "label": "G1-S checkpoint"}}, {"data": {"source": "AKT1", "target": "MCF7, T47D"}}, {"data": {"source": "BRAF", "target": "Melanoma cells"}}, {"data": {"source": "BRAF", "target": "Braf(V600E) melanoma cells"}}, {"data": {"source": "BRAF", "target": "Melanoma cell lines"}}, {"data": {"source": "CCND1", "target": "Neuroblasts"}}, {"data": {"source": "CCND1", "target": "intestinal epithelial cells"}}, {"data": {"source": "CCND1", "target": "HEK293T cells"}}, {"data": {"source": "CCND1", "target": "Circulating tumor cells (CTCs)"}}, {"data": {"source": "CCND1", "target": "Neuronal cells"}}, {"data": {"source": "CCND1", "target": "Neuroblastoma cells"}}, {"data": {"source": "CCND1", "target": "MSCs"}}, {"data": {"source": "CCND1", "target": "Tumor cells"}}, {"data": {"source": "CCND1", "target": "Glioma cells"}}, {"data": {"source": "CCND1", "target": "HaCaT cells"}}, {"data": {"source": "CCND1", "target": "Mucosal melanoma"}}, {"data": {"source": "CCND1", "target": "Testicular cells"}}, {"data": {"source": "CCND1", "target": "A549 cells"}}, {"data": {"source": "CCND1", "target": "TE-1 cells"}}, {"data": {"source": "CCND1", "target": "Chicken PGCs"}}, {"data": {"source": "CCND1", "target": "Myeloma cells"}}, {"data": {"source": "CCND1", "target": "MCF-7, MDA-MB-231"}}, {"data": {"source": "CCND1", "target": "Placental explants"}}, {"data": {"source": "CCND1", "target": "HGC-27 cells"}}, {"data": {"source": "CCND1", "target": "Epidermal stem cells"}}, {"data": {"source": "CCND1", "target": "Breast cancer cell lines"}}, {"data": {"source": "CCND1", "target": "OVCAR-3, Caov-4"}}, {"data": {"source": "CCND1", "target": "Myoblasts"}}, {"data": {"source": "CCND1", "target": "OSCC cells"}}, {"data": {"source": "CCND1", "target": "breast cancer cells"}}, {"data": {"source": "CCND1", "target": "Mesenchymal stem cells"}}, {"data": {"source": "CCND1", "target": "OVCAR-3, Caov-4 cell lines"}}, {"data": {"source": "CCND1", "target": "Cancer cells"}}, {"data": {"source": "CCND1", "target": "Ovarian cancer cells"}}, {"data": {"source": "CCND1", "target": "COS cells, osteoprogenitor C3H10T1/2 cells, chondrogenic RCJ3.1C5.18 cells"}}, {"data": {"source": "CCND1", "target": "COS cells, RCJ3.1C5.18 cells"}}, {"data": {"source": "CCND1", "target": "Mammalian cells"}}, {"data": {"source": "CCND1", "target": "RB pathway"}}, {"data": {"source": "CCND1", "target": "MGC-803 cells"}}, {"data": {"source": "CCND1", "target": "B cells"}}, {"data": {"source": "CCND1", "target": "multiciliated cells"}}, {"data": {"source": "CDKN1A", "target": "Glioma cells"}}, {"data": {"source": "CDKN1A", "target": "Testicular cells"}}, {"data": {"source": "CDKN1A", "target": "TE-1 cells"}}, {"data": {"source": "CDKN1A", "target": "Myoblasts"}}, {"data": {"source": "CDKN1A", "target": "MEFs"}}, {"data": {"source": "CDKN1A", "target": "PDCs"}}, {"data": {"source": "CDKN1A", "target": "Proliferating cells"}}, {"data": {"source": "CDKN1A", "target": "Fibroblasts"}}, {"data": {"source": "CDKN2A", "target": "Cyclin D-CDK4,CDK6"}}, {"data": {"source": "CDKN2A", "target": "Cyclin D1"}}, {"data": {"source": "CDKN2A", "target": "Leiomyosarcomatous cells"}}, {"data": {"source": "CDKN2A", "target": "Rhabdomyosarcomatous cells"}}, {"data": {"source": "CDKN2A", "target": "Astrocytes"}}, {"data": {"source": "CDKN2A", "target": "MCF-7 cells"}}, {"data": {"source": "CDKN2A", "target": "Cell lines"}}, {"data": {"source": "CDKN2A", "target": "Tumor cells"}}, {"data": {"source": "CDKN2A", "target": "CMT cells"}}, {"data": {"source": "CDKN2A", "target": "Mucosal melanoma"}}, {"data": {"source": "CDKN2A", "target": "A549 cells"}}, {"data": {"source": "CDKN2A", "target": "Melanoma cell lines"}}, {"data": {"source": "CDKN2A", "target": "Carcinoma cells"}}, {"data": {"source": "CDKN2A", "target": "MEFs"}}, {"data": {"source": "CDKN2A", "target": "Primary human melanocytes"}}, {"data": {"source": "CDKN2A", "target": "B-cell precursors"}}, {"data": {"source": "CDKN2A", "target": "Glioma cell lines"}}, {"data": {"source": "CDKN2A", "target": "T cells"}}, {"data": {"source": "CDKN2A", "target": "breast cancer cells"}}, {"data": {"source": "CDKN2A", "target": "keratinocytes"}}, {"data": {"source": "CDKN2A", "target": "ECFCs"}}, {"data": {"source": "CDKN2A", "target": "NIH3T3 fibroblasts"}}, {"data": {"source": "CDKN2A", "target": "Cervical cancer cell lines"}}, {"data": {"source": "CDKN2A", "target": "Primary cells"}}, {"data": {"source": "CDKN2A", "target": "HCC cells"}}, {"data": {"source": "CDKN2A", "target": "Gallbladder cells"}}, {"data": {"source": "CDKN2A", "target": "Proliferating cells"}}, {"data": {"source": "CDKN2A", "target": "Mouse MEL erythroleukemia cells"}}, {"data": {"source": "CDKN2A", "target": "Fibroblasts"}}, {"data": {"source": "CDKN2A", "target": "Urothelial cells"}}, {"data": {"source": "CDKN2A", "target": "retinoblastoma"}}, {"data": {"source": "CDKN2A", "target": "HAOSMCs"}}, {"data": {"source": "CDKN2A", "target": "Cyclin D-dependent kinases"}}, {"data": {"source": "CDKN2A", "target": "B cells"}}, {"data": {"source": "CDKN2B", "target": "Cyclin D-CDK4,CDK6"}}, {"data": {"source": "CDKN2B", "target": "granulocyte-monocyte precursors"}}, {"data": {"source": "CDKN2B", "target": "Melanoma cell lines"}}, {"data": {"source": "CDKN2B", "target": "CD34+ progenitors"}}, {"data": {"source": "CDKN2B", "target": "T cells"}}, {"data": {"source": "CDKN2B", "target": "Glioma cells"}}, {"data": {"source": "CDKN2B", "target": "B cells"}}, {"data": {"source": "E2F1", "target": "Glioma cells"}}, {"data": {"source": "E2F1", "target": "Beta cells"}}, {"data": {"source": "E2F1", "target": "Autophagy regulators"}}, {"data": {"source": "EGFR", "target": "GBM cells"}}, {"data": {"source": "EGFR", "target": "Glioblastoma cells"}}, {"data": {"source": "EGFR", "target": "MCF7, T47D"}}, {"data": {"source": "EGFR", "target": "Chordoma cells"}}, {"data": {"source": "ERBB2", "target": "Glioblastoma cells"}}, {"data": {"source": "ERBB2", "target": "MCF7, T47D"}}, {"data": {"source": "ESR1", "target": "RB-deficient cells"}}, {"data": {"source": "ESR1", "target": "Luminal A BC cells"}}, {"data": {"source": "ESR1", "target": "MCF7"}}, {"data": {"source": "ESR1", "target": "Breast cancer cell lines, PDX models"}}, {"data": {"source": "ESR1", "target": "MCF-7 breast cancer cells"}}, {"data": {"source": "MDM2", "target": "hMSCs"}}, {"data": {"source": "MDM2", "target": "Lymphoid cells"}}, {"data": {"source": "MDM2", "target": "stromal cells"}}, {"data": {"source": "MDM2", "target": "Tumor cells"}}, {"data": {"source": "MDM2", "target": "Astrocytes"}}, {"data": {"source": "MDM2", "target": "PDX models, PDCs"}}, {"data": {"source": "MDM2", "target": "PDX mouse models"}}, {"data": {"source": "MDM2", "target": "p53(wild-type)"}}, {"data": {"source": "MDM2", "target": "MDA-MB-231 cells"}}, {"data": {"source": "MDM2", "target": "MCF-7 cells"}}, {"data": {"source": "MTOR", "target": "PI3K/AKT/mTOR pathway"}}, {"data": {"source": "MTOR", "target": "Primary GBM cell lines"}}, {"data": {"source": "MTOR", "target": "Tumor cells"}}, {"data": {"source": "MYC", "target": "Ovarian cancer cells"}}, {"data": {"source": "MYC", "target": "Circulating tumor cells"}}, {"data": {"source": "MYC", "target": "B-cells"}}, {"data": {"source": "NRAS", "target": "Melanoma cells"}}, {"data": {"source": "NRAS", "target": "Melanoma cell lines"}}, {"data": {"source": "PIK3CA", "target": "NB cell lines"}}, {"data": {"source": "PIK3CA", "target": "AML cells"}}, {"data": {"source": "PIK3CA", "target": "Tumor cells"}}, {"data": {"source": "PIK3CA", "target": "Cell lines"}}, {"data": {"source": "PIK3CA", "target": "non-IBC cells"}}, {"data": {"source": "PIK3CA", "target": "HPV(neg) HNSCC cell lines"}}, {"data": {"source": "PIK3CA", "target": "Melanoma cells"}}, {"data": {"source": "PIK3CA", "target": "MCF7 cells"}}, {"data": {"source": "PTEN", "target": "Breast cancer cells"}}, {"data": {"source": "PTEN", "target": "Circulating tumor cells"}}, {"data": {"source": "RB1", "target": "Tumor cells"}}, {"data": {"source": "RB1", "target": "Astrocytes"}}, {"data": {"source": "RB1", "target": "pituitary cells"}}, {"data": {"source": "RB1", "target": "Endothelial cells"}}, {"data": {"source": "RB1", "target": "Neuronal cells"}}, {"data": {"source": "RB1", "target": "HaCaT cells"}}, {"data": {"source": "RB1", "target": "P114,CF41 cells"}}, {"data": {"source": "RB1", "target": "B cells"}}, {"data": {"source": "RB1", "target": "HGC-27 cells"}}, {"data": {"source": "RB1", "target": "Mouse embryo fibroblasts"}}, {"data": {"source": "RB1", "target": "Beta cells"}}, {"data": {"source": "RB1", "target": "CD34+ cells"}}, {"data": {"source": "RB1", "target": "MEFs"}}, {"data": {"source": "RB1", "target": "T-ALL cell line"}}, {"data": {"source": "RB1", "target": "Cervical cancer cell lines"}}, {"data": {"source": "RB1", "target": "Primary cells"}}, {"data": {"source": "RB1", "target": "MCF-7"}}, {"data": {"source": "RB1", "target": "Autophagy regulators"}}, {"data": {"source": "RB1", "target": "TNBC cell lines"}}, {"data": {"source": "RB1", "target": "pRb-competent cells"}}, {"data": {"source": "RB1", "target": "Breast cancer cell lines"}}, {"data": {"source": "RB1", "target": "HAOSMCs"}}, {"data": {"source": "RB1", "target": "Pituitary gland"}}, {"data": {"source": "TP53", "target": "Astrocytes"}}, {"data": {"source": "TP53", "target": "GBM cells"}}, {"data": {"source": "TP53", "target": "MEFs"}}, {"data": {"source": "TP53", "target": "IBC cells"}}, {"data": {"source": "TP53", "target": "Glioblastoma cells"}}, {"data": {"source": "AKT1", "target": "Seminal vesicle tumors"}}, {"data": {"source": "AKT1", "target": "Breast cancer"}}, {"data": {"source": "AKT1", "target": "Gliosarcoma"}}, {"data": {"source": "AKT1", "target": "Gliosarcoma, glioblastoma"}}, {"data": {"source": "AKT1", "target": "Glial cell transformation"}}, {"data": {"source": "AKT1", "target": "Lung cancer"}}, {"data": {"source": "AKT1", "target": "Melanoma"}}, {"data": {"source": "AKT1", "target": "Prostate tumor"}}, {"data": {"source": "BRAF", "target": "Melanoma"}}, {"data": {"source": "BRAF", "target": "eGBM"}}, {"data": {"source": "BRAF", "target": "Malignant melanoma"}}, {"data": {"source": "BRAF", "target": "Acral melanocytic nevus"}}, {"data": {"source": "BRAF", "target": "Acral melanoma"}}, {"data": {"source": "BRAF", "target": "Primary tumor, Secondary lesions"}}, {"data": {"source": "BRAF", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "BRAF", "target": "Cancer"}}, {"data": {"source": "BRAF", "target": "Nasal mixed exocrine-neuroendocrine carcinoma"}}, {"data": {"source": "BRAF", "target": "Brain tumors"}}, {"data": {"source": "BRAF", "target": "Solid tumors"}}, {"data": {"source": "BRAF", "target": "Metastatic melanoma"}}, {"data": {"source": "BRAF", "target": "papillary thyroid carcinoma"}}, {"data": {"source": "BRAF", "target": "thyroid tumor"}}, {"data": {"source": "BRAF", "target": "cancer"}}, {"data": {"source": "BRAF", "target": "Glioblastoma"}}, {"data": {"source": "BRAF", "target": "Low-grade serous ovarian cancer (LGSC)"}}, {"data": {"source": "BRAF", "target": "AM"}}, {"data": {"source": "BRAF", "target": "HCC"}}, {"data": {"source": "BRAF", "target": "Cutaneous melanoma"}}, {"data": {"source": "BRAF", "target": "histiocytic sarcoma"}}, {"data": {"source": "BRAF", "target": "Acral melanomas"}}, {"data": {"source": "BRAF", "target": "Tumors"}}, {"data": {"source": "BRAF", "target": "Colorectal cancer"}}, {"data": {"source": "BRAF", "target": "Melanoma, Cancer"}}, {"data": {"source": "BRAF", "target": "Melanocytic tumors"}}, {"data": {"source": "BRAF", "target": "PMM"}}, {"data": {"source": "BRAF", "target": "Mucosal melanomas"}}, {"data": {"source": "BRAF", "target": "Carcinomas"}}, {"data": {"source": "BRAF", "target": "Tumor recurrence"}}, {"data": {"source": "CCND1", "target": "Neuroblastic tumors"}}, {"data": {"source": "CCND1", "target": "Gliomas, Sarcomas, Melanoma, Breast cancer, Colorectal cancer"}}, {"data": {"source": "CCND1", "target": "Seminal vesicle tumors"}}, {"data": {"source": "CCND1", "target": "Melanoma"}}, {"data": {"source": "CCND1", "target": "Cancer"}}, {"data": {"source": "CCND1", "target": "Acral melanoma"}}, {"data": {"source": "CCND1", "target": "Anaplasia"}}, {"data": {"source": "CCND1", "target": "AM"}}, {"data": {"source": "CCND1", "target": "Tumors"}}, {"data": {"source": "CCND1", "target": "Ganglioneuroma"}}, {"data": {"source": "CCND1", "target": "Cervical carcinoma"}}, {"data": {"source": "CCND1", "target": "Adenoma"}}, {"data": {"source": "CCND1", "target": "Neoplasms"}}, {"data": {"source": "CCND1", "target": "Lymph node metastasis, depth of invasion"}}, {"data": {"source": "CCND1", "target": "Adenocarcinomas"}}, {"data": {"source": "CCND1", "target": "Esophageal conditions"}}, {"data": {"source": "CCND1", "target": "Acral melanoma (AM)"}}, {"data": {"source": "CCND1", "target": "High-grade astrocytomas"}}, {"data": {"source": "CCND1", "target": "Gallbladder cancer"}}, {"data": {"source": "CCND1", "target": "Glioblastoma, Brain metastases"}}, {"data": {"source": "CCND1", "target": "MCL"}}, {"data": {"source": "CCND1", "target": "Antiandrogen-resistant disease"}}, {"data": {"source": "CCND1", "target": "Colorectal cancer (CRC)"}}, {"data": {"source": "CCND1", "target": "Breast cancer"}}, {"data": {"source": "CCND1", "target": "Cervical cancer"}}, {"data": {"source": "CCND1", "target": "Immune-refractory cancer"}}, {"data": {"source": "CCND1", "target": "Hepatocellular carcinoma (HCC)"}}, {"data": {"source": "CCND1", "target": "Breast cancer, cancer"}}, {"data": {"source": "CCND1", "target": "Retinoblastoma"}}, {"data": {"source": "CCND1", "target": "Glioma"}}, {"data": {"source": "CCND1", "target": "OSCC"}}, {"data": {"source": "CCND1", "target": "Intestinal neoplasia"}}, {"data": {"source": "CCND1", "target": "Intestinal adenomas"}}, {"data": {"source": "CCND1", "target": "Intestinal carcinogenesis"}}, {"data": {"source": "CCND1", "target": "Varicocele"}}, {"data": {"source": "CCND1", "target": "Mammary carcinoma"}}, {"data": {"source": "CCND1", "target": "Adenocarcinoma"}}, {"data": {"source": "CCND1", "target": "diabetes"}}, {"data": {"source": "CCND1", "target": "Head and neck squamous cell carcinoma (HNSCC)"}}, {"data": {"source": "CCND1", "target": "Tumor"}}, {"data": {"source": "CCND1", "target": "Esophageal cancer"}}, {"data": {"source": "CCND1", "target": "Malignant astrocytomas"}}, {"data": {"source": "CCND1", "target": "GBM"}}, {"data": {"source": "CCND1", "target": "Human cancers"}}, {"data": {"source": "CCND1", "target": "Prostate cancer"}}, {"data": {"source": "CCND1", "target": "Nasopharyngeal carcinoma (NPC)"}}, {"data": {"source": "CCND1", "target": "Myeloma"}}, {"data": {"source": "CCND1", "target": "Mammary gland tumors"}}, {"data": {"source": "CCND1", "target": "Ovarian cancer"}}, {"data": {"source": "CCND1", "target": "Gastric carcinoma"}}, {"data": {"source": "CCND1", "target": "Glioblastoma"}}, {"data": {"source": "CCND1", "target": "Endocrine therapy-resistant breast cancer"}}, {"data": {"source": "CCND1", "target": "Hepatocarcinogenesis"}}, {"data": {"source": "CCND1", "target": "Liver tumors"}}, {"data": {"source": "CCND1", "target": "Parathyroid tumors"}}, {"data": {"source": "CCND1", "target": "Esophageal squamous cell carcinoma"}}, {"data": {"source": "CCND1", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "CCND1", "target": "Colorectal cancer"}}, {"data": {"source": "CCND1", "target": "Skin tumors"}}, {"data": {"source": "CCND1", "target": "WDLPS,DDLPS"}}, {"data": {"source": "CCND1", "target": "ER+ breast cancer"}}, {"data": {"source": "CCND1", "target": "Endometrial carcinomas"}}, {"data": {"source": "CCND1", "target": "Endometrioid-type endometrial carcinomas"}}, {"data": {"source": "CCND1", "target": "NPC"}}, {"data": {"source": "CCND1", "target": "Metastatic NPC"}}, {"data": {"source": "CCND1", "target": "Oral squamous cell carcinoma"}}, {"data": {"source": "CCND1", "target": "Therapy-refractory solid malignancies"}}, {"data": {"source": "CCND1", "target": "Synovial sarcoma"}}, {"data": {"source": "CCND1", "target": "HPV(U) tumors"}}, {"data": {"source": "CCND1", "target": "Mantle cell NHL"}}, {"data": {"source": "CCND1", "target": "Gastric cancer"}}, {"data": {"source": "CCND1", "target": "Advanced gastric cancer"}}, {"data": {"source": "CCND1", "target": "Parathyroid adenomas"}}, {"data": {"source": "CCND1", "target": "Multiple myeloma"}}, {"data": {"source": "CCND1", "target": "FAP (Familial Adenomatous Polyposis)"}}, {"data": {"source": "CCND1", "target": "Pancreatic ductal adenocarcinoma"}}, {"data": {"source": "CCND1", "target": "Mantle cell lymphoma"}}, {"data": {"source": "CCND1", "target": "Canine mammary gland cancer"}}, {"data": {"source": "CCND1", "target": "SPA"}}, {"data": {"source": "CCND1", "target": "Thin melanoma"}}, {"data": {"source": "CCND1", "target": "ESCC, esophageal dysplasia"}}, {"data": {"source": "CCND1", "target": "HNSCC"}}, {"data": {"source": "CCND1", "target": "Nonbreast solid tumors"}}, {"data": {"source": "CCND1", "target": "Salivary gland tumors"}}, {"data": {"source": "CCND1", "target": "HR-positive breast cancer"}}, {"data": {"source": "CCND1", "target": "ALM"}}, {"data": {"source": "CCND1", "target": "Multiple cancers"}}, {"data": {"source": "CCND1", "target": "Nasopharyngeal carcinoma"}}, {"data": {"source": "CCND1", "target": "Sarcomas"}}, {"data": {"source": "CCND1", "target": "breast cancer,head and neck cancer,non-small-cell lung cancer,mantle cell lymphomas"}}, {"data": {"source": "CCND1", "target": "HCC"}}, {"data": {"source": "CCND1", "target": "Advanced sarcomas"}}, {"data": {"source": "CCND1", "target": "Skin cancer"}}, {"data": {"source": "CCND1", "target": "HUC senescence"}}, {"data": {"source": "CCND1", "target": "B cell non-Hodgkin's lymphoma (B-NHL)"}}, {"data": {"source": "CCND1", "target": "Extramammary Paget's disease (EMPD)"}}, {"data": {"source": "CCND1", "target": "FPA"}}, {"data": {"source": "CCNE1", "target": "Oral cancer"}}, {"data": {"source": "CCNE1", "target": "Cancer"}}, {"data": {"source": "CCNE1", "target": "Soft tissue metastasis"}}, {"data": {"source": "CCNE1", "target": "Melanoma"}}, {"data": {"source": "CCNE1", "target": "Breast cancer"}}, {"data": {"source": "CCNE1", "target": "Pleural mesothelioma"}}, {"data": {"source": "CCNE1", "target": "OSCC"}}, {"data": {"source": "CCNE1", "target": "Prostate cancer"}}, {"data": {"source": "CCNE1", "target": "Gastric cancer"}}, {"data": {"source": "CCNE1", "target": "Advanced gastric cancer"}}, {"data": {"source": "CCNE1", "target": "HCC"}}, {"data": {"source": "CDKN1A", "target": "Seminal vesicle tumors"}}, {"data": {"source": "CDKN1A", "target": "Glioma"}}, {"data": {"source": "CDKN1A", "target": "OSCC"}}, {"data": {"source": "CDKN1A", "target": "HCC"}}, {"data": {"source": "CDKN1A", "target": "Varicocele"}}, {"data": {"source": "CDKN1A", "target": "Cervical carcinoma"}}, {"data": {"source": "CDKN1A", "target": "Breast cancer"}}, {"data": {"source": "CDKN1A", "target": "Cancer"}}, {"data": {"source": "CDKN1A", "target": "Esophageal squamous cell carcinoma"}}, {"data": {"source": "CDKN1A", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "CDKN1A", "target": "Colorectal cancer"}}, {"data": {"source": "CDKN1A", "target": "Thick melanoma"}}, {"data": {"source": "CDKN1A", "target": "Tumor"}}, {"data": {"source": "CDKN1A", "target": "HUC senescence"}}, {"data": {"source": "CDKN2A", "target": "Melanoma"}}, {"data": {"source": "CDKN2A", "target": "Glioblastomas"}}, {"data": {"source": "CDKN2A", "target": "Solid tumors"}}, {"data": {"source": "CDKN2A", "target": "Melanomas,Digestive cancers"}}, {"data": {"source": "CDKN2A", "target": "ALL, CML, ATL"}}, {"data": {"source": "CDKN2A", "target": "ALL"}}, {"data": {"source": "CDKN2A", "target": "Ovarian tumor"}}, {"data": {"source": "CDKN2A", "target": "Uterine myosarcoma"}}, {"data": {"source": "CDKN2A", "target": "Uterine leiomyosarcoma"}}, {"data": {"source": "CDKN2A", "target": "Hereditary cutaneous melanoma"}}, {"data": {"source": "CDKN2A", "target": "Human tumors"}}, {"data": {"source": "CDKN2A", "target": "Sarcoma"}}, {"data": {"source": "CDKN2A", "target": "Melanoma, multiple cancers"}}, {"data": {"source": "CDKN2A", "target": "Familial cutaneous malignant melanoma"}}, {"data": {"source": "CDKN2A", "target": "Melanoma,Neural system tumors"}}, {"data": {"source": "CDKN2A", "target": "Hibernoma-like areas"}}, {"data": {"source": "CDKN2A", "target": "Primary cutaneous melanoma (PCM)"}}, {"data": {"source": "CDKN2A", "target": "Amelanotic melanoma"}}, {"data": {"source": "CDKN2A", "target": "Familial malignant melanoma"}}, {"data": {"source": "CDKN2A", "target": "Familial melanoma"}}, {"data": {"source": "CDKN2A", "target": "Familial melanoma, multiple melanoma"}}, {"data": {"source": "CDKN2A", "target": "Cancer"}}, {"data": {"source": "CDKN2A", "target": "Low-grade gliomas"}}, {"data": {"source": "CDKN2A", "target": "Astrocytomas"}}, {"data": {"source": "CDKN2A", "target": "Glioblastoma"}}, {"data": {"source": "CDKN2A", "target": "High-grade astrocytomas, glioma"}}, {"data": {"source": "CDKN2A", "target": "Astrocytomas, glioma"}}, {"data": {"source": "CDKN2A", "target": "Uveal melanoma"}}, {"data": {"source": "CDKN2A", "target": "eGBM"}}, {"data": {"source": "CDKN2A", "target": "Leukemia"}}, {"data": {"source": "CDKN2A", "target": "Pediatric ALL"}}, {"data": {"source": "CDKN2A", "target": "Oral cancer"}}, {"data": {"source": "CDKN2A", "target": "Head and neck cancer"}}, {"data": {"source": "CDKN2A", "target": "Astrocytic tumor, Oligodendroglial tumor"}}, {"data": {"source": "CDKN2A", "target": "Metastases to pelvis and spine"}}, {"data": {"source": "CDKN2A", "target": "Primary tumor"}}, {"data": {"source": "CDKN2A", "target": "Adenoma"}}, {"data": {"source": "CDKN2A", "target": "OSCC"}}, {"data": {"source": "CDKN2A", "target": "Malignant melanoma"}}, {"data": {"source": "CDKN2A", "target": "Cancer predisposition syndrome"}}, {"data": {"source": "CDKN2A", "target": "Malignant mesothelioma, Other cancers"}}, {"data": {"source": "CDKN2A", "target": "Malignant mesothelioma"}}, {"data": {"source": "CDKN2A", "target": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"source": "CDKN2A", "target": "Glioma"}}, {"data": {"source": "CDKN2A", "target": "Lymphoid tumors"}}, {"data": {"source": "CDKN2A", "target": "Mucosal melanoma"}}, {"data": {"source": "CDKN2A", "target": "Oligodendroglioma"}}, {"data": {"source": "CDKN2A", "target": "Anaplastic oligodendroglioma"}}, {"data": {"source": "CDKN2A", "target": "WHO grade II oligodendroglioma"}}, {"data": {"source": "CDKN2A", "target": "Barrett's adenocarcinomas"}}, {"data": {"source": "CDKN2A", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "CDKN2A", "target": "Melanoma, tumors"}}, {"data": {"source": "CDKN2A", "target": "Hereditary melanoma"}}, {"data": {"source": "CDKN2A", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Carcinomas"}}, {"data": {"source": "CDKN2A", "target": "Osteosarcoma"}}, {"data": {"source": "CDKN2A", "target": "Tumors"}}, {"data": {"source": "CDKN2A", "target": "Soft tissue metastasis"}}, {"data": {"source": "CDKN2A", "target": "Melanocytic neoplasms"}}, {"data": {"source": "CDKN2A", "target": "Lower grade astrocytomas"}}, {"data": {"source": "CDKN2A", "target": "Esophageal conditions"}}, {"data": {"source": "CDKN2A", "target": "High-grade astrocytomas"}}, {"data": {"source": "CDKN2A", "target": "Dermatofibrosarcoma protuberans"}}, {"data": {"source": "CDKN2A", "target": "Fibrosarcomatous DFSP"}}, {"data": {"source": "CDKN2A", "target": "Ependymoma"}}, {"data": {"source": "CDKN2A", "target": "FGFR-altered IGs"}}, {"data": {"source": "CDKN2A", "target": "Cholangiocarcinoma"}}, {"data": {"source": "CDKN2A", "target": "Glioblastoma, Brain metastases"}}, {"data": {"source": "CDKN2A", "target": "ER+ breast cancer"}}, {"data": {"source": "CDKN2A", "target": "Serous ovarian tumor"}}, {"data": {"source": "CDKN2A", "target": "Melanoma, GBM"}}, {"data": {"source": "CDKN2A", "target": "Breast cancer"}}, {"data": {"source": "CDKN2A", "target": "Prostate cancer"}}, {"data": {"source": "CDKN2A", "target": "Non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "CDKN2A", "target": "Pleural mesothelioma"}}, {"data": {"source": "CDKN2A", "target": "PDAC"}}, {"data": {"source": "CDKN2A", "target": "Lung adenocarcinoma"}}, {"data": {"source": "CDKN2A", "target": "PM"}}, {"data": {"source": "CDKN2A", "target": "Ewing's sarcoma"}}, {"data": {"source": "CDKN2A", "target": "Malignancies"}}, {"data": {"source": "CDKN2A", "target": "BRAF inhibitor-resistant tumor"}}, {"data": {"source": "CDKN2A", "target": "tumor"}}, {"data": {"source": "CDKN2A", "target": "Head and neck squamous cell carcinoma (HNSCC)"}}, {"data": {"source": "CDKN2A", "target": "BCC"}}, {"data": {"source": "CDKN2A", "target": "Tumor"}}, {"data": {"source": "CDKN2A", "target": "Esophageal cancer"}}, {"data": {"source": "CDKN2A", "target": "MHPC"}}, {"data": {"source": "CDKN2A", "target": "Malignant astrocytomas"}}, {"data": {"source": "CDKN2A", "target": "GBM"}}, {"data": {"source": "CDKN2A", "target": "Familial human melanoma"}}, {"data": {"source": "CDKN2A", "target": "Ovarian cancer"}}, {"data": {"source": "CDKN2A", "target": "Gastric carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Lung cancer"}}, {"data": {"source": "CDKN2A", "target": "Atherosclerosis, Type 2 diabetes mellitus (T2DM)"}}, {"data": {"source": "CDKN2A", "target": "T2DM, T2DM-CAD"}}, {"data": {"source": "CDKN2A", "target": "Familial melanoma, Sporadic melanoma"}}, {"data": {"source": "CDKN2A", "target": "Non-small cell lung cancer"}}, {"data": {"source": "CDKN2A", "target": "Cutaneous malignant melanoma"}}, {"data": {"source": "CDKN2A", "target": "Esophageal carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Retinoblastoma, Osteosarcoma"}}, {"data": {"source": "CDKN2A", "target": "Skin tumors"}}, {"data": {"source": "CDKN2A", "target": "WDLPS,DDLPS"}}, {"data": {"source": "CDKN2A", "target": "gliomas, cancers"}}, {"data": {"source": "CDKN2A", "target": "MPM"}}, {"data": {"source": "CDKN2A", "target": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma"}}, {"data": {"source": "CDKN2A", "target": "Diffuse astrocytic glioma"}}, {"data": {"source": "CDKN2A", "target": "Pleomorphic xanthoastrocytoma"}}, {"data": {"source": "CDKN2A", "target": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma"}}, {"data": {"source": "CDKN2A", "target": "HPV-positive carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Endometrioid-type endometrial carcinomas"}}, {"data": {"source": "CDKN2A", "target": "NPC"}}, {"data": {"source": "CDKN2A", "target": "MPNST"}}, {"data": {"source": "CDKN2A", "target": "Bladder tumors"}}, {"data": {"source": "CDKN2A", "target": "Human tumor cell lines"}}, {"data": {"source": "CDKN2A", "target": "Pituitary adenomas"}}, {"data": {"source": "CDKN2A", "target": "Tumours"}}, {"data": {"source": "CDKN2A", "target": "Pituitary tumours"}}, {"data": {"source": "CDKN2A", "target": "Leukemia, many cancers"}}, {"data": {"source": "CDKN2A", "target": "Human cancers"}}, {"data": {"source": "CDKN2A", "target": "Meningeal hemangiopericytomas"}}, {"data": {"source": "CDKN2A", "target": "Chordoma"}}, {"data": {"source": "CDKN2A", "target": "T2DM-CAD"}}, {"data": {"source": "CDKN2A", "target": "Atherosclerosis, T2DM"}}, {"data": {"source": "CDKN2A", "target": "T2DM"}}, {"data": {"source": "CDKN2A", "target": "Squamous cell carcinoma"}}, {"data": {"source": "CDKN2A", "target": "T-cell acute lymphoblastic leukemia"}}, {"data": {"source": "CDKN2A", "target": "Human cancers, malignant melanoma"}}, {"data": {"source": "CDKN2A", "target": "ESOS"}}, {"data": {"source": "CDKN2A", "target": "Multiple myeloma"}}, {"data": {"source": "CDKN2A", "target": "Pancreatic cancer, melanoma"}}, {"data": {"source": "CDKN2A", "target": "Sarcomas"}}, {"data": {"source": "CDKN2A", "target": "ALL T, ATL, CML"}}, {"data": {"source": "CDKN2A", "target": "Lung cancer, Colon cancer"}}, {"data": {"source": "CDKN2A", "target": "Mantle cell NHL"}}, {"data": {"source": "CDKN2A", "target": "Neurofibromas, malignant peripheral nerve sheath tumors"}}, {"data": {"source": "CDKN2A", "target": "Skin cancer, SCCs, BCCs"}}, {"data": {"source": "CDKN2A", "target": "Carcinogenesis"}}, {"data": {"source": "CDKN2A", "target": "Moyamoya disease (MMD)"}}, {"data": {"source": "CDKN2A", "target": "Familial melanoma, Tumours"}}, {"data": {"source": "CDKN2A", "target": "Cervical cancer"}}, {"data": {"source": "CDKN2A", "target": "Pancreatic ductal adenocarcinoma"}}, {"data": {"source": "CDKN2A", "target": "Gallbladder cancer"}}, {"data": {"source": "CDKN2A", "target": "SPA"}}, {"data": {"source": "CDKN2A", "target": "Ovarian tumors"}}, {"data": {"source": "CDKN2A", "target": "Anaplastic astrocytomas, GBMs"}}, {"data": {"source": "CDKN2A", "target": "ESCC"}}, {"data": {"source": "CDKN2A", "target": "NSCLC"}}, {"data": {"source": "CDKN2A", "target": "HNSCC"}}, {"data": {"source": "CDKN2A", "target": "HCC"}}, {"data": {"source": "CDKN2A", "target": "Non-small cell lung carcinoma"}}, {"data": {"source": "CDKN2A", "target": "histiocytic sarcoma"}}, {"data": {"source": "CDKN2A", "target": "Head and neck squamous cell carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Salivary gland tumors"}}, {"data": {"source": "CDKN2A", "target": "Nasopharyngeal carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Esophageal squamous cell carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Leptomeningeal metastases of lung adenocarcinoma"}}, {"data": {"source": "CDKN2A", "target": "Diffuse high-grade glioma (DHG)"}}, {"data": {"source": "CDKN2A", "target": "Retinoblastoma"}}, {"data": {"source": "CDKN2A", "target": "Tumor, normal skin tissue"}}, {"data": {"source": "CDKN2A", "target": "Plasmacytoma"}}, {"data": {"source": "CDKN2A", "target": "B cell non-Hodgkin's lymphoma (B-NHL)"}}, {"data": {"source": "CDKN2A", "target": "Various tumor types"}}, {"data": {"source": "CDKN2A", "target": "Melanoma, Pancreatic cancer"}}, {"data": {"source": "CDKN2A", "target": "Liposarcoma, lipoma, liponecrosis"}}, {"data": {"source": "CDKN2A", "target": "Liposarcoma"}}, {"data": {"source": "CDKN2A", "target": "Basal cell carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Prostate carcinoma"}}, {"data": {"source": "CDKN2A", "target": "Oligodendrogliomas"}}, {"data": {"source": "CDKN2A", "target": "Parathyroid adenomas"}}, {"data": {"source": "CDKN2A", "target": "Head and neck tumors"}}, {"data": {"source": "CDKN2A", "target": "Liposarcoma, Lipoma"}}, {"data": {"source": "CDKN2A", "target": "FPA"}}, {"data": {"source": "CDKN2A", "target": "Metastatic melanoma"}}, {"data": {"source": "CDKN2A", "target": "sPNET, GBM"}}, {"data": {"source": "CDKN2B", "target": "Tumors"}}, {"data": {"source": "CDKN2B", "target": "Hematopoietic malignancies"}}, {"data": {"source": "CDKN2B", "target": "Glioblastomas"}}, {"data": {"source": "CDKN2B", "target": "Solid tumors"}}, {"data": {"source": "CDKN2B", "target": "ALL, CML, ATL"}}, {"data": {"source": "CDKN2B", "target": "ALL"}}, {"data": {"source": "CDKN2B", "target": "Human tumors"}}, {"data": {"source": "CDKN2B", "target": "Breast cancer"}}, {"data": {"source": "CDKN2B", "target": "Cancer"}}, {"data": {"source": "CDKN2B", "target": "Melanoma"}}, {"data": {"source": "CDKN2B", "target": "Low-grade gliomas"}}, {"data": {"source": "CDKN2B", "target": "BTC"}}, {"data": {"source": "CDKN2B", "target": "Oral cancer"}}, {"data": {"source": "CDKN2B", "target": "Head and neck cancer"}}, {"data": {"source": "CDKN2B", "target": "Malignant mesothelioma, Other cancers"}}, {"data": {"source": "CDKN2B", "target": "Anaplastic oligodendroglioma"}}, {"data": {"source": "CDKN2B", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "CDKN2B", "target": "Fibrosarcomatous DFSP"}}, {"data": {"source": "CDKN2B", "target": "Prostate cancer"}}, {"data": {"source": "CDKN2B", "target": "Non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "CDKN2B", "target": "Atherosclerosis, Type 2 diabetes mellitus (T2DM)"}}, {"data": {"source": "CDKN2B", "target": "T2DM, T2DM-CAD"}}, {"data": {"source": "CDKN2B", "target": "Esophageal carcinoma"}}, {"data": {"source": "CDKN2B", "target": "Familial melanoma"}}, {"data": {"source": "CDKN2B", "target": "Retinoblastoma, Osteosarcoma"}}, {"data": {"source": "CDKN2B", "target": "Skin tumors"}}, {"data": {"source": "CDKN2B", "target": "MPM"}}, {"data": {"source": "CDKN2B", "target": "Pleomorphic xanthoastrocytoma"}}, {"data": {"source": "CDKN2B", "target": "MPNST"}}, {"data": {"source": "CDKN2B", "target": "Human cancers"}}, {"data": {"source": "CDKN2B", "target": "T2DM-CAD"}}, {"data": {"source": "CDKN2B", "target": "Atherosclerosis, T2DM"}}, {"data": {"source": "CDKN2B", "target": "T2DM"}}, {"data": {"source": "CDKN2B", "target": "T-cell acute lymphoblastic leukemia"}}, {"data": {"source": "CDKN2B", "target": "Multiple myeloma"}}, {"data": {"source": "CDKN2B", "target": "ALL T, ATL, CML"}}, {"data": {"source": "CDKN2B", "target": "Lung cancer, Colon cancer"}}, {"data": {"source": "CDKN2B", "target": "Glioma"}}, {"data": {"source": "CDKN2B", "target": "Mantle cell NHL"}}, {"data": {"source": "CDKN2B", "target": "Colorectal cancer"}}, {"data": {"source": "CDKN2B", "target": "Non-small cell lung cancer"}}, {"data": {"source": "CDKN2B", "target": "NSCLC"}}, {"data": {"source": "CDKN2B", "target": "Salivary gland tumors"}}, {"data": {"source": "CDKN2B", "target": "Diffuse high-grade glioma (DHG)"}}, {"data": {"source": "CDKN2B", "target": "Tumor"}}, {"data": {"source": "CDKN2B", "target": "B cell non-Hodgkin's lymphoma (B-NHL)"}}, {"data": {"source": "CDKN2B", "target": "Various tumor types"}}, {"data": {"source": "CDKN2B", "target": "Malignant melanoma"}}, {"data": {"source": "CDKN2B", "target": "Prostate carcinoma"}}, {"data": {"source": "CDKN2B", "target": "Parathyroid adenomas"}}, {"data": {"source": "E2F1", "target": "Sarcoma"}}, {"data": {"source": "E2F1", "target": "Glioma"}}, {"data": {"source": "E2F1", "target": "Breast cancer"}}, {"data": {"source": "E2F1", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "E2F1", "target": "Tumors"}}, {"data": {"source": "E2F1", "target": "MHPCs"}}, {"data": {"source": "E2F1", "target": "Multiple myeloma"}}, {"data": {"source": "EGFR", "target": "NSCLC"}}, {"data": {"source": "EGFR", "target": "Seminal vesicle tumors"}}, {"data": {"source": "EGFR", "target": "Astrocytic tumor, Oligodendroglial tumor"}}, {"data": {"source": "EGFR", "target": "Primary lesion, Metastatic lesion"}}, {"data": {"source": "EGFR", "target": "Multiple cancer types"}}, {"data": {"source": "EGFR", "target": "Acquired resistance"}}, {"data": {"source": "EGFR", "target": "GBM, GS"}}, {"data": {"source": "EGFR", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "EGFR", "target": "GBM"}}, {"data": {"source": "EGFR", "target": "Glioblastomas"}}, {"data": {"source": "EGFR", "target": "Glioblastoma multiforme (GBM)"}}, {"data": {"source": "EGFR", "target": "Tumors"}}, {"data": {"source": "EGFR", "target": "Penile squamous cell carcinoma"}}, {"data": {"source": "EGFR", "target": "PMA"}}, {"data": {"source": "EGFR", "target": "Metaplastic breast carcinoma"}}, {"data": {"source": "EGFR", "target": "Hepatoid adenocarcinoma of the stomach (HAS)"}}, {"data": {"source": "EGFR", "target": "Disease progression"}}, {"data": {"source": "EGFR", "target": "NAC-resistant tumors"}}, {"data": {"source": "EGFR", "target": "Nasopharyngeal carcinoma"}}, {"data": {"source": "EGFR", "target": "NPC (nasopharyngeal carcinoma)"}}, {"data": {"source": "EGFR", "target": "Non-small cell lung cancer"}}, {"data": {"source": "EGFR", "target": "Squamous cell lung cancer"}}, {"data": {"source": "EGFR", "target": "EGFR-amplified tumours"}}, {"data": {"source": "EGFR", "target": "Breast cancer"}}, {"data": {"source": "EGFR", "target": "Non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "EGFR", "target": "Lung cancer"}}, {"data": {"source": "EGFR", "target": "Amplified tumors"}}, {"data": {"source": "EGFR", "target": "Lung adenocarcinoma (LUAD)"}}, {"data": {"source": "EGFR", "target": "Advanced non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "EGFR", "target": "Glioblastoma"}}, {"data": {"source": "EGFR", "target": "Brain cancer"}}, {"data": {"source": "EGFR", "target": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma"}}, {"data": {"source": "EGFR", "target": "Diffuse astrocytic glioma"}}, {"data": {"source": "EGFR", "target": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma"}}, {"data": {"source": "EGFR", "target": "Gliosarcoma"}}, {"data": {"source": "EGFR", "target": "Gliosarcoma, glioblastoma"}}, {"data": {"source": "EGFR", "target": "Tumor"}}, {"data": {"source": "EGFR", "target": "Pituitary neuroendocrine tumors (PitNET)"}}, {"data": {"source": "EGFR", "target": "Cervical carcinoma"}}, {"data": {"source": "EGFR", "target": "Epithelial cancers"}}, {"data": {"source": "EGFR", "target": "HCC"}}, {"data": {"source": "EGFR", "target": "Chordoma"}}, {"data": {"source": "EGFR", "target": "PeSCCA"}}, {"data": {"source": "EGFR", "target": "Desmoplastic small round cell tumor (DSRCT)"}}, {"data": {"source": "EGFR", "target": "Lung metastases (LM)"}}, {"data": {"source": "EGFR", "target": "Metastatic breast cancer (mBC)"}}, {"data": {"source": "EGFR", "target": "Cancer"}}, {"data": {"source": "EGFR", "target": "Hepatocellular carcinoma (HCC)"}}, {"data": {"source": "EGFR", "target": "METex 14 alteration"}}, {"data": {"source": "EGFR", "target": "Lung metastases"}}, {"data": {"source": "EGFR", "target": "Pleomorphic xanthoastrocytoma"}}, {"data": {"source": "ERBB2", "target": "Metastatic breast cancer"}}, {"data": {"source": "ERBB2", "target": "Breast cancer"}}, {"data": {"source": "ERBB2", "target": "BTC"}}, {"data": {"source": "ERBB2", "target": "Cancer"}}, {"data": {"source": "ERBB2", "target": "Hepatoid adenocarcinoma of the stomach (HAS)"}}, {"data": {"source": "ERBB2", "target": "HER2-positive breast cancer"}}, {"data": {"source": "ERBB2", "target": "ER-positive, HER2-negative breast cancer"}}, {"data": {"source": "ERBB2", "target": "Triple negative breast cancer"}}, {"data": {"source": "ERBB2", "target": "Endocrine resistance"}}, {"data": {"source": "ERBB2", "target": "NAC-resistant tumors"}}, {"data": {"source": "ERBB2", "target": "Hormone receptor-positive, HER2-negative breast cancer"}}, {"data": {"source": "ERBB2", "target": "Advanced breast cancer"}}, {"data": {"source": "ERBB2", "target": "metastatic breast cancer"}}, {"data": {"source": "ERBB2", "target": "Disease"}}, {"data": {"source": "ERBB2", "target": "Metastatic extramammary Paget's disease"}}, {"data": {"source": "ERBB2", "target": "Advanced-stage breast cancer"}}, {"data": {"source": "ERBB2", "target": "Advanced non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "ERBB2", "target": "Non-small cell lung cancer (NSCLC)"}}, {"data": {"source": "ERBB2", "target": "HER2-low tumors"}}, {"data": {"source": "ERBB2", "target": "Glioblastoma"}}, {"data": {"source": "ERBB2", "target": "Advanced/metastatic breast cancer"}}, {"data": {"source": "ERBB2", "target": "HCC"}}, {"data": {"source": "ERBB2", "target": "HR+/HER2+ metastatic breast cancer"}}, {"data": {"source": "ERBB2", "target": "Metastatic HR+/HER2- breast cancer"}}, {"data": {"source": "ERBB2", "target": "Early breast cancer"}}, {"data": {"source": "ERBB2", "target": "Metastatic breast cancer (MBC)"}}, {"data": {"source": "ERBB2", "target": "HER2-low breast cancer"}}, {"data": {"source": "ERBB2", "target": "Metastatic breast cancer (mBC)"}}, {"data": {"source": "ERBB2", "target": "HER2+ advanced breast cancer"}}, {"data": {"source": "ERBB2", "target": "HER2-positive advanced breast cancer"}}, {"data": {"source": "ERBB2", "target": "HER2-positive/HR-positive advanced breast cancer"}}, {"data": {"source": "ERBB2", "target": "Cancers"}}, {"data": {"source": "ERBB2", "target": "Triple-negative breast cancer"}}, {"data": {"source": "ERBB2", "target": "Stage III and IV tumors"}}, {"data": {"source": "ESR1", "target": "Breast cancer"}}, {"data": {"source": "ESR1", "target": "Metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "Estrogen receptor-positive metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "ER-positive breast cancer"}}, {"data": {"source": "ESR1", "target": "ER+ xenografts"}}, {"data": {"source": "ESR1", "target": "ER+/RB-deficient xenografts"}}, {"data": {"source": "ESR1", "target": "Advanced estrogen receptor-positive, HER2-negative breast cancer"}}, {"data": {"source": "ESR1", "target": "Peritoneal metastasis"}}, {"data": {"source": "ESR1", "target": "Breast cancer, gastric cancer with bone metastasis"}}, {"data": {"source": "ESR1", "target": "Cancer"}}, {"data": {"source": "ESR1", "target": "ER+ breast cancer"}}, {"data": {"source": "ESR1", "target": "Advanced breast cancer"}}, {"data": {"source": "ESR1", "target": "Endocrine resistance"}}, {"data": {"source": "ESR1", "target": "ER伪+ breast cancer"}}, {"data": {"source": "ESR1", "target": "breast cancer"}}, {"data": {"source": "ESR1", "target": "tumors"}}, {"data": {"source": "ESR1", "target": "Tumors"}}, {"data": {"source": "ESR1", "target": "HR+/HER2- metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "Metastatic ER+ breast cancer"}}, {"data": {"source": "ESR1", "target": "Advanced/metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "HR+ metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "HR+/HER2+ metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "luminal androgen receptor (LAR) breast cancer"}}, {"data": {"source": "ESR1", "target": "Metastatic disease"}}, {"data": {"source": "ESR1", "target": "Endocrine therapy-resistant ESR1(+) breast cancer"}}, {"data": {"source": "ESR1", "target": "ER-positive, HER2-negative metastatic breast cancer"}}, {"data": {"source": "ESR1", "target": "ER-positive, HER2-negative breast cancer"}}, {"data": {"source": "ESR1", "target": "ER-positive, HER2-positive breast cancer"}}, {"data": {"source": "ESR1", "target": "ERα-positive breast cancer"}}, {"data": {"source": "ESR1", "target": "Resistant tumors"}}, {"data": {"source": "ESR1", "target": "Advanced cancers"}}, {"data": {"source": "ESR1", "target": "Triple-negative breast cancer"}}, {"data": {"source": "ESR1", "target": "Estrogen receptor-positive breast tumors"}}, {"data": {"source": "ESR1", "target": "Estrogen receptor-positive breast cancer"}}, {"data": {"source": "ESR1", "target": "Estrogen-accelerating PDX"}}, {"data": {"source": "ESR1", "target": "Breast tumors"}}, {"data": {"source": "MDM2", "target": "Well-differentiated liposarcoma, Dedifferentiated liposarcoma"}}, {"data": {"source": "MDM2", "target": "Liposarcomas"}}, {"data": {"source": "MDM2", "target": "Adipocytic tumors, atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL)"}}, {"data": {"source": "MDM2", "target": "ALT/WDL, DDL"}}, {"data": {"source": "MDM2", "target": "Dedifferentiated liposarcoma"}}, {"data": {"source": "MDM2", "target": "Lipomatous tumor"}}, {"data": {"source": "MDM2", "target": "DDLPS"}}, {"data": {"source": "MDM2", "target": "ALT/WDL, DDLPS"}}, {"data": {"source": "MDM2", "target": "Low-grade central osteosarcoma"}}, {"data": {"source": "MDM2", "target": "Osteosarcoma, Liposarcoma"}}, {"data": {"source": "MDM2", "target": "ALT"}}, {"data": {"source": "MDM2", "target": "Malignant melanoma"}}, {"data": {"source": "MDM2", "target": "MPLPS"}}, {"data": {"source": "MDM2", "target": "DLOS"}}, {"data": {"source": "MDM2", "target": "Neoplastic tissue"}}, {"data": {"source": "MDM2", "target": "Osteosarcoma"}}, {"data": {"source": "MDM2", "target": "Atypical lipomatous tumor, Well-differentiated liposarcoma"}}, {"data": {"source": "MDM2", "target": "Tumor"}}, {"data": {"source": "MDM2", "target": "Liposarcoma"}}, {"data": {"source": "MDM2", "target": "Liposarcoma, Lipoma"}}, {"data": {"source": "MDM2", "target": "WDLPS, DDLPS"}}, {"data": {"source": "MDM2", "target": "Rhabdomyosarcoma"}}, {"data": {"source": "MDM2", "target": "Salivary gland tumor"}}, {"data": {"source": "MDM2", "target": "Lung adenocarcinoma, liposarcoma"}}, {"data": {"source": "MDM2", "target": "Fatty tumors"}}, {"data": {"source": "MDM2", "target": "GBM"}}, {"data": {"source": "MDM2", "target": "Well-differentiated and dedifferentiated liposarcomas"}}, {"data": {"source": "MDM2", "target": "Malignant gliomas"}}, {"data": {"source": "MDM2", "target": "Metastases to pelvis and spine"}}, {"data": {"source": "MDM2", "target": "Alveolar subtype"}}, {"data": {"source": "MDM2", "target": "Well-differentiated liposarcomas, Dedifferentiated liposarcomas"}}, {"data": {"source": "MDM2", "target": "Malignant fibrous histiocytoma"}}, {"data": {"source": "MDM2", "target": "Neuroblastoma"}}, {"data": {"source": "MDM2", "target": "Tumors"}}, {"data": {"source": "MDM2", "target": "Sclerosing liposarcoma"}}, {"data": {"source": "MDM2", "target": "Pleural tumor"}}, {"data": {"source": "MDM2", "target": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"source": "MDM2", "target": "Glioblastoma"}}, {"data": {"source": "MDM2", "target": "Glioma"}}, {"data": {"source": "MDM2", "target": "Spindle cell lipoma, pleomorphic lipoma"}}, {"data": {"source": "MDM2", "target": "Lipoma"}}, {"data": {"source": "MDM2", "target": "ARMS"}}, {"data": {"source": "MDM2", "target": "ERMS"}}, {"data": {"source": "MDM2", "target": "RP sarcoma"}}, {"data": {"source": "MDM2", "target": "Soft tissue sarcoma"}}, {"data": {"source": "MDM2", "target": "Sarcomatoid CRCC"}}, {"data": {"source": "MDM2", "target": "Uterine Adenosarcomas"}}, {"data": {"source": "MDM2", "target": "Cancer"}}, {"data": {"source": "MDM2", "target": "Mantle cell lymphoma"}}, {"data": {"source": "MDM2", "target": "Liposarcoma (WDLPS, DDLPS)"}}, {"data": {"source": "MDM2", "target": "Acral melanoma (AM)"}}, {"data": {"source": "MDM2", "target": "Glioblastomas"}}, {"data": {"source": "MDM2", "target": "Sarcomas"}}, {"data": {"source": "MDM2", "target": "Melanoma"}}, {"data": {"source": "MDM2", "target": "Liposarcomatous differentiation"}}, {"data": {"source": "MDM2", "target": "GBM (glioblastoma)"}}, {"data": {"source": "MDM2", "target": "Parosteal osteosarcoma"}}, {"data": {"source": "MDM2", "target": "PMA"}}, {"data": {"source": "MDM2", "target": "FGFR-altered IGs"}}, {"data": {"source": "MDM2", "target": "Intimal sarcoma"}}, {"data": {"source": "MDM2", "target": "Hepatoid adenocarcinoma of the stomach (HAS)"}}, {"data": {"source": "MDM2", "target": "Melanoma, GBM"}}, {"data": {"source": "MDM2", "target": "WDLPS,DDLPS"}}, {"data": {"source": "MDM2", "target": "Atypical spindle cell/pleomorphic lipomatous tumor"}}, {"data": {"source": "MDM2", "target": "IS"}}, {"data": {"source": "MDM2", "target": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma"}}, {"data": {"source": "MDM2", "target": "Diffuse astrocytic glioma"}}, {"data": {"source": "MDM2", "target": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma"}}, {"data": {"source": "MDM2", "target": "Gliosarcoma"}}, {"data": {"source": "MDM2", "target": "Gliosarcoma, glioblastoma"}}, {"data": {"source": "MDM2", "target": "MPNST"}}, {"data": {"source": "MDM2", "target": "Undifferentiated sarcoma"}}, {"data": {"source": "MDM2", "target": "ALT/WDL"}}, {"data": {"source": "MDM2", "target": "Benign lipomatous lesions"}}, {"data": {"source": "MDM2", "target": "UHGPS,DDL"}}, {"data": {"source": "MDM2", "target": "Malignant lipomatous tumors"}}, {"data": {"source": "MDM2", "target": "UHGPS"}}, {"data": {"source": "MDM2", "target": "Lipoma, ALT/WDL"}}, {"data": {"source": "MDM2", "target": "Retroperitoneal pleomorphic MFH, dedifferentiated liposarcoma"}}, {"data": {"source": "MDM2", "target": "Inflammatory MFH"}}, {"data": {"source": "MDM2", "target": "POS"}}, {"data": {"source": "MDM2", "target": "Atypical lipomatous tumor, well-differentiated liposarcoma, dedifferentiated liposarcoma"}}, {"data": {"source": "MDM2", "target": "Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)"}}, {"data": {"source": "MDM2", "target": "UPSC sarcomas"}}, {"data": {"source": "MDM2", "target": "Primary lesion"}}, {"data": {"source": "MDM2", "target": "Soft tissue sarcomas"}}, {"data": {"source": "MDM2", "target": "Mesenchymal tumors"}}, {"data": {"source": "MDM2", "target": "APLT"}}, {"data": {"source": "MDM2", "target": "Dedifferentiated osteosarcoma"}}, {"data": {"source": "MDM2", "target": "WDLS, DDLS"}}, {"data": {"source": "MDM2", "target": "Sarcoma"}}, {"data": {"source": "MDM2", "target": "Well-differentiated spindle cell liposarcoma"}}, {"data": {"source": "MDM2", "target": "WDL,DDL"}}, {"data": {"source": "MDM2", "target": "UHGPS, DDLS"}}, {"data": {"source": "MDM2", "target": "Inflammatory myofibroblastic tumor"}}, {"data": {"source": "MDM2", "target": "p-SCs"}}, {"data": {"source": "MDM2", "target": "Lipomatous neoplasms"}}, {"data": {"source": "MDM2", "target": "Atypical lipomatous tumor"}}, {"data": {"source": "MDM2", "target": "Follicle center lymphomas, extranodal marginal zone lymphomas, mantle cell lymphomas"}}, {"data": {"source": "MDM2", "target": "Cervical carcinoma"}}, {"data": {"source": "MDM2", "target": "Cancers"}}, {"data": {"source": "MDM2", "target": "PCNSL"}}, {"data": {"source": "MDM2", "target": "Anaplastic oligodendrogliomas"}}, {"data": {"source": "MDM2", "target": "METex 14 alteration"}}, {"data": {"source": "MDM2", "target": "Glioblastoma (GB)"}}, {"data": {"source": "MDM2", "target": "Breast cancer"}}, {"data": {"source": "MDM2", "target": "Triple negative cancer"}}, {"data": {"source": "MDM2", "target": "Luminal A cancer"}}, {"data": {"source": "MDM2", "target": "Solid tumors"}}, {"data": {"source": "MDM2", "target": "Bone tumor"}}, {"data": {"source": "MDM2", "target": "ALT, parosteal osteosarcoma"}}, {"data": {"source": "MDM2", "target": "DDLPS,PLPS"}}, {"data": {"source": "MDM2", "target": "Ossifying fibroma (OF)"}}, {"data": {"source": "MDM2", "target": "Juvenile ossifying fibroma (JOF)"}}, {"data": {"source": "MDM2", "target": "Pleomorphic xanthoastrocytoma"}}, {"data": {"source": "MTOR", "target": "Malignant peripheral nerve sheath tumors"}}, {"data": {"source": "MTOR", "target": "Triple negative breast cancer"}}, {"data": {"source": "MTOR", "target": "HR+, HER2- breast cancer"}}, {"data": {"source": "MTOR", "target": "GBM"}}, {"data": {"source": "MTOR", "target": "Resistance in hormone-receptor-positive breast cancer"}}, {"data": {"source": "MTOR", "target": "HR+/HER2- breast cancer"}}, {"data": {"source": "MTOR", "target": "Advanced ER+ breast cancer"}}, {"data": {"source": "MTOR", "target": "Endocrine resistance"}}, {"data": {"source": "MTOR", "target": "Endocrine-resistant breast cancer"}}, {"data": {"source": "MTOR", "target": "Breast cancer"}}, {"data": {"source": "MTOR", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "MTOR", "target": "PEComa"}}, {"data": {"source": "MTOR", "target": "Myeloproliferative neoplasms (MPN)"}}, {"data": {"source": "MTOR", "target": "Cancer"}}, {"data": {"source": "MTOR", "target": "Neuroendocrine tumors (NETs)"}}, {"data": {"source": "MTOR", "target": "Hormone-resistant tumors"}}, {"data": {"source": "MTOR", "target": "Non-clear cell RCC"}}, {"data": {"source": "MTOR", "target": "ICC"}}, {"data": {"source": "MTOR", "target": "HCC"}}, {"data": {"source": "MTOR", "target": "Head and neck squamous cell carcinoma (HNSCC)"}}, {"data": {"source": "MTOR", "target": "Tumor"}}, {"data": {"source": "MTOR", "target": "HNSCC"}}, {"data": {"source": "MTOR", "target": "Advanced breast cancer"}}, {"data": {"source": "MTOR", "target": "Osteosarcoma"}}, {"data": {"source": "MTOR", "target": "Metastatic breast cancer"}}, {"data": {"source": "MTOR", "target": "Recurrent glioblastoma"}}, {"data": {"source": "MTOR", "target": "Luminal ABC"}}, {"data": {"source": "MTOR", "target": "Dedifferentiated liposarcoma (DDL), leiomyosarcoma (LMS)"}}, {"data": {"source": "MTOR", "target": "histiocytic sarcoma"}}, {"data": {"source": "MTOR", "target": "Recurrent tumors"}}, {"data": {"source": "MTOR", "target": "Hormone receptor-positive (HR+) breast cancer"}}, {"data": {"source": "MTOR", "target": "ER(+)/FGFR1(+) metastatic breast cancer"}}, {"data": {"source": "MTOR", "target": "ER+ metastatic breast cancer"}}, {"data": {"source": "MTOR", "target": "HR+ ABC"}}, {"data": {"source": "MTOR", "target": "Melanoma"}}, {"data": {"source": "MTOR", "target": "Oral cancer, OSCC"}}, {"data": {"source": "MTOR", "target": "Metastatic NPC"}}, {"data": {"source": "MTOR", "target": "Gynecologic cancers"}}, {"data": {"source": "MTOR", "target": "metastatic breast cancer"}}, {"data": {"source": "MTOR", "target": "Breast cancer,RAS-mutant cancers"}}, {"data": {"source": "MYC", "target": "Osteosarcoma"}}, {"data": {"source": "MYC", "target": "Metastatic colorectal cancer"}}, {"data": {"source": "MYC", "target": "Lymphoproliferative disorder (LPD)"}}, {"data": {"source": "MYC", "target": "Pediatric medulloblastoma (MB)"}}, {"data": {"source": "MYC", "target": "Adult tumors"}}, {"data": {"source": "MYC", "target": "Cancer"}}, {"data": {"source": "MYC", "target": "Metaplastic breast carcinoma"}}, {"data": {"source": "MYC", "target": "Ovarian cancer"}}, {"data": {"source": "MYC", "target": "Breast cancer"}}, {"data": {"source": "MYC", "target": "Mammary gland tumors"}}, {"data": {"source": "MYC", "target": "Polycystic kidney disease"}}, {"data": {"source": "MYC", "target": "Hepatocarcinogenesis"}}, {"data": {"source": "MYC", "target": "Liver tumors"}}, {"data": {"source": "MYC", "target": "HCC"}}, {"data": {"source": "MYC", "target": "Medulloblastoma (Group3/4)"}}, {"data": {"source": "MYC", "target": "Lung adenocarcinoma"}}, {"data": {"source": "MYC", "target": "Tumor"}}, {"data": {"source": "MYC", "target": "PCNSL"}}, {"data": {"source": "MYC", "target": "Burkitt lymphoma"}}, {"data": {"source": "MYC", "target": "Triple-negative breast cancer (TNBC)"}}, {"data": {"source": "MYC", "target": "BRCA(mut)/TNBC"}}, {"data": {"source": "NF1", "target": "Acral melanoma"}}, {"data": {"source": "NF1", "target": "Acquired resistance"}}, {"data": {"source": "NF1", "target": "Soft tissue sarcoma"}}, {"data": {"source": "NF1", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "NF1", "target": "Malignant peripheral nerve sheath tumors (MPNSTs)"}}, {"data": {"source": "NF1", "target": "ESOS"}}, {"data": {"source": "NF1", "target": "Cancer"}}, {"data": {"source": "NF1", "target": "AM"}}, {"data": {"source": "NF1", "target": "histiocytic sarcoma"}}, {"data": {"source": "NF1", "target": "CA-Para"}}, {"data": {"source": "NF1", "target": "CA-Pheo"}}, {"data": {"source": "NF1", "target": "NF1-associated PNF"}}, {"data": {"source": "NF1", "target": "Liposarcoma (LPS)"}}, {"data": {"source": "NRAS", "target": "Melanoma"}}, {"data": {"source": "NRAS", "target": "Malignant melanoma"}}, {"data": {"source": "NRAS", "target": "Acral melanocytic nevus"}}, {"data": {"source": "NRAS", "target": "Acral melanoma"}}, {"data": {"source": "NRAS", "target": "Acute Myeloid Leukemia (AML)"}}, {"data": {"source": "NRAS", "target": "Metastatic melanoma"}}, {"data": {"source": "NRAS", "target": "Solid tumors"}}, {"data": {"source": "NRAS", "target": "NRAS-mutant melanoma"}}, {"data": {"source": "NRAS", "target": "Cancer"}}, {"data": {"source": "NRAS", "target": "Low-grade serous ovarian cancer (LGSC)"}}, {"data": {"source": "NRAS", "target": "AM"}}, {"data": {"source": "NRAS", "target": "histiocytic sarcoma"}}, {"data": {"source": "NRAS", "target": "Melanoma, Cancer"}}, {"data": {"source": "NRAS", "target": "EAs"}}, {"data": {"source": "NRAS", "target": "Melanocytic tumors"}}, {"data": {"source": "NRAS", "target": "Non-invasive follicular thyroid neoplasm"}}, {"data": {"source": "PIK3CA", "target": "Breast cancer"}}, {"data": {"source": "PIK3CA", "target": "CA"}}, {"data": {"source": "PIK3CA", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "PIK3CA", "target": "Metaplastic breast carcinoma"}}, {"data": {"source": "PIK3CA", "target": "Metastatic breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Triple negative breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Advanced breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Cancer"}}, {"data": {"source": "PIK3CA", "target": "AML"}}, {"data": {"source": "PIK3CA", "target": "NSCLC"}}, {"data": {"source": "PIK3CA", "target": "PIK3CA-mutated advanced breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Advanced ER+ breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Endocrine resistance"}}, {"data": {"source": "PIK3CA", "target": "Endocrine-resistant breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Melanoma"}}, {"data": {"source": "PIK3CA", "target": "Squamous cell lung cancer"}}, {"data": {"source": "PIK3CA", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "PIK3CA", "target": "Myeloproliferative neoplasms (MPN)"}}, {"data": {"source": "PIK3CA", "target": "Peritoneal metastasis"}}, {"data": {"source": "PIK3CA", "target": "Metastasis"}}, {"data": {"source": "PIK3CA", "target": "Hormone-resistant tumors"}}, {"data": {"source": "PIK3CA", "target": "Colorectal cancer"}}, {"data": {"source": "PIK3CA", "target": "ER-positive, HER2-negative metastatic breast cancer"}}, {"data": {"source": "PIK3CA", "target": "Diabetes"}}, {"data": {"source": "PIK3CA", "target": "Lung squamous cell carcinoma (LUSC)"}}, {"data": {"source": "PIK3CA", "target": "NRAS-mutant melanoma"}}, {"data": {"source": "PIK3CA", "target": "Breast tumors"}}, {"data": {"source": "PIK3CA", "target": "HER2-negative/HR-positive breast cancer"}}, {"data": {"source": "PIK3CA", "target": "non-IBC"}}, {"data": {"source": "PIK3CA", "target": "Tumor"}}, {"data": {"source": "PIK3CA", "target": "HPV(neg) HNSCC"}}, {"data": {"source": "PIK3CA", "target": "HCC"}}, {"data": {"source": "PIK3CA", "target": "Recurrent glioblastoma"}}, {"data": {"source": "PIK3CA", "target": "Luminal ABC"}}, {"data": {"source": "PIK3CA", "target": "histiocytic sarcoma"}}, {"data": {"source": "PIK3CA", "target": "Salivary gland tumors"}}, {"data": {"source": "PIK3CA", "target": "Recurrent tumors"}}, {"data": {"source": "PIK3CA", "target": "NRAS melanoma"}}, {"data": {"source": "PIK3CA", "target": "Gynecologic cancers"}}, {"data": {"source": "PIK3CA", "target": "Carcinomas"}}, {"data": {"source": "PTEN", "target": "PFS"}}, {"data": {"source": "PTEN", "target": "Malignant melanoma"}}, {"data": {"source": "PTEN", "target": "GBM"}}, {"data": {"source": "PTEN", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "PTEN", "target": "High-grade astrocytic tumors"}}, {"data": {"source": "PTEN", "target": "Melanoma"}}, {"data": {"source": "PTEN", "target": "FGFR-altered IGs"}}, {"data": {"source": "PTEN", "target": "Metaplastic breast carcinoma"}}, {"data": {"source": "PTEN", "target": "Breast cancer"}}, {"data": {"source": "PTEN", "target": "Glioblastoma"}}, {"data": {"source": "PTEN", "target": "Cancer"}}, {"data": {"source": "PTEN", "target": "Tumor"}}, {"data": {"source": "PTEN", "target": "Gliosarcoma"}}, {"data": {"source": "PTEN", "target": "Prostate cancer"}}, {"data": {"source": "PTEN", "target": "Chordoma"}}, {"data": {"source": "PTEN", "target": "Liposarcoma"}}, {"data": {"source": "PTEN", "target": "HPV(U) tumors"}}, {"data": {"source": "PTEN", "target": "Breast tumors"}}, {"data": {"source": "PTEN", "target": "HCC"}}, {"data": {"source": "PTEN", "target": "MBC"}}, {"data": {"source": "PTEN", "target": "histiocytic sarcoma"}}, {"data": {"source": "PTEN", "target": "Salivary gland tumors"}}, {"data": {"source": "PTEN", "target": "Glioblastoma (GB)"}}, {"data": {"source": "PTEN", "target": "CA-Para"}}, {"data": {"source": "RB1", "target": "Sarcoma"}}, {"data": {"source": "RB1", "target": "Seminal vesicle tumors"}}, {"data": {"source": "RB1", "target": "Mesothelioma"}}, {"data": {"source": "RB1", "target": "Low-grade central osteosarcoma"}}, {"data": {"source": "RB1", "target": "Osteosarcoma"}}, {"data": {"source": "RB1", "target": "Multiple myeloma (MM)"}}, {"data": {"source": "RB1", "target": "Cancer"}}, {"data": {"source": "RB1", "target": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"source": "RB1", "target": "Glioblastoma"}}, {"data": {"source": "RB1", "target": "Glioma"}}, {"data": {"source": "RB1", "target": "Retinoblastoma"}}, {"data": {"source": "RB1", "target": "Lymphoid tumors"}}, {"data": {"source": "RB1", "target": "Melanoma"}}, {"data": {"source": "RB1", "target": "Metastases"}}, {"data": {"source": "RB1", "target": "Pituitary adenomas"}}, {"data": {"source": "RB1", "target": "Esophageal conditions"}}, {"data": {"source": "RB1", "target": "High-grade astrocytomas"}}, {"data": {"source": "RB1", "target": "Tumors"}}, {"data": {"source": "RB1", "target": "Glioblastoma, Brain metastases"}}, {"data": {"source": "RB1", "target": "Glioblastoma (GBM)"}}, {"data": {"source": "RB1", "target": "HHT"}}, {"data": {"source": "RB1", "target": "Triple negative breast cancer"}}, {"data": {"source": "RB1", "target": "Breast cancer"}}, {"data": {"source": "RB1", "target": "ER+ breast cancer"}}, {"data": {"source": "RB1", "target": "Solid tumors"}}, {"data": {"source": "RB1", "target": "Rb-deficient tumors"}}, {"data": {"source": "RB1", "target": "ER(+) breast cancer"}}, {"data": {"source": "RB1", "target": "Estrogen receptor-positive, HER2-positive breast cancer"}}, {"data": {"source": "RB1", "target": "CRPC"}}, {"data": {"source": "RB1", "target": "Pleural mesothelioma"}}, {"data": {"source": "RB1", "target": "Hepatocellular carcinoma (HCC)"}}, {"data": {"source": "RB1", "target": "MPNST"}}, {"data": {"source": "RB1", "target": "Diet-induced obesity (DIO)"}}, {"data": {"source": "RB1", "target": "TNBC"}}, {"data": {"source": "RB1", "target": "tumor"}}, {"data": {"source": "RB1", "target": "Atypical meningiomas"}}, {"data": {"source": "RB1", "target": "Esophageal cancer"}}, {"data": {"source": "RB1", "target": "Malignant astrocytomas"}}, {"data": {"source": "RB1", "target": "GBM"}}, {"data": {"source": "RB1", "target": "Human cancers"}}, {"data": {"source": "RB1", "target": "Liver tumor"}}, {"data": {"source": "RB1", "target": "Lung cancer, Colon cancer"}}, {"data": {"source": "RB1", "target": "Tumor"}}, {"data": {"source": "RB1", "target": "Metastatic breast cancer"}}, {"data": {"source": "RB1", "target": "Ovarian cancer"}}, {"data": {"source": "RB1", "target": "Gastric carcinoma"}}, {"data": {"source": "RB1", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "RB1", "target": "Esophageal squamous cell carcinoma"}}, {"data": {"source": "RB1", "target": "Canine mammary carcinoma"}}, {"data": {"source": "RB1", "target": "Retinoblastoma, Osteosarcoma"}}, {"data": {"source": "RB1", "target": "WDLPS,DDLPS"}}, {"data": {"source": "RB1", "target": "osteosarcoma"}}, {"data": {"source": "RB1", "target": "Atypical spindle cell/pleomorphic lipomatous tumor"}}, {"data": {"source": "RB1", "target": "Endometrial carcinomas"}}, {"data": {"source": "RB1", "target": "Squamous Cell Carcinomas"}}, {"data": {"source": "RB1", "target": "Meningeal hemangiopericytomas"}}, {"data": {"source": "RB1", "target": "MHPCs"}}, {"data": {"source": "RB1", "target": "Synovial sarcoma"}}, {"data": {"source": "RB1", "target": "Spindle cell lipoma, pleomorphic lipoma"}}, {"data": {"source": "RB1", "target": "Spindle cell lipoma"}}, {"data": {"source": "RB1", "target": "Liposarcoma"}}, {"data": {"source": "RB1", "target": "Childhood retinoblastoma"}}, {"data": {"source": "RB1", "target": "Bilateral retinoblastoma"}}, {"data": {"source": "RB1", "target": "Sarcomas"}}, {"data": {"source": "RB1", "target": "Human tumors"}}, {"data": {"source": "RB1", "target": "Lung adenocarcinoma"}}, {"data": {"source": "RB1", "target": "Cervical cancer"}}, {"data": {"source": "RB1", "target": "Multiple myeloma"}}, {"data": {"source": "RB1", "target": "Pancreatic ductal adenocarcinoma"}}, {"data": {"source": "RB1", "target": "Mantle cell lymphoma"}}, {"data": {"source": "RB1", "target": "SPA"}}, {"data": {"source": "RB1", "target": "Breast cancer, melanoma, leukemia, lymphoma"}}, {"data": {"source": "RB1", "target": "Triple-negative breast cancer"}}, {"data": {"source": "RB1", "target": "RB1-deficient tumors"}}, {"data": {"source": "RB1", "target": "HR+ breast cancer"}}, {"data": {"source": "RB1", "target": "cancers"}}, {"data": {"source": "RB1", "target": "Neuroendocrine tumors (NETs)"}}, {"data": {"source": "RB1", "target": "PV"}}, {"data": {"source": "RB1", "target": "HCC"}}, {"data": {"source": "RB1", "target": "Glioblastoma (GB)"}}, {"data": {"source": "RB1", "target": "HUC senescence"}}, {"data": {"source": "RB1", "target": "SCLC"}}, {"data": {"source": "RB1", "target": "Endocrine therapy resistance"}}, {"data": {"source": "RB1", "target": "Triple-negative breast cancer (TNBC)"}}, {"data": {"source": "RB1", "target": "FPA"}}, {"data": {"source": "TP53", "target": "Adenocarcinomas"}}, {"data": {"source": "TP53", "target": "Uterine leiomyosarcoma"}}, {"data": {"source": "TP53", "target": "Osteosarcoma"}}, {"data": {"source": "TP53", "target": "Tumor"}}, {"data": {"source": "TP53", "target": "Melanoma"}}, {"data": {"source": "TP53", "target": "Multiple myeloma (MM)"}}, {"data": {"source": "TP53", "target": "Astrocytic tumor, Oligodendroglial tumor"}}, {"data": {"source": "TP53", "target": "Primary lesion, Metastatic lesion"}}, {"data": {"source": "TP53", "target": "Thymic lymphomas"}}, {"data": {"source": "TP53", "target": "Cancer"}}, {"data": {"source": "TP53", "target": "Anaplasia"}}, {"data": {"source": "TP53", "target": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"source": "TP53", "target": "Glioblastoma"}}, {"data": {"source": "TP53", "target": "Glioma"}}, {"data": {"source": "TP53", "target": "Lymphoid tumors"}}, {"data": {"source": "TP53", "target": "Acute Myeloid Leukemia (AML)"}}, {"data": {"source": "TP53", "target": "Soft tissue sarcoma"}}, {"data": {"source": "TP53", "target": "IDH-wildtype glioblastoma"}}, {"data": {"source": "TP53", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "TP53", "target": "B-cell neoplasms"}}, {"data": {"source": "TP53", "target": "Nasal mixed exocrine-neuroendocrine carcinoma"}}, {"data": {"source": "TP53", "target": "GBM"}}, {"data": {"source": "TP53", "target": "FGFR-altered IGs"}}, {"data": {"source": "TP53", "target": "Tumors"}}, {"data": {"source": "TP53", "target": "DPedHGG"}}, {"data": {"source": "TP53", "target": "Metaplastic breast carcinoma"}}, {"data": {"source": "TP53", "target": "ER+ breast cancer"}}, {"data": {"source": "TP53", "target": "Medulloblastoma"}}, {"data": {"source": "TP53", "target": "Atypical meningiomas"}}, {"data": {"source": "TP53", "target": "Prostate cancer"}}, {"data": {"source": "TP53", "target": "WDLPS,DDLPS"}}, {"data": {"source": "TP53", "target": "sPNET, GBM"}}, {"data": {"source": "TP53", "target": "GBM, sPNET"}}, {"data": {"source": "TP53", "target": "Diffuse cerebral glioma, pleomorphic xanthoastrocytoma"}}, {"data": {"source": "TP53", "target": "Diffuse astrocytic glioma"}}, {"data": {"source": "TP53", "target": "Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma"}}, {"data": {"source": "TP53", "target": "Metastatic breast cancer"}}, {"data": {"source": "TP53", "target": "Endometrial carcinomas"}}, {"data": {"source": "TP53", "target": "Endometrioid-type endometrial carcinomas"}}, {"data": {"source": "TP53", "target": "Colon Cancer"}}, {"data": {"source": "TP53", "target": "Human cancers"}}, {"data": {"source": "TP53", "target": "Liposarcoma"}}, {"data": {"source": "TP53", "target": "HR+/HER2- metastatic breast cancer"}}, {"data": {"source": "TP53", "target": "HPV(U) tumors"}}, {"data": {"source": "TP53", "target": "IBC"}}, {"data": {"source": "TP53", "target": "OSCC"}}, {"data": {"source": "TP53", "target": "Skin cancer, SCCs, BCCs"}}, {"data": {"source": "TP53", "target": "Senescence"}}, {"data": {"source": "TP53", "target": "Astrocytomas"}}, {"data": {"source": "TP53", "target": "Malignancies"}}, {"data": {"source": "TP53", "target": "Thick melanoma"}}, {"data": {"source": "TP53", "target": "ESCC"}}, {"data": {"source": "TP53", "target": "Ovarian cancer"}}, {"data": {"source": "TP53", "target": "NSCLC"}}, {"data": {"source": "TP53", "target": "HCC"}}, {"data": {"source": "TP53", "target": "Breast cancer"}}, {"data": {"source": "TP53", "target": "Anaplastic oligodendrogliomas"}}, {"data": {"source": "TP53", "target": "Melanocytic tumors"}}, {"data": {"source": "TP53", "target": "Glioblastomas"}}, {"data": {"source": "TP53", "target": "Glioblastoma (GB)"}}, {"data": {"source": "TP53", "target": "HUC senescence"}}, {"data": {"source": "TP53", "target": "Li-Fraumeni syndrome"}}, {"data": {"source": "TP53", "target": "Marginal zone lymphoma/Splenic B-cell lymphoma"}}, {"data": {"source": "TP53", "target": "FPA"}}, {"data": {"source": "TP53", "target": "High-grade glioma"}}, {"data": {"source": "TP53", "target": "Ossifying fibroma (OF)"}}, {"data": {"source": "TP53", "target": "Pleomorphic xanthoastrocytoma"}}, {"data": {"source": "AKT1", "target": "Palbociclib"}}, {"data": {"source": "AKT1", "target": "SBX"}}, {"data": {"source": "AKT1", "target": "PL"}}, {"data": {"source": "AKT1", "target": "Notopterol"}}, {"data": {"source": "AKT1", "target": "Capivasertib"}}, {"data": {"source": "AKT1", "target": "Capivasertib, anti-HER2 agents, endocrine treatment"}}, {"data": {"source": "BRAF", "target": "Cobimetinib, ALK inhibitors"}}, {"data": {"source": "BRAF", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "BRAF", "target": "CDK4/6 inhibitors, BRAF/MEK-targeting agents"}}, {"data": {"source": "BRAF", "target": "CDK4/6 inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "BRAF", "target": "BRAF inhibitors, MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "BRAF", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "BRAF", "target": "Vemurafenib"}}, {"data": {"source": "BRAF", "target": "GLS1i"}}, {"data": {"source": "BRAF", "target": "anti-PD-1"}}, {"data": {"source": "BRAF", "target": "vemurafenib"}}, {"data": {"source": "BRAF", "target": "Tyrosine kinase inhibitors"}}, {"data": {"source": "BRAF", "target": "BRAF inhibitors"}}, {"data": {"source": "BRAF", "target": "Trametinib, BKM120, LEE011"}}, {"data": {"source": "BRAF", "target": "Palbociclib,BRAF inhibitors,MEK inhibitors"}}, {"data": {"source": "BRAF", "target": "Encorafenib, Cetuximab, CDK4/6 inhibitors"}}, {"data": {"source": "BRAF", "target": "MEK inhibitors"}}, {"data": {"source": "BRAF", "target": "Trametinib, Dabrafenib"}}, {"data": {"source": "BRAF", "target": "Pembrolizumab, Durvalumab, Atezolizumab, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "BRAF", "target": "mTOR inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "BRAF", "target": "BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "CCND1", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "CCND1", "target": "NMBA"}}, {"data": {"source": "CCND1", "target": "Abemaciclib, Ribociclib, Lenvatinib"}}, {"data": {"source": "CCND1", "target": "letrozole, everolimus, palbociclib"}}, {"data": {"source": "CCND1", "target": "GRN163L"}}, {"data": {"source": "CCND1", "target": "Palbociclib,Abemaciclib"}}, {"data": {"source": "CCND1", "target": "ZEN-3694"}}, {"data": {"source": "CCND1", "target": "LEE011"}}, {"data": {"source": "CCND1", "target": "Alcohol"}}, {"data": {"source": "CCND1", "target": "Mannoprotein"}}, {"data": {"source": "CCND1", "target": "PI3K/mTOR inhibitors"}}, {"data": {"source": "CCND1", "target": "Quercetin"}}, {"data": {"source": "CCND1", "target": "Bortezomib (BTZ)"}}, {"data": {"source": "CCND1", "target": "SB431542"}}, {"data": {"source": "CCND1", "target": "PD-0332991"}}, {"data": {"source": "CCND1", "target": "3-carene"}}, {"data": {"source": "CCND1", "target": "Erufosine"}}, {"data": {"source": "CCND1", "target": "LPS"}}, {"data": {"source": "CCND1", "target": "Luteoloside"}}, {"data": {"source": "CCND1", "target": "CTL, ERA"}}, {"data": {"source": "CCND1", "target": "BZD"}}, {"data": {"source": "CCND1", "target": "berberine, evodiamine"}}, {"data": {"source": "CCND1", "target": "MCA"}}, {"data": {"source": "CCND1", "target": "EGCG"}}, {"data": {"source": "CCND1", "target": "HLCA"}}, {"data": {"source": "CCND1", "target": "Palbociclib"}}, {"data": {"source": "CCND1", "target": "Resveratrol"}}, {"data": {"source": "CCND1", "target": "Vitamin K2, Vitamin K3"}}, {"data": {"source": "CCND1", "target": "GAA"}}, {"data": {"source": "CCND1", "target": "Artemisinin"}}, {"data": {"source": "CCND1", "target": "Smurf2 siRNA"}}, {"data": {"source": "CCND1", "target": "SAHA"}}, {"data": {"source": "CCND1", "target": "Rosiglitazone"}}, {"data": {"source": "CCND1", "target": "EESB"}}, {"data": {"source": "CCND1", "target": "AST"}}, {"data": {"source": "CCND1", "target": "9za"}}, {"data": {"source": "CCND1", "target": "cis-nerolidol,trans-nerolidol"}}, {"data": {"source": "CCND1", "target": "Butein"}}, {"data": {"source": "CCND1", "target": "BRAF inhibitors"}}, {"data": {"source": "CCND1", "target": "Salidroside"}}, {"data": {"source": "CCND1", "target": "IB-MECA"}}, {"data": {"source": "CCND1", "target": "PFE"}}, {"data": {"source": "CCND1", "target": "Metformin"}}, {"data": {"source": "CCND1", "target": "Abemaciclib"}}, {"data": {"source": "CCND1", "target": "ERBB2 inhibitors, EGFR inhibitors"}}, {"data": {"source": "CCND1", "target": "BBR"}}, {"data": {"source": "CCND1", "target": "AB680"}}, {"data": {"source": "CCND1", "target": "PS1"}}, {"data": {"source": "CCND1", "target": "SRJ23"}}, {"data": {"source": "CCND1", "target": "Geldanamycin"}}, {"data": {"source": "CCND1", "target": "Flavopiridol,Doxorubicin"}}, {"data": {"source": "CCND1", "target": "Ceritinib, Ribociclib"}}, {"data": {"source": "CCND1", "target": "TMOC"}}, {"data": {"source": "CCND1", "target": "Rapamycin"}}, {"data": {"source": "CCNE1", "target": "elacestrant"}}, {"data": {"source": "CCNE1", "target": "PD-0332991"}}, {"data": {"source": "CCNE1", "target": "SBX"}}, {"data": {"source": "CCNE1", "target": "EGCG"}}, {"data": {"source": "CCNE1", "target": "AST"}}, {"data": {"source": "CCNE1", "target": "Butein"}}, {"data": {"source": "CCNE1", "target": "Palbociclib"}}, {"data": {"source": "CCNE1", "target": "ERBB2 inhibitors, EGFR inhibitors"}}, {"data": {"source": "CDKN1A", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "CDKN1A", "target": "Abemaciclib, lenvatinib"}}, {"data": {"source": "CDKN1A", "target": "Mannoprotein"}}, {"data": {"source": "CDKN1A", "target": "Bortezomib (BTZ)"}}, {"data": {"source": "CDKN1A", "target": "Propionate"}}, {"data": {"source": "CDKN1A", "target": "Talazoparib"}}, {"data": {"source": "CDKN1A", "target": "BZD"}}, {"data": {"source": "CDKN1A", "target": "berberine, evodiamine"}}, {"data": {"source": "CDKN1A", "target": "MCA"}}, {"data": {"source": "CDKN1A", "target": "Resveratrol"}}, {"data": {"source": "CDKN1A", "target": "Endosulfan"}}, {"data": {"source": "CDKN1A", "target": "KT"}}, {"data": {"source": "CDKN1A", "target": "GAA"}}, {"data": {"source": "CDKN1A", "target": "Smurf2 siRNA"}}, {"data": {"source": "CDKN1A", "target": "SAHA"}}, {"data": {"source": "CDKN1A", "target": "Rosiglitazone"}}, {"data": {"source": "CDKN1A", "target": "EESB"}}, {"data": {"source": "CDKN1A", "target": "AST"}}, {"data": {"source": "CDKN1A", "target": "PFE"}}, {"data": {"source": "CDKN1A", "target": "BBR"}}, {"data": {"source": "CDKN1A", "target": "TMOC"}}, {"data": {"source": "CDKN2A", "target": "Enzalutamide"}}, {"data": {"source": "CDKN2A", "target": "PARP inhibitors"}}, {"data": {"source": "CDKN2A", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "CDKN2A", "target": "Palbociclib"}}, {"data": {"source": "CDKN2A", "target": "NMBA"}}, {"data": {"source": "CDKN2A", "target": "Imatinib"}}, {"data": {"source": "CDKN2A", "target": "palbociclib, trametinib"}}, {"data": {"source": "CDKN2A", "target": "Palbociclib, Letrozole"}}, {"data": {"source": "CDKN2A", "target": "MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy"}}, {"data": {"source": "CDKN2A", "target": "palbociclib"}}, {"data": {"source": "CDKN2A", "target": "Combined drugs"}}, {"data": {"source": "CDKN2A", "target": "Doxorubicin"}}, {"data": {"source": "CDKN2A", "target": "Alcohol"}}, {"data": {"source": "CDKN2A", "target": "3-carene"}}, {"data": {"source": "CDKN2A", "target": "EGCG"}}, {"data": {"source": "CDKN2A", "target": "Resveratrol"}}, {"data": {"source": "CDKN2A", "target": "Artemisinin"}}, {"data": {"source": "CDKN2A", "target": "ATRA"}}, {"data": {"source": "CDKN2A", "target": "Abemaciclib"}}, {"data": {"source": "CDKN2A", "target": "Osimertinib, Palbociclib"}}, {"data": {"source": "CDKN2A", "target": "Osimertinib, palbociclib"}}, {"data": {"source": "CDKN2A", "target": "palbociclib,celecoxib"}}, {"data": {"source": "CDKN2A", "target": "CDK4/6 inhibitors, immunotherapy"}}, {"data": {"source": "CDKN2A", "target": "Palbociclib, Cetuximab"}}, {"data": {"source": "CDKN2A", "target": "5-aza-2'-deoxycytidine"}}, {"data": {"source": "CDKN2A", "target": "PD0332991"}}, {"data": {"source": "CDKN2A", "target": "TMOC"}}, {"data": {"source": "CDKN2A", "target": "BRAF/MEK inhibitors"}}, {"data": {"source": "CDKN2A", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "CDKN2B", "target": "PARP inhibitors"}}, {"data": {"source": "CDKN2B", "target": "palbociclib, trametinib"}}, {"data": {"source": "CDKN2B", "target": "Palbociclib"}}, {"data": {"source": "CDKN2B", "target": "Combined drugs"}}, {"data": {"source": "CDKN2B", "target": "Osimertinib, Palbociclib"}}, {"data": {"source": "CDKN2B", "target": "Osimertinib, palbociclib"}}, {"data": {"source": "CDKN2B", "target": "PD0332991"}}, {"data": {"source": "E2F1", "target": "DBF"}}, {"data": {"source": "E2F1", "target": "Alcohol"}}, {"data": {"source": "E2F1", "target": "elacestrant"}}, {"data": {"source": "E2F1", "target": "Erk1/2 inhibitors,CDK4/6 inhibitors"}}, {"data": {"source": "EGFR", "target": "Osimertinib"}}, {"data": {"source": "EGFR", "target": "EGFR and HER2 inhibitors"}}, {"data": {"source": "EGFR", "target": "EGFR blockers, CDK4/6 inhibitors"}}, {"data": {"source": "EGFR", "target": "Cetuximab, Afatinib, Palbociclib"}}, {"data": {"source": "EGFR", "target": "palbociclib, erlotinib"}}, {"data": {"source": "EGFR", "target": "EGFR-TKIs"}}, {"data": {"source": "EGFR", "target": "Necitumumab, afatinib, erlotinib"}}, {"data": {"source": "EGFR", "target": "MEK inhibitors, EGFR inhibitors"}}, {"data": {"source": "EGFR", "target": "CDK4/6 inhibitors, EGFR inhibitors"}}, {"data": {"source": "EGFR", "target": "EGFR-TKI"}}, {"data": {"source": "EGFR", "target": "Combined drugs"}}, {"data": {"source": "EGFR", "target": "Anti-EGFR therapy,CDK4/6 inhibitors"}}, {"data": {"source": "EGFR", "target": "Tyrosine kinase inhibitors"}}, {"data": {"source": "EGFR", "target": "Temozolomide, CDK4/6 inhibitors, EGFR inhibitors"}}, {"data": {"source": "EGFR", "target": "PD 0332991"}}, {"data": {"source": "EGFR", "target": "EGFR inhibitors"}}, {"data": {"source": "EGFR", "target": "Osimertinib, Palbociclib"}}, {"data": {"source": "EGFR", "target": "Osimertinib, palbociclib"}}, {"data": {"source": "EGFR", "target": "Palbociclib,Erlotinib"}}, {"data": {"source": "EGFR", "target": "B7-H3"}}, {"data": {"source": "EGFR", "target": "Palbociclib"}}, {"data": {"source": "EGFR", "target": "EGFR inhibitors, HER2 inhibitors"}}, {"data": {"source": "EGFR", "target": "Afatinib,Palbociclib"}}, {"data": {"source": "EGFR", "target": "multi-kinase inhibitors"}}, {"data": {"source": "ERBB2", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "ERBB2", "target": "Palbociclib"}}, {"data": {"source": "ERBB2", "target": "Neoadjuvant therapy"}}, {"data": {"source": "ERBB2", "target": "Palbociclib, Fulvestrant"}}, {"data": {"source": "ERBB2", "target": "EGFR and HER2 inhibitors"}}, {"data": {"source": "ERBB2", "target": "Fulvestrant, Capivasertib"}}, {"data": {"source": "ERBB2", "target": "Trastuzumab"}}, {"data": {"source": "ERBB2", "target": "Abemaciclib, fulvestrant, palbociclib, ribociclib"}}, {"data": {"source": "ERBB2", "target": "HER2-directed therapy, Chemotherapy"}}, {"data": {"source": "ERBB2", "target": "CDK4/6 inhibitor"}}, {"data": {"source": "ERBB2", "target": "ribociclib,palbociclib,abemaciclib"}}, {"data": {"source": "ERBB2", "target": "Neratinib,Trastuzumab deruxtecan,Palbociclib"}}, {"data": {"source": "ERBB2", "target": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"source": "ERBB2", "target": "CDK4/6 inhibitors, Aromatase inhibitors"}}, {"data": {"source": "ERBB2", "target": "Trastuzumab deruxtecan"}}, {"data": {"source": "ERBB2", "target": "Camizestrant, Fulvestrant"}}, {"data": {"source": "ERBB2", "target": "CDK4/6 inhibitors, anti-HER2"}}, {"data": {"source": "ERBB2", "target": "Dalpiciclib, pyrotinib"}}, {"data": {"source": "ERBB2", "target": "Tucatinib, letrozole, palbociclib"}}, {"data": {"source": "ERBB2", "target": "Ribociclib"}}, {"data": {"source": "ERBB2", "target": "Aromatase inhibitors"}}, {"data": {"source": "ERBB2", "target": "trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine"}}, {"data": {"source": "ERBB2", "target": "Ibrutinib"}}, {"data": {"source": "ERBB2", "target": "EGFR inhibitors, HER2 inhibitors"}}, {"data": {"source": "ERBB2", "target": "Tucatinib, Palbociclib, Fulvestrant"}}, {"data": {"source": "ERBB2", "target": "Palbociclib, Abemaciclib, Ribociclib"}}, {"data": {"source": "ERBB2", "target": "Pertuzumab,T-DM1,Tyrosine kinase inhibitors"}}, {"data": {"source": "ESR1", "target": "Tamoxifen"}}, {"data": {"source": "ESR1", "target": "Letrozole"}}, {"data": {"source": "ESR1", "target": "Fulvestrant, BKM120"}}, {"data": {"source": "ESR1", "target": "Pemrametostat, Fulvestrant"}}, {"data": {"source": "ESR1", "target": "Fulvestrant"}}, {"data": {"source": "ESR1", "target": "Fulvestrant, Camizestrant"}}, {"data": {"source": "ESR1", "target": "LH-RH agonist, aromatase inhibitor"}}, {"data": {"source": "ESR1", "target": "Elacestrant"}}, {"data": {"source": "ESR1", "target": "Endocrine therapy"}}, {"data": {"source": "ESR1", "target": "Aromatase inhibitors"}}, {"data": {"source": "ESR1", "target": "Hormone therapy"}}, {"data": {"source": "ESR1", "target": "ER伪 inhibitors"}}, {"data": {"source": "ESR1", "target": "Anti-estrogens"}}, {"data": {"source": "ESR1", "target": "Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "ESR1", "target": "elacestrant, fulvestrant"}}, {"data": {"source": "ESR1", "target": "ATP-competitive inhibitors"}}, {"data": {"source": "ESR1", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "ESR1", "target": "GPX4 inhibitors"}}, {"data": {"source": "ESR1", "target": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"source": "ESR1", "target": "Selective ER degraders"}}, {"data": {"source": "ESR1", "target": "Camizestrant, Fulvestrant"}}, {"data": {"source": "ESR1", "target": "Fulvestrant, aromatase inhibitors"}}, {"data": {"source": "ESR1", "target": "Fulvestrant, anastrozole"}}, {"data": {"source": "ESR1", "target": "Tucatinib, letrozole, palbociclib"}}, {"data": {"source": "ESR1", "target": "SERD, SSH-CDK4/6 inhibitors"}}, {"data": {"source": "ESR1", "target": "Palbociclib"}}, {"data": {"source": "ESR1", "target": "Abemaciclib"}}, {"data": {"source": "ESR1", "target": "Antiestrogens"}}, {"data": {"source": "ESR1", "target": "Tucatinib, Palbociclib, Fulvestrant"}}, {"data": {"source": "ESR1", "target": "fulvestrant"}}, {"data": {"source": "ESR1", "target": "tamoxifen,aromatase inhibitors"}}, {"data": {"source": "ESR1", "target": "H3B-6545, fulvestrant"}}, {"data": {"source": "ESR1", "target": "H3B-6545"}}, {"data": {"source": "ESR1", "target": "Camizestrant"}}, {"data": {"source": "MDM2", "target": "Inhibitors of CDK4 and MDM2"}}, {"data": {"source": "MDM2", "target": "CDK4 inhibitors, MDM2 inhibitors, cediranib, eribulin, crizotinib"}}, {"data": {"source": "MDM2", "target": "MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy"}}, {"data": {"source": "MDM2", "target": "Bortezomib"}}, {"data": {"source": "MDM2", "target": "Anti-MDM2 therapies"}}, {"data": {"source": "MDM2", "target": "MDM2 inhibitors"}}, {"data": {"source": "MDM2", "target": "Palbociclib"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors,ET"}}, {"data": {"source": "MTOR", "target": "MTOR"}}, {"data": {"source": "MTOR", "target": "Palbociclib, Everolimus"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "Alpelisib, MLN0128, palbociclib"}}, {"data": {"source": "MTOR", "target": "Alpelisib"}}, {"data": {"source": "MTOR", "target": "nab-sirolimus"}}, {"data": {"source": "MTOR", "target": "PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators"}}, {"data": {"source": "MTOR", "target": "deucravacitinib, CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "Everolimus, sunitinib"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors"}}, {"data": {"source": "MTOR", "target": "VEGF inhibitors, mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "MLN0128"}}, {"data": {"source": "MTOR", "target": "Palbociclib, MLN0128"}}, {"data": {"source": "MTOR", "target": "Abemaciclib, lenvatinib"}}, {"data": {"source": "MTOR", "target": "mTOR inhibitor"}}, {"data": {"source": "MTOR", "target": "Palbociclib"}}, {"data": {"source": "MTOR", "target": "Everolimus"}}, {"data": {"source": "MTOR", "target": "Rapamycin"}}, {"data": {"source": "MTOR", "target": "RMC-6272"}}, {"data": {"source": "MTOR", "target": "PI3K inhibitors, mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "E6201"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors, PI3K/mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "FMD"}}, {"data": {"source": "MTOR", "target": "PIK3CA/mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "Ribociclib, everolimus"}}, {"data": {"source": "MTOR", "target": "fulvestrant"}}, {"data": {"source": "MTOR", "target": "mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "Everolimus,Palbociclib,Ribociclib,Abemaciclib,Alpelisib"}}, {"data": {"source": "MTOR", "target": "PI3K/mTOR inhibitors, fulvestrant"}}, {"data": {"source": "MTOR", "target": "PI3K/mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "Aromatase inhibitors, mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "MTOR", "target": "PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "MTOR", "target": "mTOR inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "MTOR", "target": "Gedatolisib"}}, {"data": {"source": "MTOR", "target": "mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "MTOR", "target": "CDK4/6 inhibitors,mTOR inhibitors"}}, {"data": {"source": "MYC", "target": "Abiraterone"}}, {"data": {"source": "MYC", "target": "Palbociclib"}}, {"data": {"source": "MYC", "target": "Olaparib, Palbociclib"}}, {"data": {"source": "MYC", "target": "palbociclib"}}, {"data": {"source": "MYC", "target": "Abemaciclib, lenvatinib"}}, {"data": {"source": "MYC", "target": "Luteoloside"}}, {"data": {"source": "MYC", "target": "RMC-6272"}}, {"data": {"source": "MYC", "target": "Doxazosin"}}, {"data": {"source": "MYC", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "MYC", "target": "Olaparib"}}, {"data": {"source": "MYC", "target": "TGF-β"}}, {"data": {"source": "NF1", "target": "Palbociclib, fulvestrant"}}, {"data": {"source": "NF1", "target": "Cobimetinib"}}, {"data": {"source": "NRAS", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "NRAS", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "NRAS", "target": "MEK1/2 inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "NRAS", "target": "Binimetinib, Ribociclib"}}, {"data": {"source": "NRAS", "target": "Palbociclib,BRAF inhibitors,MEK inhibitors"}}, {"data": {"source": "NRAS", "target": "MEK inhibitors"}}, {"data": {"source": "NRAS", "target": "Binimetinib"}}, {"data": {"source": "NRAS", "target": "CDK4/6 inhibitors, MEK inhibitors"}}, {"data": {"source": "NRAS", "target": "BRAF/MEK inhibitors"}}, {"data": {"source": "PIK3CA", "target": "PI3K inhibitors, FGFR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "PI3K inhibitors"}}, {"data": {"source": "PIK3CA", "target": "PI3K inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors"}}, {"data": {"source": "PIK3CA", "target": "Piqray, Fulvestrant"}}, {"data": {"source": "PIK3CA", "target": "Alpelisib"}}, {"data": {"source": "PIK3CA", "target": "Alpelisib, MLN0128, palbociclib"}}, {"data": {"source": "PIK3CA", "target": "PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators"}}, {"data": {"source": "PIK3CA", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors"}}, {"data": {"source": "PIK3CA", "target": "Capivasertib, fulvestrant"}}, {"data": {"source": "PIK3CA", "target": "letrozole, everolimus, palbociclib"}}, {"data": {"source": "PIK3CA", "target": "KRAS inhibitors, PI3K inhibitors, HSP90 inhibitors, CDK4/6 inhibitors, SHP2 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "Alpelisib, Ribociclib"}}, {"data": {"source": "PIK3CA", "target": "Ribociclib, Alpelisib"}}, {"data": {"source": "PIK3CA", "target": "Palbociclib"}}, {"data": {"source": "PIK3CA", "target": "Palbociclib, 7rh"}}, {"data": {"source": "PIK3CA", "target": "Neratinib,Trastuzumab deruxtecan,Palbociclib"}}, {"data": {"source": "PIK3CA", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "PI3K inhibitors, HSP90 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "Osimertinib"}}, {"data": {"source": "PIK3CA", "target": "CDK4/6 inhibitors, PI3K/mTOR inhibitors"}}, {"data": {"source": "PIK3CA", "target": "FMD"}}, {"data": {"source": "PIK3CA", "target": "Palbociclib, Fulvestrant"}}, {"data": {"source": "PIK3CA", "target": "PIK3CA/mTOR inhibitors"}}, {"data": {"source": "PIK3CA", "target": "PIK3CA inhibitors, AR inhibitors, BCL2 inhibitors"}}, {"data": {"source": "PIK3CA", "target": "alpelisib"}}, {"data": {"source": "PIK3CA", "target": "Everolimus,Palbociclib,Ribociclib,Abemaciclib,Alpelisib"}}, {"data": {"source": "PIK3CA", "target": "CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors"}}, {"data": {"source": "PIK3CA", "target": "Gedatolisib"}}, {"data": {"source": "PTEN", "target": "mTOR inhibitor"}}, {"data": {"source": "PTEN", "target": "Capivasertib, fulvestrant"}}, {"data": {"source": "PTEN", "target": "Palbociclib"}}, {"data": {"source": "PTEN", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "PTEN", "target": "TMOC"}}, {"data": {"source": "RB1", "target": "NMBA"}}, {"data": {"source": "RB1", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "RB1", "target": "Palbociclib"}}, {"data": {"source": "RB1", "target": "CDK4/6 inhibitor"}}, {"data": {"source": "RB1", "target": "Abemaciclib, Ribociclib, Lenvatinib"}}, {"data": {"source": "RB1", "target": "CDK4/6 inhibitors, MEK inhibitors"}}, {"data": {"source": "RB1", "target": "Alpelisib, Ribociclib"}}, {"data": {"source": "RB1", "target": "Abemaciclib"}}, {"data": {"source": "RB1", "target": "TQB3616"}}, {"data": {"source": "RB1", "target": "LEE011"}}, {"data": {"source": "RB1", "target": "abemaciclib"}}, {"data": {"source": "RB1", "target": "MPT0L145, abemaciclib"}}, {"data": {"source": "RB1", "target": "elacestrant"}}, {"data": {"source": "RB1", "target": "HMBA"}}, {"data": {"source": "RB1", "target": "SAHA"}}, {"data": {"source": "RB1", "target": "CDK inhibitors"}}, {"data": {"source": "RB1", "target": "Erk1/2 inhibitors,CDK4/6 inhibitors"}}, {"data": {"source": "RB1", "target": "G1T38"}}, {"data": {"source": "RB1", "target": "Dalpiciclib"}}, {"data": {"source": "RB1", "target": "Palbociclib,Erlotinib"}}, {"data": {"source": "RB1", "target": "PL"}}, {"data": {"source": "RB1", "target": "Ribociclib"}}, {"data": {"source": "RB1", "target": "PD-0332991, LEE011"}}, {"data": {"source": "RB1", "target": "rapamycin"}}, {"data": {"source": "RB1", "target": "palbociclib"}}, {"data": {"source": "RB1", "target": "palbociclib, doxorubicin, AZD1775"}}, {"data": {"source": "RB1", "target": "ARV-825, Fulvestrant, Palbociclib"}}, {"data": {"source": "RB1", "target": "Ceritinib, Ribociclib"}}, {"data": {"source": "RB1", "target": "Palbociclib, Abemaciclib"}}, {"data": {"source": "RB1", "target": "PF-7006"}}, {"data": {"source": "TP53", "target": "palbociclib, erlotinib"}}, {"data": {"source": "TP53", "target": "RP-6306, Gemcitabine"}}, {"data": {"source": "TP53", "target": "Talazoparib"}}, {"data": {"source": "TP53", "target": "Piceatannol"}}, {"data": {"source": "TP53", "target": "KT"}}, {"data": {"source": "TP53", "target": "Doxazosin"}}, {"data": {"source": "TP53", "target": "Osimertinib"}}, {"data": {"source": "TP53", "target": "doxorubicin"}}, {"data": {"source": "TP53", "target": "RP-6306, gemcitabine"}}, {"data": {"source": "TP53", "target": "TP53-modulating drugs"}}, {"data": {"source": "TP53", "target": "MDM2 inhibitors"}}, {"data": {"source": "AKT1", "target": "PI3K"}}, {"data": {"source": "AKT1", "target": "EGFR, HER2, AKT"}}, {"data": {"source": "AKT1", "target": "IL-17 signaling"}}, {"data": {"source": "AKT1", "target": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"source": "BRAF", "target": "RAS-BRAF"}}, {"data": {"source": "BRAF", "target": "RAS-RAF-MEK-ERK"}}, {"data": {"source": "BRAF", "target": "BRAF/MEK, ALK, CDK4/6"}}, {"data": {"source": "BRAF", "target": "Mitogen-activated protein kinase pathway"}}, {"data": {"source": "BRAF", "target": "RAS-MAPK"}}, {"data": {"source": "BRAF", "target": "MAPK"}}, {"data": {"source": "BRAF", "target": "BRAF pathway"}}, {"data": {"source": "CCND1", "target": "RAS-BRAF"}}, {"data": {"source": "CCND1", "target": "p16-cdk4-cyclin D1-pRb"}}, {"data": {"source": "CCND1", "target": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway"}}, {"data": {"source": "CCND1", "target": "CDK4/CDK6-cyclin D1 pathway"}}, {"data": {"source": "CCND1", "target": "Ubiquitin-proteasome system"}}, {"data": {"source": "CCND1", "target": "Cell-cycle pathway"}}, {"data": {"source": "CCND1", "target": "PI3K-AKT, CCND1-CDK4/6"}}, {"data": {"source": "CCND1", "target": "pRb"}}, {"data": {"source": "CCND1", "target": "Cell cycle"}}, {"data": {"source": "CCND1", "target": "Cell-cycle markers"}}, {"data": {"source": "CCND1", "target": "PI3K/AKT"}}, {"data": {"source": "CCND1", "target": "AKT/mTOR"}}, {"data": {"source": "CCND1", "target": "G1-phase pathway"}}, {"data": {"source": "CCND1", "target": "G1-S transition"}}, {"data": {"source": "CCND1", "target": "MEK, p38, ERK1/2"}}, {"data": {"source": "CCND1", "target": "AP-1"}}, {"data": {"source": "CCND1", "target": "G1 phase"}}, {"data": {"source": "CCND1", "target": "p38 MAPK"}}, {"data": {"source": "CCND1", "target": "PI3K/AKT pathway"}}, {"data": {"source": "CCND1", "target": "ERK1/2"}}, {"data": {"source": "CCND1", "target": "STAT3,Erk,p38"}}, {"data": {"source": "CCND1", "target": "CDK4-cyclin D1 pathway"}}, {"data": {"source": "CCND1", "target": "Cell cycle progression"}}, {"data": {"source": "CCND1", "target": "G1-S regulatory pathway"}}, {"data": {"source": "CCND1", "target": "RAS/MAPK"}}, {"data": {"source": "CCND1", "target": "G1/S transition"}}, {"data": {"source": "CCND1", "target": "Cyclin D/CDK4"}}, {"data": {"source": "CCND1", "target": "Cyclin D1/CDK4"}}, {"data": {"source": "CCND1", "target": "Cyclin pathway"}}, {"data": {"source": "CCND1", "target": "ER-cyclin D1-CDK4/6-RB pathway"}}, {"data": {"source": "CCND1", "target": "Cyclin signaling"}}, {"data": {"source": "CCND1", "target": "CDK4/6-cyclin D1"}}, {"data": {"source": "CCND1", "target": "Wnt, Hippo"}}, {"data": {"source": "CCND1", "target": "CDKN2A-CCND-CDK4/6-Rb"}}, {"data": {"source": "CCND1", "target": "Akt/GSK-3/Cdc2 pathway"}}, {"data": {"source": "CCND1", "target": "mTORC1/2"}}, {"data": {"source": "CCND1", "target": "PKC,MAPK"}}, {"data": {"source": "CCND1", "target": "G1 arrest"}}, {"data": {"source": "CCND1", "target": "PI3K/AKT/mTOR, Cell-cycle machinery"}}, {"data": {"source": "CCNE1", "target": "PI3K/AKT"}}, {"data": {"source": "CCNE1", "target": "G1-S transition"}}, {"data": {"source": "CCNE1", "target": "MEK, p38, ERK1/2"}}, {"data": {"source": "CCNE1", "target": "G1-S regulatory pathway"}}, {"data": {"source": "CDKN1A", "target": "Cell cycle"}}, {"data": {"source": "CDKN1A", "target": "Cell-cycle markers"}}, {"data": {"source": "CDKN1A", "target": "STAT3,Erk,p38"}}, {"data": {"source": "CDKN2A", "target": "Raf-Mek-Erk pathway"}}, {"data": {"source": "CDKN2A", "target": "Cell cycle pathway"}}, {"data": {"source": "CDKN2A", "target": "FAMMM"}}, {"data": {"source": "CDKN2A", "target": "RB1,TP53"}}, {"data": {"source": "CDKN2A", "target": "p16INK4/CDK4/RB"}}, {"data": {"source": "CDKN2A", "target": "Cell cycle control"}}, {"data": {"source": "CDKN2A", "target": "Rb-CDK4,p53"}}, {"data": {"source": "CDKN2A", "target": "Rb pathway"}}, {"data": {"source": "CDKN2A", "target": "p16-cdk4-cyclin D1-pRb"}}, {"data": {"source": "CDKN2A", "target": "Rb-CDK4, p53 pathways"}}, {"data": {"source": "CDKN2A", "target": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway"}}, {"data": {"source": "CDKN2A", "target": "p16INK4a/cyclin D/CDK4/6/RB pathway"}}, {"data": {"source": "CDKN2A", "target": "MEK"}}, {"data": {"source": "CDKN2A", "target": "Cell-cycle pathway"}}, {"data": {"source": "CDKN2A", "target": "G1-phase pathway"}}, {"data": {"source": "CDKN2A", "target": "Cyclin D-CDK4/6-Rb-INK4"}}, {"data": {"source": "CDKN2A", "target": "Cell cycle"}}, {"data": {"source": "CDKN2A", "target": "CDK4/6/RB pathway"}}, {"data": {"source": "CDKN2A", "target": "p53 pathway"}}, {"data": {"source": "CDKN2A", "target": "CDK4-pRb, p53"}}, {"data": {"source": "CDKN2A", "target": "pRB"}}, {"data": {"source": "CDKN2A", "target": "P16(INK4A)-CDK4/6-RB"}}, {"data": {"source": "CDKN2A", "target": "Pigmentation pathway"}}, {"data": {"source": "CDKN2A", "target": "G1 cyclin-dependent kinase"}}, {"data": {"source": "CDKN2A", "target": "TGFB"}}, {"data": {"source": "CDKN2A", "target": "COX-2/Wnt"}}, {"data": {"source": "CDKN2A", "target": "Cyclin pathway"}}, {"data": {"source": "CDKN2A", "target": "p53, p16"}}, {"data": {"source": "CDKN2A", "target": "CDKN2A-CCND-CDK4/6-Rb"}}, {"data": {"source": "CDKN2A", "target": "Rb/p16INK4a/cyclin D-dependent kinase"}}, {"data": {"source": "CDKN2A", "target": "Rb and p53/MDM2/p14ARF"}}, {"data": {"source": "CDKN2A", "target": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"source": "CDKN2A", "target": "RAR signaling"}}, {"data": {"source": "CDKN2A", "target": "Cyclin D-CDK4/6"}}, {"data": {"source": "CDKN2A", "target": "MAPK, Cell cycle"}}, {"data": {"source": "CDKN2B", "target": "Raf-Mek-Erk pathway"}}, {"data": {"source": "CDKN2B", "target": "RB1,TP53"}}, {"data": {"source": "CDKN2B", "target": "Rb-CDK4, p53 pathways"}}, {"data": {"source": "CDKN2B", "target": "MEK"}}, {"data": {"source": "CDKN2B", "target": "Cell-cycle pathway"}}, {"data": {"source": "CDKN2B", "target": "TGF beta"}}, {"data": {"source": "CDKN2B", "target": "TGF-beta"}}, {"data": {"source": "CDKN2B", "target": "TGFB"}}, {"data": {"source": "CDKN2B", "target": "Cyclin pathway"}}, {"data": {"source": "CDKN2B", "target": "Akt/GSK-3/Cdc2 pathway"}}, {"data": {"source": "CDKN2B", "target": "Cell cycle"}}, {"data": {"source": "CDKN2B", "target": "Cyclin D-CDK4/6"}}, {"data": {"source": "E2F1", "target": "CDK4/6,Erk1/2"}}, {"data": {"source": "E2F1", "target": "mTORC1/2,CDK4/6"}}, {"data": {"source": "E2F1", "target": "mTORC1/2"}}, {"data": {"source": "EGFR", "target": "EGFR"}}, {"data": {"source": "EGFR", "target": "EGFR-TKI pathway"}}, {"data": {"source": "EGFR", "target": "MAPK, AKT, STAT3, Src, Abl"}}, {"data": {"source": "EGFR", "target": "p16-CDK4/6-RB,AREG/EGFR"}}, {"data": {"source": "EGFR", "target": "CDK4/6,IGF1R/FGFR/EGFR"}}, {"data": {"source": "EGFR", "target": "EGFR, HER2, AKT"}}, {"data": {"source": "EGFR", "target": "EGFR, HER2"}}, {"data": {"source": "EGFR", "target": "Akt/GSK-3/Cdc2 pathway"}}, {"data": {"source": "EGFR", "target": "EGFR signaling"}}, {"data": {"source": "ERBB2", "target": "Cell cycle pathway"}}, {"data": {"source": "ERBB2", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "ERBB2", "target": "Cell-cycle pathway"}}, {"data": {"source": "ERBB2", "target": "EGFR, HER2, AKT"}}, {"data": {"source": "ERBB2", "target": "EGFR, HER2"}}, {"data": {"source": "ERBB2", "target": "Estrogen signaling, HER2 signaling"}}, {"data": {"source": "ERBB2", "target": "Akt/GSK-3/Cdc2 pathway"}}, {"data": {"source": "ESR1", "target": "Cell cycle pathway"}}, {"data": {"source": "ESR1", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "ESR1", "target": "PIK3CA/mTOR"}}, {"data": {"source": "ESR1", "target": "MAP kinase pathway"}}, {"data": {"source": "ESR1", "target": "ATR:CHK1"}}, {"data": {"source": "ESR1", "target": "mTORC1/2,CDK4/6,ER"}}, {"data": {"source": "ESR1", "target": "Estrogen signaling, HER2 signaling"}}, {"data": {"source": "ESR1", "target": "Growth factor receptor signaling"}}, {"data": {"source": "MDM2", "target": "Retinoblastoma pathway"}}, {"data": {"source": "MDM2", "target": "Cell cycle control"}}, {"data": {"source": "MDM2", "target": "12q13-15 region"}}, {"data": {"source": "MDM2", "target": "TP53 pathway"}}, {"data": {"source": "MDM2", "target": "Rb and p53/MDM2/p14ARF"}}, {"data": {"source": "MDM2", "target": "Cell cycle"}}, {"data": {"source": "MDM2", "target": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"source": "MTOR", "target": "mTOR"}}, {"data": {"source": "MTOR", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "MTOR", "target": "MTOR"}}, {"data": {"source": "MTOR", "target": "PI3K/AKT/mTOR, CDK4/6"}}, {"data": {"source": "MTOR", "target": "CDK4/6"}}, {"data": {"source": "MTOR", "target": "PI3K/Akt/mTOR"}}, {"data": {"source": "MTOR", "target": "PI3K/Akt/mTOR,CDK4/6/RB"}}, {"data": {"source": "MTOR", "target": "PIK3CA/mTOR"}}, {"data": {"source": "MTOR", "target": "PI3K/mTOR"}}, {"data": {"source": "MTOR", "target": "PI3K/AKT/mTOR signaling pathway"}}, {"data": {"source": "MTOR", "target": "MAPK, mTORC1/p70S6K, src/FAK"}}, {"data": {"source": "MTOR", "target": "AKT/mTOR"}}, {"data": {"source": "MTOR", "target": "mTOR/p70-S6k"}}, {"data": {"source": "MTOR", "target": "PI3K/AKT, PTEN, mTOR"}}, {"data": {"source": "MTOR", "target": "PI3K-mTOR"}}, {"data": {"source": "MTOR", "target": "mTORC1"}}, {"data": {"source": "MTOR", "target": "Metabolic pathway, ROS signaling pathway, HIF1a, mTOR signaling"}}, {"data": {"source": "MTOR", "target": "PI3K-AKT, mTOR, CDK4/6"}}, {"data": {"source": "MTOR", "target": "PI3K"}}, {"data": {"source": "MTOR", "target": "MTORC1, E2F, MYC"}}, {"data": {"source": "MTOR", "target": "PI3K/mTOR, CDK4/6"}}, {"data": {"source": "MTOR", "target": "PI3K, AKT, mTOR"}}, {"data": {"source": "MTOR", "target": "AKT/mTOR axis"}}, {"data": {"source": "MTOR", "target": "AKT/mTOR pathway"}}, {"data": {"source": "MTOR", "target": "PI3K-mTOR pathway,RAS/RAF/MAPK pathway"}}, {"data": {"source": "MYC", "target": "Amplifications"}}, {"data": {"source": "MYC", "target": "HR"}}, {"data": {"source": "MYC", "target": "p38 MAPK"}}, {"data": {"source": "MYC", "target": "JNK/CDK4-dependent pSmad3L"}}, {"data": {"source": "MYC", "target": "Endocrine signaling"}}, {"data": {"source": "MYC", "target": "Beta-catenin-Tcf"}}, {"data": {"source": "MYC", "target": "MTORC1, E2F, MYC"}}, {"data": {"source": "MYC", "target": "Wnt signaling"}}, {"data": {"source": "MYC", "target": "G1 arrest"}}, {"data": {"source": "NF1", "target": "RAS-MAPK"}}, {"data": {"source": "NF1", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "NRAS", "target": "RAS-BRAF"}}, {"data": {"source": "NRAS", "target": "RAS-RAF-MEK-ERK"}}, {"data": {"source": "NRAS", "target": "MAPK"}}, {"data": {"source": "NRAS", "target": "MAPK, PI3K, CDK4/6"}}, {"data": {"source": "NRAS", "target": "Mitogen-activated protein kinase pathway"}}, {"data": {"source": "NRAS", "target": "RAS-MAPK"}}, {"data": {"source": "NRAS", "target": "Senescence escape"}}, {"data": {"source": "NRAS", "target": "MAPK, Cell cycle"}}, {"data": {"source": "PIK3CA", "target": "PI3K pathway"}}, {"data": {"source": "PIK3CA", "target": "PI3K/AKT"}}, {"data": {"source": "PIK3CA", "target": "PIK3CA-AKT"}}, {"data": {"source": "PIK3CA", "target": "PI3K/AKT pathway"}}, {"data": {"source": "PIK3CA", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "PIK3CA", "target": "PI3K"}}, {"data": {"source": "PIK3CA", "target": "PI3K, AKT"}}, {"data": {"source": "PIK3CA", "target": "PI3K-AKT"}}, {"data": {"source": "PIK3CA", "target": "PI3K/Akt/mTOR"}}, {"data": {"source": "PIK3CA", "target": "PI3K/Akt/mTOR,CDK4/6/RB"}}, {"data": {"source": "PIK3CA", "target": "PIK3CA/mTOR"}}, {"data": {"source": "PIK3CA", "target": "PI3K/mTOR"}}, {"data": {"source": "PIK3CA", "target": "PI3K-AKT, CCND1-CDK4/6"}}, {"data": {"source": "PIK3CA", "target": "PI3K/AKT/mTOR signaling pathway"}}, {"data": {"source": "PIK3CA", "target": "PI3K, Cell-cycle, Apoptosis"}}, {"data": {"source": "PIK3CA", "target": "MAPK, PI3K, S6K1"}}, {"data": {"source": "PIK3CA", "target": "Notch, PI3K/AKT"}}, {"data": {"source": "PIK3CA", "target": "PI3K-AKT, mTOR, CDK4/6"}}, {"data": {"source": "PIK3CA", "target": "PI3K, AKT, mTOR"}}, {"data": {"source": "PIK3CA", "target": "MAPK, AKT"}}, {"data": {"source": "PIK3CA", "target": "mTOR pathway"}}, {"data": {"source": "PIK3CA", "target": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"source": "PIK3CA", "target": "S6K1"}}, {"data": {"source": "PTEN", "target": "DNA repair pathway"}}, {"data": {"source": "PTEN", "target": "PTEN-related pathways"}}, {"data": {"source": "PTEN", "target": "PI3K/AKT, PTEN, mTOR"}}, {"data": {"source": "PTEN", "target": "Cell cycle progression"}}, {"data": {"source": "PTEN", "target": "PI3K pathway"}}, {"data": {"source": "PTEN", "target": "PI3K-PTEN-AKT-FoxO3a"}}, {"data": {"source": "PTEN", "target": "Endocrine signaling"}}, {"data": {"source": "PTEN", "target": "PI3K"}}, {"data": {"source": "PTEN", "target": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"source": "RB1", "target": "Rb1"}}, {"data": {"source": "RB1", "target": "Cell cycle control"}}, {"data": {"source": "RB1", "target": "p16-cdk4-cyclin D1-pRb"}}, {"data": {"source": "RB1", "target": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway"}}, {"data": {"source": "RB1", "target": "G1/S transition"}}, {"data": {"source": "RB1", "target": "G1-S checkpoint"}}, {"data": {"source": "RB1", "target": "p16INK4a/cyclin D/CDK4/6/RB pathway"}}, {"data": {"source": "RB1", "target": "CDK4/6-RB"}}, {"data": {"source": "RB1", "target": "PI3K/Akt/mTOR,CDK4/6/RB"}}, {"data": {"source": "RB1", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "RB1", "target": "Cell cycle"}}, {"data": {"source": "RB1", "target": "c-Myc"}}, {"data": {"source": "RB1", "target": "G1-phase pathway"}}, {"data": {"source": "RB1", "target": "NF-魏B"}}, {"data": {"source": "RB1", "target": "NF-魏B, AKT"}}, {"data": {"source": "RB1", "target": "Cyclin D-CDK4/6-Rb-INK4"}}, {"data": {"source": "RB1", "target": "TGF-beta"}}, {"data": {"source": "RB1", "target": "CDK4/6/RB pathway"}}, {"data": {"source": "RB1", "target": "pRB"}}, {"data": {"source": "RB1", "target": "Cyclin D-CDK4/6-INK4-Rb"}}, {"data": {"source": "RB1", "target": "Rb pathway"}}, {"data": {"source": "RB1", "target": "G1 control pathway"}}, {"data": {"source": "RB1", "target": "pRb pathway"}}, {"data": {"source": "RB1", "target": "G1 cyclin-dependent kinase"}}, {"data": {"source": "RB1", "target": "CDK4/6,Erk1/2"}}, {"data": {"source": "RB1", "target": "CDK4/6-RB pathway"}}, {"data": {"source": "RB1", "target": "p16-CDK4/6-RB,AREG/EGFR"}}, {"data": {"source": "RB1", "target": "Cyclin D1-CDK4/6-retinoblastoma pathway"}}, {"data": {"source": "RB1", "target": "BRAF pathway"}}, {"data": {"source": "RB1", "target": "PI3K/mTOR"}}, {"data": {"source": "RB1", "target": "Cyclin D-CDK4/6-Rb pathway"}}, {"data": {"source": "RB1", "target": "ER-cyclin D1-CDK4/6-RB pathway"}}, {"data": {"source": "RB1", "target": "CDK-Rb-E2F"}}, {"data": {"source": "RB1", "target": "CDKN2A-CCND-CDK4/6-Rb"}}, {"data": {"source": "RB1", "target": "mTORC1/2"}}, {"data": {"source": "RB1", "target": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"source": "RB1", "target": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"source": "RB1", "target": "MAPK, Akt"}}, {"data": {"source": "RB1", "target": "CDK4/6-Rb-E2F pathway"}}, {"data": {"source": "RB1", "target": "Cyclin D-CDK4/6-Rb"}}, {"data": {"source": "RB1", "target": "CKI-CDK-Rb pathway"}}, {"data": {"source": "TP53", "target": "Cell cycle control"}}, {"data": {"source": "TP53", "target": "p53 control, growth signaling, cell cycle control"}}, {"data": {"source": "TP53", "target": "p53 pathway"}}, {"data": {"source": "TP53", "target": "Hedgehog, Akt, p53"}}, {"data": {"source": "TP53", "target": "Cell cycle progression"}}, {"data": {"source": "TP53", "target": "NOTCH"}}, {"data": {"source": "TP53", "target": "DNA damage response"}}, {"data": {"source": "TP53", "target": "p53, p16"}}, {"data": {"source": "TP53", "target": "Wnt signaling"}}, {"data": {"source": "TP53", "target": "TP53 pathway"}}, {"data": {"source": "TP53", "target": "ARF-p53"}}, {"data": {"source": "TP53", "target": "Rb and p53/MDM2/p14ARF"}}, {"data": {"source": "TP53", "target": "Rb-CDK4,p53"}}, {"data": {"source": "TP53", "target": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"source": "TP53", "target": "Retinoblastoma pathway"}}, {"data": {"source": "Melanoma cells", "target": "Melanoma"}}, {"data": {"source": "Braf(V600E) melanoma cells", "target": "Melanoma"}}, {"data": {"source": "Melanoma cell lines", "target": "Melanoma"}}, {"data": {"source": "intestinal epithelial cells", "target": "Adenoma"}}, {"data": {"source": "Circulating tumor cells (CTCs)", "target": "Breast cancer"}}, {"data": {"source": "Tumor cells", "target": "Breast cancer"}}, {"data": {"source": "Glioma cells", "target": "Glioma"}}, {"data": {"source": "Testicular cells", "target": "Varicocele"}}, {"data": {"source": "Myeloma cells", "target": "Myeloma"}}, {"data": {"source": "Breast cancer cell lines", "target": "Endocrine therapy-resistant breast cancer"}}, {"data": {"source": "OVCAR-3, Caov-4", "target": "Ovarian cancer"}}, {"data": {"source": "OSCC cells", "target": "Oral squamous cell carcinoma"}}, {"data": {"source": "breast cancer cells", "target": "Breast cancer"}}, {"data": {"source": "OVCAR-3, Caov-4 cell lines", "target": "Ovarian cancer"}}, {"data": {"source": "Cancer cells", "target": "Cancer"}}, {"data": {"source": "Ovarian cancer cells", "target": "Ovarian cancer"}}, {"data": {"source": "MGC-803 cells", "target": "Gastric cancer"}}, {"data": {"source": "B cells", "target": "B cell non-Hodgkin's lymphoma (B-NHL)"}}, {"data": {"source": "Leiomyosarcomatous cells", "target": "Uterine leiomyosarcoma"}}, {"data": {"source": "Rhabdomyosarcomatous cells", "target": "Uterine leiomyosarcoma"}}, {"data": {"source": "Astrocytes", "target": "Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma"}}, {"data": {"source": "MCF-7 cells", "target": "Breast cancer"}}, {"data": {"source": "Cell lines", "target": "BRAF inhibitor-resistant tumor"}}, {"data": {"source": "CMT cells", "target": "Breast cancer"}}, {"data": {"source": "Carcinoma cells", "target": "HPV-positive carcinoma"}}, {"data": {"source": "Glioma cell lines", "target": "Glioblastoma"}}, {"data": {"source": "T cells", "target": "T-cell acute lymphoblastic leukemia"}}, {"data": {"source": "keratinocytes", "target": "Carcinogenesis"}}, {"data": {"source": "ECFCs", "target": "Moyamoya disease (MMD)"}}, {"data": {"source": "Cervical cancer cell lines", "target": "Cervical cancer"}}, {"data": {"source": "HCC cells", "target": "Hepatocellular carcinoma"}}, {"data": {"source": "Gallbladder cells", "target": "Gallbladder cancer"}}, {"data": {"source": "Melanoma cell lines", "target": "Metastatic melanoma"}}, {"data": {"source": "GBM cells", "target": "GBM"}}, {"data": {"source": "Glioblastoma cells", "target": "Glioblastoma"}}, {"data": {"source": "Chordoma cells", "target": "Chordoma"}}, {"data": {"source": "RB-deficient cells", "target": "ER+/RB-deficient xenografts"}}, {"data": {"source": "Luminal A BC cells", "target": "Breast cancer"}}, {"data": {"source": "MCF7", "target": "Breast cancer"}}, {"data": {"source": "Breast cancer cell lines, PDX models", "target": "Breast cancer"}}, {"data": {"source": "MCF-7 breast cancer cells", "target": "Breast cancer"}}, {"data": {"source": "hMSCs", "target": "Osteosarcoma, Liposarcoma"}}, {"data": {"source": "Lymphoid cells", "target": "Tumor"}}, {"data": {"source": "Tumor cells", "target": "Tumor"}}, {"data": {"source": "MDA-MB-231 cells", "target": "Triple negative cancer"}}, {"data": {"source": "MCF-7 cells", "target": "Luminal A cancer"}}, {"data": {"source": "Primary GBM cell lines", "target": "GBM"}}, {"data": {"source": "Tumor cells", "target": "ICC"}}, {"data": {"source": "B-cells", "target": "Burkitt lymphoma"}}, {"data": {"source": "Melanoma cells", "target": "NRAS-mutant melanoma"}}, {"data": {"source": "AML cells", "target": "AML"}}, {"data": {"source": "Tumor cells", "target": "Colorectal cancer"}}, {"data": {"source": "Cell lines", "target": "Colorectal cancer"}}, {"data": {"source": "non-IBC cells", "target": "non-IBC"}}, {"data": {"source": "HPV(neg) HNSCC cell lines", "target": "HPV(neg) HNSCC"}}, {"data": {"source": "Melanoma cells", "target": "NRAS melanoma"}}, {"data": {"source": "Breast cancer cells", "target": "Breast cancer"}}, {"data": {"source": "pituitary cells", "target": "Pituitary adenomas"}}, {"data": {"source": "Endothelial cells", "target": "HHT"}}, {"data": {"source": "Neuronal cells", "target": "Diet-induced obesity (DIO)"}}, {"data": {"source": "TNBC cell lines", "target": "Triple-negative breast cancer"}}, {"data": {"source": "Breast cancer cell lines", "target": "Breast cancer"}}, {"data": {"source": "IBC cells", "target": "IBC"}}, {"data": {"source": "Melanoma cells", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Braf(V600E) melanoma cells", "target": "Vemurafenib"}}, {"data": {"source": "Braf(V600E) melanoma cells", "target": "GLS1i"}}, {"data": {"source": "Melanoma cells", "target": "Trametinib, BKM120, LEE011"}}, {"data": {"source": "Melanoma cell lines", "target": "MEK inhibitors"}}, {"data": {"source": "MSCs", "target": "GRN163L"}}, {"data": {"source": "Mucosal melanoma", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "MCF-7, MDA-MB-231", "target": "CTL, ERA"}}, {"data": {"source": "OVCAR-3, Caov-4", "target": "HLCA"}}, {"data": {"source": "Myoblasts", "target": "GAA"}}, {"data": {"source": "OSCC cells", "target": "Metformin"}}, {"data": {"source": "Mesenchymal stem cells", "target": "GRN163L"}}, {"data": {"source": "Cancer cells", "target": "IB-MECA"}}, {"data": {"source": "Ovarian cancer cells", "target": "IB-MECA"}}, {"data": {"source": "Primary human melanocytes", "target": "ATRA"}}, {"data": {"source": "GBM cells", "target": "palbociclib, erlotinib"}}, {"data": {"source": "Chordoma cells", "target": "Afatinib,Palbociclib"}}, {"data": {"source": "RB-deficient cells", "target": "Pemrametostat, Fulvestrant"}}, {"data": {"source": "Breast cancer cell lines, PDX models", "target": "Camizestrant"}}, {"data": {"source": "PI3K/AKT/mTOR pathway", "target": "CDK4/6 inhibitors,ET"}}, {"data": {"source": "Primary GBM cell lines", "target": "Palbociclib, Everolimus"}}, {"data": {"source": "Tumor cells", "target": "Palbociclib, MLN0128"}}, {"data": {"source": "Ovarian cancer cells", "target": "Olaparib, Palbociclib"}}, {"data": {"source": "Melanoma cells", "target": "MEK1/2 inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "NB cell lines", "target": "PI3K inhibitors, FGFR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "AML cells", "target": "CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors"}}, {"data": {"source": "Tumor cells", "target": "Alpelisib, Ribociclib"}}, {"data": {"source": "Cell lines", "target": "Ribociclib, Alpelisib"}}, {"data": {"source": "Tumor cells", "target": "Ribociclib, Alpelisib"}}, {"data": {"source": "HPV(neg) HNSCC cell lines", "target": "Alpelisib"}}, {"data": {"source": "Melanoma cells", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Neuronal cells", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "P114,CF41 cells", "target": "Palbociclib"}}, {"data": {"source": "pRb-competent cells", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Breast cancer cell lines", "target": "Palbociclib"}}, {"data": {"source": "MCF7, T47D", "target": "EGFR, HER2, AKT"}}, {"data": {"source": "HEK293T cells", "target": "CDK4/CDK6-cyclin D1 pathway"}}, {"data": {"source": "Neuroblastoma cells", "target": "pRb"}}, {"data": {"source": "MSCs", "target": "Cell cycle"}}, {"data": {"source": "Testicular cells", "target": "Cell cycle"}}, {"data": {"source": "OVCAR-3, Caov-4 cell lines", "target": "Cyclin D/CDK4"}}, {"data": {"source": "Ovarian cancer cells", "target": "Cyclin D1/CDK4"}}, {"data": {"source": "ECFCs", "target": "Cell cycle"}}, {"data": {"source": "CD34+ progenitors", "target": "TGF-beta"}}, {"data": {"source": "Luminal A BC cells", "target": "ATR:CHK1"}}, {"data": {"source": "PI3K/AKT/mTOR pathway", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Primary GBM cell lines", "target": "MTOR"}}, {"data": {"source": "Circulating tumor cells", "target": "Endocrine signaling"}}, {"data": {"source": "Tumor cells", "target": "PI3K, Cell-cycle, Apoptosis"}}, {"data": {"source": "HPV(neg) HNSCC cell lines", "target": "PI3K"}}, {"data": {"source": "Melanoma cells", "target": "S6K1"}}, {"data": {"source": "Breast cancer cells", "target": "PI3K-PTEN-AKT-FoxO3a"}}, {"data": {"source": "CD34+ cells", "target": "TGF-beta"}}, {"data": {"source": "T-ALL cell line", "target": "pRb pathway"}}, {"data": {"source": "Pituitary gland", "target": "CKI-CDK-Rb pathway"}}, {"data": {"source": "IBC cells", "target": "NOTCH"}}, {"data": {"source": "Lung cancer", "target": "Notopterol"}}, {"data": {"source": "Breast cancer", "target": "Capivasertib"}}, {"data": {"source": "Breast cancer", "target": "Capivasertib, anti-HER2 agents, endocrine treatment"}}, {"data": {"source": "Cancer", "target": "Cobimetinib, ALK inhibitors"}}, {"data": {"source": "Solid tumors", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "CDK4/6 inhibitors, BRAF/MEK-targeting agents"}}, {"data": {"source": "Melanoma", "target": "CDK4/6 inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "Melanoma", "target": "BRAF inhibitors, MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "Vemurafenib"}}, {"data": {"source": "Melanoma", "target": "GLS1i"}}, {"data": {"source": "Metastatic melanoma", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Cancer", "target": "anti-PD-1"}}, {"data": {"source": "Melanoma", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "papillary thyroid carcinoma", "target": "vemurafenib"}}, {"data": {"source": "Acral melanoma", "target": "BRAF inhibitors"}}, {"data": {"source": "Melanoma", "target": "Trametinib, BKM120, LEE011"}}, {"data": {"source": "Melanoma", "target": "Palbociclib,BRAF inhibitors,MEK inhibitors"}}, {"data": {"source": "Cancer", "target": "BRAF inhibitors"}}, {"data": {"source": "Colorectal cancer", "target": "Encorafenib, Cetuximab, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "MEK inhibitors"}}, {"data": {"source": "Metastatic melanoma", "target": "Trametinib, Dabrafenib"}}, {"data": {"source": "Metastatic melanoma", "target": "Pembrolizumab, Durvalumab, Atezolizumab, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "Melanoma", "target": "mTOR inhibitors, BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "PMM", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Mucosal melanomas", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "BRAF inhibitors, MEK inhibitors"}}, {"data": {"source": "Cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Esophageal conditions", "target": "NMBA"}}, {"data": {"source": "Antiandrogen-resistant disease", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Immune-refractory cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Hepatocellular carcinoma (HCC)", "target": "Abemaciclib, Ribociclib, Lenvatinib"}}, {"data": {"source": "Breast cancer", "target": "letrozole, everolimus, palbociclib"}}, {"data": {"source": "Prostate cancer", "target": "PD-0332991"}}, {"data": {"source": "Tumor", "target": "Erufosine"}}, {"data": {"source": "Ovarian cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Ovarian cancer", "target": "HLCA"}}, {"data": {"source": "Tumor", "target": "Palbociclib"}}, {"data": {"source": "Tumor", "target": "Vitamin K2, Vitamin K3"}}, {"data": {"source": "Esophageal squamous cell carcinoma", "target": "SAHA"}}, {"data": {"source": "Colorectal cancer", "target": "EESB"}}, {"data": {"source": "Colorectal cancer", "target": "Palbociclib"}}, {"data": {"source": "Cancer", "target": "Salidroside"}}, {"data": {"source": "Oral squamous cell carcinoma", "target": "Metformin"}}, {"data": {"source": "Advanced gastric cancer", "target": "ERBB2 inhibitors, EGFR inhibitors"}}, {"data": {"source": "Cancer", "target": "IB-MECA"}}, {"data": {"source": "Ovarian cancer", "target": "IB-MECA"}}, {"data": {"source": "Nonbreast solid tumors", "target": "Palbociclib"}}, {"data": {"source": "HCC", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Advanced sarcomas", "target": "Flavopiridol,Doxorubicin"}}, {"data": {"source": "Breast cancer", "target": "elacestrant"}}, {"data": {"source": "Breast cancer", "target": "Palbociclib"}}, {"data": {"source": "HCC", "target": "Abemaciclib, lenvatinib"}}, {"data": {"source": "Cancer", "target": "Talazoparib"}}, {"data": {"source": "Cancer", "target": "PARP inhibitors"}}, {"data": {"source": "Osteosarcoma", "target": "Palbociclib"}}, {"data": {"source": "Dermatofibrosarcoma protuberans", "target": "Imatinib"}}, {"data": {"source": "Serous ovarian tumor", "target": "Palbociclib, Letrozole"}}, {"data": {"source": "Melanoma, GBM", "target": "MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy"}}, {"data": {"source": "Non-small cell lung cancer (NSCLC)", "target": "Combined drugs"}}, {"data": {"source": "PM", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Ewing's sarcoma", "target": "Doxorubicin"}}, {"data": {"source": "Non-small cell lung cancer", "target": "Osimertinib, Palbociclib"}}, {"data": {"source": "NSCLC", "target": "Osimertinib, palbociclib"}}, {"data": {"source": "HCC", "target": "palbociclib,celecoxib"}}, {"data": {"source": "Cancer", "target": "CDK4/6 inhibitors, immunotherapy"}}, {"data": {"source": "Head and neck squamous cell carcinoma", "target": "Palbociclib, Cetuximab"}}, {"data": {"source": "Melanoma", "target": "BRAF/MEK inhibitors"}}, {"data": {"source": "Multiple myeloma", "target": "Erk1/2 inhibitors,CDK4/6 inhibitors"}}, {"data": {"source": "Disease progression", "target": "Osimertinib"}}, {"data": {"source": "NAC-resistant tumors", "target": "EGFR and HER2 inhibitors"}}, {"data": {"source": "Nasopharyngeal carcinoma", "target": "EGFR blockers, CDK4/6 inhibitors"}}, {"data": {"source": "NPC (nasopharyngeal carcinoma)", "target": "Cetuximab, Afatinib, Palbociclib"}}, {"data": {"source": "GBM", "target": "palbociclib, erlotinib"}}, {"data": {"source": "Non-small cell lung cancer", "target": "EGFR-TKIs"}}, {"data": {"source": "Squamous cell lung cancer", "target": "Necitumumab, afatinib, erlotinib"}}, {"data": {"source": "EGFR-amplified tumours", "target": "CDK4/6 inhibitors, EGFR inhibitors"}}, {"data": {"source": "NSCLC", "target": "EGFR-TKI"}}, {"data": {"source": "Non-small cell lung cancer (NSCLC)", "target": "Osimertinib"}}, {"data": {"source": "Lung cancer", "target": "Osimertinib"}}, {"data": {"source": "Lung cancer", "target": "PD 0332991"}}, {"data": {"source": "Non-small cell lung cancer (NSCLC)", "target": "EGFR inhibitors"}}, {"data": {"source": "Epithelial cancers", "target": "EGFR inhibitors"}}, {"data": {"source": "Brain cancer", "target": "EGFR inhibitors"}}, {"data": {"source": "NSCLC", "target": "Osimertinib"}}, {"data": {"source": "Desmoplastic small round cell tumor (DSRCT)", "target": "B7-H3"}}, {"data": {"source": "Lung metastases (LM)", "target": "EGFR-TKIs"}}, {"data": {"source": "Metastatic breast cancer (mBC)", "target": "Palbociclib"}}, {"data": {"source": "Chordoma", "target": "Afatinib,Palbociclib"}}, {"data": {"source": "Hepatocellular carcinoma (HCC)", "target": "multi-kinase inhibitors"}}, {"data": {"source": "Lung metastases", "target": "EGFR-TKIs"}}, {"data": {"source": "Metastatic breast cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Breast cancer", "target": "Neoadjuvant therapy"}}, {"data": {"source": "ER-positive, HER2-negative breast cancer", "target": "Palbociclib, Fulvestrant"}}, {"data": {"source": "Endocrine resistance", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Hormone receptor-positive, HER2-negative breast cancer", "target": "Fulvestrant, Capivasertib"}}, {"data": {"source": "Metastatic breast cancer", "target": "Trastuzumab"}}, {"data": {"source": "Breast cancer", "target": "Abemaciclib, fulvestrant, palbociclib, ribociclib"}}, {"data": {"source": "Breast cancer", "target": "Trastuzumab"}}, {"data": {"source": "Breast cancer", "target": "HER2-directed therapy, Chemotherapy"}}, {"data": {"source": "metastatic breast cancer", "target": "CDK4/6 inhibitor"}}, {"data": {"source": "Advanced-stage breast cancer", "target": "ribociclib,palbociclib,abemaciclib"}}, {"data": {"source": "Breast cancer", "target": "Neratinib,Trastuzumab deruxtecan,Palbociclib"}}, {"data": {"source": "Advanced/metastatic breast cancer", "target": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"source": "Metastatic breast cancer", "target": "CDK4/6 inhibitors, Aromatase inhibitors"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"source": "Advanced breast cancer", "target": "CDK4/6 inhibitors, Endocrine therapy"}}, {"data": {"source": "Breast cancer", "target": "Trastuzumab deruxtecan"}}, {"data": {"source": "Advanced breast cancer", "target": "Camizestrant, Fulvestrant"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors, anti-HER2"}}, {"data": {"source": "Breast cancer", "target": "Dalpiciclib, pyrotinib"}}, {"data": {"source": "HR+/HER2+ metastatic breast cancer", "target": "Tucatinib, letrozole, palbociclib"}}, {"data": {"source": "Advanced breast cancer", "target": "Ribociclib"}}, {"data": {"source": "Metastatic HR+/HER2- breast cancer", "target": "Palbociclib"}}, {"data": {"source": "Advanced breast cancer", "target": "Aromatase inhibitors"}}, {"data": {"source": "HER2-positive advanced breast cancer", "target": "trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine"}}, {"data": {"source": "Cancers", "target": "Ibrutinib"}}, {"data": {"source": "Breast cancer", "target": "Tucatinib, Palbociclib, Fulvestrant"}}, {"data": {"source": "Advanced breast cancer", "target": "Palbociclib, Abemaciclib, Ribociclib"}}, {"data": {"source": "Breast cancer", "target": "Tamoxifen"}}, {"data": {"source": "Estrogen receptor-positive metastatic breast cancer", "target": "Letrozole"}}, {"data": {"source": "ER+ xenografts", "target": "Fulvestrant, BKM120"}}, {"data": {"source": "ER+/RB-deficient xenografts", "target": "Pemrametostat, Fulvestrant"}}, {"data": {"source": "Advanced estrogen receptor-positive, HER2-negative breast cancer", "target": "Fulvestrant"}}, {"data": {"source": "Metastatic breast cancer", "target": "Fulvestrant, Camizestrant"}}, {"data": {"source": "Breast cancer", "target": "LH-RH agonist, aromatase inhibitor"}}, {"data": {"source": "Metastatic breast cancer", "target": "Elacestrant"}}, {"data": {"source": "Breast cancer", "target": "Endocrine therapy"}}, {"data": {"source": "Breast cancer", "target": "Fulvestrant"}}, {"data": {"source": "ER伪+ breast cancer", "target": "Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Breast cancer", "target": "elacestrant, fulvestrant"}}, {"data": {"source": "tumors", "target": "ATP-competitive inhibitors"}}, {"data": {"source": "Metastatic breast cancer", "target": "Aromatase inhibitors"}}, {"data": {"source": "Breast cancer", "target": "Letrozole"}}, {"data": {"source": "Breast cancer", "target": "GPX4 inhibitors"}}, {"data": {"source": "Cancer", "target": "Selective ER degraders"}}, {"data": {"source": "HR+ metastatic breast cancer", "target": "Aromatase inhibitors"}}, {"data": {"source": "Metastatic breast cancer", "target": "Fulvestrant"}}, {"data": {"source": "Metastatic breast cancer", "target": "Fulvestrant, aromatase inhibitors"}}, {"data": {"source": "Metastatic breast cancer", "target": "Fulvestrant, anastrozole"}}, {"data": {"source": "Endocrine therapy-resistant ESR1(+) breast cancer", "target": "SERD, SSH-CDK4/6 inhibitors"}}, {"data": {"source": "ER-positive, HER2-negative metastatic breast cancer", "target": "Palbociclib"}}, {"data": {"source": "ER-positive, HER2-negative breast cancer", "target": "Palbociclib"}}, {"data": {"source": "Breast cancer", "target": "Abemaciclib"}}, {"data": {"source": "Estrogen receptor-positive breast tumors", "target": "Antiestrogens"}}, {"data": {"source": "Breast cancer", "target": "fulvestrant"}}, {"data": {"source": "Breast cancer", "target": "tamoxifen,aromatase inhibitors"}}, {"data": {"source": "Breast cancer", "target": "H3B-6545, fulvestrant"}}, {"data": {"source": "Breast cancer", "target": "H3B-6545"}}, {"data": {"source": "ER-positive breast cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Breast cancer", "target": "Camizestrant"}}, {"data": {"source": "Liposarcoma", "target": "Inhibitors of CDK4 and MDM2"}}, {"data": {"source": "Sarcomas", "target": "CDK4 inhibitors, MDM2 inhibitors, cediranib, eribulin, crizotinib"}}, {"data": {"source": "Liposarcoma", "target": "MDM2 inhibitors"}}, {"data": {"source": "HR+, HER2- breast cancer", "target": "MTOR"}}, {"data": {"source": "GBM", "target": "Palbociclib, Everolimus"}}, {"data": {"source": "Resistance in hormone-receptor-positive breast cancer", "target": "CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "HR+/HER2- breast cancer", "target": "CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "Hepatocellular carcinoma", "target": "Alpelisib, MLN0128, palbociclib"}}, {"data": {"source": "Hepatocellular carcinoma", "target": "Alpelisib"}}, {"data": {"source": "PEComa", "target": "nab-sirolimus"}}, {"data": {"source": "Myeloproliferative neoplasms (MPN)", "target": "PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators"}}, {"data": {"source": "Neuroendocrine tumors (NETs)", "target": "Everolimus, sunitinib"}}, {"data": {"source": "Hormone-resistant tumors", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Non-clear cell RCC", "target": "VEGF inhibitors, mTOR inhibitors"}}, {"data": {"source": "ICC", "target": "MLN0128"}}, {"data": {"source": "ICC", "target": "Palbociclib, MLN0128"}}, {"data": {"source": "Head and neck squamous cell carcinoma (HNSCC)", "target": "Palbociclib"}}, {"data": {"source": "Breast cancer", "target": "Everolimus"}}, {"data": {"source": "Tumor", "target": "Rapamycin"}}, {"data": {"source": "Breast cancer", "target": "RMC-6272"}}, {"data": {"source": "Advanced breast cancer", "target": "PI3K inhibitors, mTOR inhibitors"}}, {"data": {"source": "Osteosarcoma", "target": "Palbociclib, Everolimus"}}, {"data": {"source": "Recurrent glioblastoma", "target": "CDK4/6 inhibitors, PI3K/mTOR inhibitors"}}, {"data": {"source": "Cancer", "target": "FMD"}}, {"data": {"source": "Luminal ABC", "target": "PIK3CA/mTOR inhibitors"}}, {"data": {"source": "Metastatic breast cancer", "target": "CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors, PI3K/mTOR inhibitors"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "Hormone receptor-positive (HR+) breast cancer", "target": "fulvestrant"}}, {"data": {"source": "ER(+)/FGFR1(+) metastatic breast cancer", "target": "mTOR inhibitors"}}, {"data": {"source": "ER+ metastatic breast cancer", "target": "Everolimus"}}, {"data": {"source": "HR+ ABC", "target": "PI3K/mTOR inhibitors, fulvestrant"}}, {"data": {"source": "Melanoma", "target": "Rapamycin"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors"}}, {"data": {"source": "Oral cancer, OSCC", "target": "PI3K inhibitors, mTOR inhibitors"}}, {"data": {"source": "Cancer", "target": "PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors"}}, {"data": {"source": "Gynecologic cancers", "target": "Gedatolisib"}}, {"data": {"source": "Breast cancer", "target": "mTOR inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Cancer", "target": "CDK4/6 inhibitors,mTOR inhibitors"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors,mTOR inhibitors"}}, {"data": {"source": "Cancer", "target": "Palbociclib"}}, {"data": {"source": "Ovarian cancer", "target": "Olaparib, Palbociclib"}}, {"data": {"source": "Ovarian cancer", "target": "Doxazosin"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Triple-negative breast cancer (TNBC)", "target": "Olaparib"}}, {"data": {"source": "BRCA(mut)/TNBC", "target": "Olaparib, Palbociclib"}}, {"data": {"source": "histiocytic sarcoma", "target": "Cobimetinib"}}, {"data": {"source": "NRAS-mutant melanoma", "target": "MEK1/2 inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "Binimetinib, Ribociclib"}}, {"data": {"source": "NRAS-mutant melanoma", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Melanoma", "target": "Binimetinib"}}, {"data": {"source": "Melanoma", "target": "CDK4/6 inhibitors, MEK inhibitors"}}, {"data": {"source": "Metastatic breast cancer", "target": "PI3K inhibitors"}}, {"data": {"source": "Advanced breast cancer", "target": "PI3K inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Breast cancer", "target": "PI3K inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Cancer", "target": "PI3K inhibitors"}}, {"data": {"source": "AML", "target": "CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors"}}, {"data": {"source": "PIK3CA-mutated advanced breast cancer", "target": "Piqray, Fulvestrant"}}, {"data": {"source": "Breast cancer", "target": "Alpelisib"}}, {"data": {"source": "Breast cancer", "target": "Capivasertib, fulvestrant"}}, {"data": {"source": "Colorectal cancer", "target": "Alpelisib, Ribociclib"}}, {"data": {"source": "Colorectal cancer", "target": "Ribociclib, Alpelisib"}}, {"data": {"source": "Lung squamous cell carcinoma (LUSC)", "target": "PI3K inhibitors"}}, {"data": {"source": "Cancer", "target": "PI3K inhibitors, HSP90 inhibitors"}}, {"data": {"source": "HPV(neg) HNSCC", "target": "Alpelisib"}}, {"data": {"source": "Advanced breast cancer", "target": "Palbociclib, Fulvestrant"}}, {"data": {"source": "HCC", "target": "alpelisib"}}, {"data": {"source": "NRAS melanoma", "target": "MEK inhibitors, CDK4/6 inhibitors"}}, {"data": {"source": "Tumors", "target": "Palbociclib"}}, {"data": {"source": "Estrogen receptor-positive, HER2-positive breast cancer", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "CRPC", "target": "CDK4/6 inhibitor"}}, {"data": {"source": "MPNST", "target": "CDK4/6 inhibitors, MEK inhibitors"}}, {"data": {"source": "Diet-induced obesity (DIO)", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "TNBC", "target": "Palbociclib"}}, {"data": {"source": "Glioblastoma", "target": "abemaciclib"}}, {"data": {"source": "Glioblastoma", "target": "MPT0L145, abemaciclib"}}, {"data": {"source": "tumor", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Liver tumor", "target": "Palbociclib"}}, {"data": {"source": "Lung cancer, Colon cancer", "target": "Palbociclib"}}, {"data": {"source": "Breast cancer, melanoma, leukemia, lymphoma", "target": "G1T38"}}, {"data": {"source": "RB1-deficient tumors", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Tumors", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Multiple myeloma", "target": "Palbociclib"}}, {"data": {"source": "Tumor", "target": "Ribociclib"}}, {"data": {"source": "Sarcoma", "target": "palbociclib, doxorubicin, AZD1775"}}, {"data": {"source": "Cancer", "target": "ARV-825, Fulvestrant, Palbociclib"}}, {"data": {"source": "SCLC", "target": "Abemaciclib"}}, {"data": {"source": "Triple-negative breast cancer (TNBC)", "target": "CDK4/6 inhibitors"}}, {"data": {"source": "Tumor", "target": "PF-7006"}}, {"data": {"source": "ER+ breast cancer", "target": "RP-6306, Gemcitabine"}}, {"data": {"source": "Prostate cancer", "target": "Piceatannol"}}, {"data": {"source": "HCC", "target": "doxorubicin"}}, {"data": {"source": "Tumor", "target": "RP-6306, gemcitabine"}}, {"data": {"source": "Glial cell transformation", "target": "PI3K"}}, {"data": {"source": "Lung cancer", "target": "IL-17 signaling"}}, {"data": {"source": "Melanoma", "target": "p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT"}}, {"data": {"source": "Melanoma", "target": "RAS-BRAF"}}, {"data": {"source": "Melanoma", "target": "RAS-RAF-MEK-ERK"}}, {"data": {"source": "Low-grade serous ovarian cancer (LGSC)", "target": "Mitogen-activated protein kinase pathway"}}, {"data": {"source": "histiocytic sarcoma", "target": "RAS-MAPK"}}, {"data": {"source": "Tumors", "target": "BRAF pathway"}}, {"data": {"source": "Melanocytic tumors", "target": "RAS-RAF-MEK-ERK"}}, {"data": {"source": "Mucosal melanomas", "target": "MAPK"}}, {"data": {"source": "High-grade astrocytomas", "target": "p16-cdk4-cyclin D1-pRb"}}, {"data": {"source": "Glioblastoma, Brain metastases", "target": "CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway"}}, {"data": {"source": "MCL", "target": "Ubiquitin-proteasome system"}}, {"data": {"source": "Breast cancer", "target": "PI3K-AKT, CCND1-CDK4/6"}}, {"data": {"source": "Varicocele", "target": "Cell cycle"}}, {"data": {"source": "Breast cancer", "target": "Cell-cycle markers"}}, {"data": {"source": "Prostate cancer", "target": "G1-S transition"}}, {"data": {"source": "Colorectal cancer", "target": "STAT3,Erk,p38"}}, {"data": {"source": "Cancer", "target": "CDK4-cyclin D1 pathway"}}, {"data": {"source": "HPV(U) tumors", "target": "Cell cycle progression"}}, {"data": {"source": "Gastric cancer", "target": "G1-S regulatory pathway"}}, {"data": {"source": "Multiple myeloma", "target": "RAS/MAPK"}}, {"data": {"source": "Ovarian cancer", "target": "Cyclin D/CDK4"}}, {"data": {"source": "Ovarian cancer", "target": "Cyclin D1/CDK4"}}, {"data": {"source": "Salivary gland tumors", "target": "Cyclin pathway"}}, {"data": {"source": "Breast cancer", "target": "ER-cyclin D1-CDK4/6-RB pathway"}}, {"data": {"source": "Breast cancer", "target": "Cyclin signaling"}}, {"data": {"source": "HR-positive breast cancer", "target": "CDK4/6-cyclin D1"}}, {"data": {"source": "Ovarian cancer", "target": "Wnt, Hippo"}}, {"data": {"source": "Sarcomas", "target": "CDKN2A-CCND-CDK4/6-Rb"}}, {"data": {"source": "Tumor", "target": "PKC,MAPK"}}, {"data": {"source": "Primary cutaneous melanoma (PCM)", "target": "FAMMM"}}, {"data": {"source": "Low-grade gliomas", "target": "RB1,TP53"}}, {"data": {"source": "Melanoma", "target": "p16INK4/CDK4/RB"}}, {"data": {"source": "Glioma", "target": "Cell cycle control"}}, {"data": {"source": "ER+ breast cancer", "target": "p16INK4a/cyclin D/CDK4/6/RB pathway"}}, {"data": {"source": "Solid tumors", "target": "Cyclin D-CDK4/6-Rb-INK4"}}, {"data": {"source": "Cancer", "target": "Cyclin D-CDK4/6-Rb-INK4"}}, {"data": {"source": "MPNST", "target": "pRB"}}, {"data": {"source": "Meningeal hemangiopericytomas", "target": "Rb pathway"}}, {"data": {"source": "Melanoma", "target": "Cell cycle"}}, {"data": {"source": "Melanoma", "target": "Pigmentation pathway"}}, {"data": {"source": "Moyamoya disease (MMD)", "target": "Cell cycle"}}, {"data": {"source": "HCC", "target": "COX-2/Wnt"}}, {"data": {"source": "Melanoma", "target": "RAR signaling"}}, {"data": {"source": "Diffuse high-grade glioma (DHG)", "target": "Cell cycle"}}, {"data": {"source": "Cancer", "target": "Cyclin D-CDK4/6"}}, {"data": {"source": "Melanoma", "target": "MAPK, Cell cycle"}}, {"data": {"source": "Multiple myeloma", "target": "CDK4/6,Erk1/2"}}, {"data": {"source": "Squamous cell lung cancer", "target": "EGFR"}}, {"data": {"source": "Lung cancer", "target": "EGFR-TKI pathway"}}, {"data": {"source": "Brain cancer", "target": "MAPK, AKT, STAT3, Src, Abl"}}, {"data": {"source": "Chordoma", "target": "CDK4/6,IGF1R/FGFR/EGFR"}}, {"data": {"source": "Metastatic breast cancer (mBC)", "target": "EGFR, HER2"}}, {"data": {"source": "METex 14 alteration", "target": "EGFR signaling"}}, {"data": {"source": "Breast cancer", "target": "Cell cycle pathway"}}, {"data": {"source": "Breast cancer", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Triple-negative breast cancer", "target": "Estrogen signaling, HER2 signaling"}}, {"data": {"source": "Endocrine resistance", "target": "PIK3CA/mTOR"}}, {"data": {"source": "ER伪+ breast cancer", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Tumors", "target": "MAP kinase pathway"}}, {"data": {"source": "Breast cancer", "target": "ATR:CHK1"}}, {"data": {"source": "Breast cancer", "target": "mTORC1/2,CDK4/6,ER"}}, {"data": {"source": "Adipocytic tumors, atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL)", "target": "Retinoblastoma pathway"}}, {"data": {"source": "Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)", "target": "12q13-15 region"}}, {"data": {"source": "Anaplastic oligodendrogliomas", "target": "TP53 pathway"}}, {"data": {"source": "METex 14 alteration", "target": "Cell cycle"}}, {"data": {"source": "Glioblastoma (GB)", "target": "pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN"}}, {"data": {"source": "Ossifying fibroma (OF)", "target": "Retinoblastoma pathway"}}, {"data": {"source": "Juvenile ossifying fibroma (JOF)", "target": "Retinoblastoma pathway"}}, {"data": {"source": "Malignant peripheral nerve sheath tumors", "target": "mTOR"}}, {"data": {"source": "Triple negative breast cancer", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "GBM", "target": "MTOR"}}, {"data": {"source": "Resistance in hormone-receptor-positive breast cancer", "target": "PI3K/AKT/mTOR, CDK4/6"}}, {"data": {"source": "HR+/HER2- breast cancer", "target": "CDK4/6"}}, {"data": {"source": "Advanced ER+ breast cancer", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Breast cancer", "target": "PI3K/Akt/mTOR"}}, {"data": {"source": "Cancer", "target": "PI3K/Akt/mTOR,CDK4/6/RB"}}, {"data": {"source": "Endocrine resistance", "target": "PI3K/mTOR"}}, {"data": {"source": "HCC", "target": "MAPK, mTORC1/p70S6K, src/FAK"}}, {"data": {"source": "Tumor", "target": "mTOR/p70-S6k"}}, {"data": {"source": "HNSCC", "target": "mTOR"}}, {"data": {"source": "Breast cancer", "target": "PI3K/AKT, PTEN, mTOR"}}, {"data": {"source": "Breast cancer", "target": "PI3K-mTOR"}}, {"data": {"source": "Osteosarcoma", "target": "mTOR"}}, {"data": {"source": "Metastatic breast cancer", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Cancer", "target": "PI3K-AKT, mTOR, CDK4/6"}}, {"data": {"source": "histiocytic sarcoma", "target": "PI3K"}}, {"data": {"source": "Breast cancer", "target": "PI3K/mTOR, CDK4/6"}}, {"data": {"source": "Endocrine-resistant breast cancer", "target": "PI3K, AKT, mTOR"}}, {"data": {"source": "Recurrent tumors", "target": "PI3K/mTOR"}}, {"data": {"source": "HR+ ABC", "target": "PI3K/mTOR"}}, {"data": {"source": "Melanoma", "target": "mTOR/p70-S6k"}}, {"data": {"source": "Gynecologic cancers", "target": "PI3K/mTOR"}}, {"data": {"source": "metastatic breast cancer", "target": "AKT/mTOR pathway"}}, {"data": {"source": "Cancer", "target": "mTOR"}}, {"data": {"source": "Breast cancer,RAS-mutant cancers", "target": "PI3K-mTOR pathway,RAS/RAF/MAPK pathway"}}, {"data": {"source": "Lymphoproliferative disorder (LPD)", "target": "Amplifications"}}, {"data": {"source": "Cancer", "target": "HR"}}, {"data": {"source": "Polycystic kidney disease", "target": "JNK/CDK4-dependent pSmad3L"}}, {"data": {"source": "Tumor", "target": "Beta-catenin-Tcf"}}, {"data": {"source": "Triple-negative breast cancer (TNBC)", "target": "Wnt signaling"}}, {"data": {"source": "BRCA(mut)/TNBC", "target": "Wnt signaling"}}, {"data": {"source": "Melanoma", "target": "MAPK"}}, {"data": {"source": "Melanoma", "target": "MAPK, PI3K, CDK4/6"}}, {"data": {"source": "Melanoma", "target": "Senescence escape"}}, {"data": {"source": "Breast cancer", "target": "PI3K pathway"}}, {"data": {"source": "CA", "target": "PI3K/AKT"}}, {"data": {"source": "Breast cancer", "target": "PI3K"}}, {"data": {"source": "Cancer", "target": "PI3K/AKT"}}, {"data": {"source": "Breast cancer", "target": "PI3K, AKT"}}, {"data": {"source": "Melanoma", "target": "PI3K-AKT"}}, {"data": {"source": "Colorectal cancer", "target": "PI3K, Cell-cycle, Apoptosis"}}, {"data": {"source": "Diabetes", "target": "PI3K/AKT pathway"}}, {"data": {"source": "Lung squamous cell carcinoma (LUSC)", "target": "PI3K"}}, {"data": {"source": "NRAS-mutant melanoma", "target": "MAPK, PI3K, S6K1"}}, {"data": {"source": "Breast tumors", "target": "PI3K pathway"}}, {"data": {"source": "Tumor", "target": "Notch, PI3K/AKT"}}, {"data": {"source": "HPV(neg) HNSCC", "target": "PI3K"}}, {"data": {"source": "Breast cancer", "target": "PI3K/AKT"}}, {"data": {"source": "Tumor", "target": "PI3K"}}, {"data": {"source": "Salivary gland tumors", "target": "PI3K pathway"}}, {"data": {"source": "HCC", "target": "MAPK, AKT"}}, {"data": {"source": "HCC", "target": "mTOR pathway"}}, {"data": {"source": "NRAS melanoma", "target": "S6K1"}}, {"data": {"source": "PFS", "target": "DNA repair pathway"}}, {"data": {"source": "Breast cancer", "target": "PTEN-related pathways"}}, {"data": {"source": "Breast cancer", "target": "PI3K-PTEN-AKT-FoxO3a"}}, {"data": {"source": "Cancer", "target": "CDK4/6-RB"}}, {"data": {"source": "Lung cancer, Colon cancer", "target": "NF-魏B, AKT"}}, {"data": {"source": "Squamous Cell Carcinomas", "target": "Cyclin D-CDK4/6-INK4-Rb"}}, {"data": {"source": "Human tumors", "target": "G1 control pathway"}}, {"data": {"source": "Glioblastoma", "target": "CDK4/6-RB pathway"}}, {"data": {"source": "Breast cancer", "target": "Cyclin D1-CDK4/6-retinoblastoma pathway"}}, {"data": {"source": "HR+ breast cancer", "target": "Cyclin D-CDK4/6-Rb pathway"}}, {"data": {"source": "Breast cancer", "target": "CDK-Rb-E2F"}}, {"data": {"source": "Neuroendocrine tumors (NETs)", "target": "Cell cycle"}}, {"data": {"source": "Glioblastoma", "target": "MAPK, Akt"}}, {"data": {"source": "Breast cancer", "target": "CDK4/6-Rb-E2F pathway"}}, {"data": {"source": "Endocrine therapy resistance", "target": "Cyclin D-CDK4/6-Rb"}}, {"data": {"source": "GBM", "target": "p53 control, growth signaling, cell cycle control"}}, {"data": {"source": "Colon Cancer", "target": "Hedgehog, Akt, p53"}}, {"data": {"source": "IBC", "target": "NOTCH"}}, {"data": {"source": "Melanocytic tumors", "target": "ARF-p53"}}, {"data": {"source": "Notopterol", "target": "IL-17 signaling"}}, {"data": {"source": "Tyrosine kinase inhibitors", "target": "BRAF/MEK, ALK, CDK4/6"}}, {"data": {"source": "letrozole, everolimus, palbociclib", "target": "PI3K-AKT, CCND1-CDK4/6"}}, {"data": {"source": "GRN163L", "target": "Cell cycle"}}, {"data": {"source": "PI3K/mTOR inhibitors", "target": "AKT/mTOR"}}, {"data": {"source": "PD-0332991", "target": "G1-S transition"}}, {"data": {"source": "Luteoloside", "target": "p38 MAPK"}}, {"data": {"source": "Artemisinin", "target": "ERK1/2"}}, {"data": {"source": "EESB", "target": "STAT3,Erk,p38"}}, {"data": {"source": "Salidroside", "target": "CDK4-cyclin D1 pathway"}}, {"data": {"source": "IB-MECA", "target": "Cyclin D1/CDK4"}}, {"data": {"source": "Erufosine", "target": "Cell cycle"}}, {"data": {"source": "palbociclib, trametinib", "target": "MEK"}}, {"data": {"source": "palbociclib,celecoxib", "target": "COX-2/Wnt"}}, {"data": {"source": "BRAF/MEK inhibitors", "target": "MAPK, Cell cycle"}}, {"data": {"source": "MEK inhibitors, CDK4/6 inhibitors", "target": "MAPK, Cell cycle"}}, {"data": {"source": "Erk1/2 inhibitors,CDK4/6 inhibitors", "target": "CDK4/6,Erk1/2"}}, {"data": {"source": "Necitumumab, afatinib, erlotinib", "target": "EGFR"}}, {"data": {"source": "PD 0332991", "target": "EGFR-TKI pathway"}}, {"data": {"source": "Palbociclib,Erlotinib", "target": "p16-CDK4/6-RB,AREG/EGFR"}}, {"data": {"source": "Palbociclib", "target": "EGFR, HER2"}}, {"data": {"source": "Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "CDK4/6 inhibitors,ET", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Palbociclib, Everolimus", "target": "MTOR"}}, {"data": {"source": "CDK4/6 inhibitors, mTOR inhibitors", "target": "PI3K/AKT/mTOR, CDK4/6"}}, {"data": {"source": "CDK4/6 inhibitors, mTOR inhibitors", "target": "CDK4/6"}}, {"data": {"source": "Abemaciclib, lenvatinib", "target": "MAPK, mTORC1/p70S6K, src/FAK"}}, {"data": {"source": "Rapamycin", "target": "mTOR/p70-S6k"}}, {"data": {"source": "RMC-6272", "target": "mTORC1"}}, {"data": {"source": "Palbociclib, Everolimus", "target": "mTOR"}}, {"data": {"source": "FMD", "target": "PI3K-AKT, mTOR, CDK4/6"}}, {"data": {"source": "CDK4/6 inhibitors", "target": "MTORC1, E2F, MYC"}}, {"data": {"source": "CDK4/6 inhibitors, mTOR inhibitors", "target": "PI3K/mTOR, CDK4/6"}}, {"data": {"source": "PI3K/mTOR inhibitors, fulvestrant", "target": "PI3K/mTOR"}}, {"data": {"source": "PI3K/mTOR inhibitors", "target": "AKT/mTOR axis"}}, {"data": {"source": "Gedatolisib", "target": "PI3K/mTOR"}}, {"data": {"source": "CDK4/6 inhibitors,mTOR inhibitors", "target": "mTOR"}}, {"data": {"source": "Palbociclib", "target": "HR"}}, {"data": {"source": "Olaparib", "target": "Wnt signaling"}}, {"data": {"source": "Olaparib, Palbociclib", "target": "Wnt signaling"}}, {"data": {"source": "Binimetinib, Ribociclib", "target": "MAPK"}}, {"data": {"source": "PI3K inhibitors, CDK4/6 inhibitors", "target": "PI3K"}}, {"data": {"source": "Ribociclib, Alpelisib", "target": "PI3K, Cell-cycle, Apoptosis"}}, {"data": {"source": "MEK inhibitors, CDK4/6 inhibitors", "target": "MAPK, PI3K, S6K1"}}, {"data": {"source": "Alpelisib", "target": "PI3K"}}, {"data": {"source": "alpelisib", "target": "MAPK, AKT"}}, {"data": {"source": "alpelisib", "target": "mTOR pathway"}}, {"data": {"source": "MEK inhibitors, CDK4/6 inhibitors", "target": "S6K1"}}, {"data": {"source": "CDK4/6 inhibitors", "target": "G1-S checkpoint"}}, {"data": {"source": "Alpelisib, Ribociclib", "target": "PI3K/AKT/mTOR"}}, {"data": {"source": "Palbociclib", "target": "Cell cycle"}}, {"data": {"source": "Palbociclib", "target": "NF-魏B"}}, {"data": {"source": "Palbociclib", "target": "NF-魏B, AKT"}}, {"data": {"source": "LEE011", "target": "Cell cycle"}}, {"data": {"source": "TP53-modulating drugs", "target": "Wnt signaling"}}]}